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(54) Title: DUAL FUNCTION PROTEINS FOR TREATING METABOLIC DISORDERS
(57) Abstract: The present invention relates to the identification of new proteins comprising fibroblast growth factor 2 1 (FGF21)
and other metabolic regulators, including variants thereof, known to improve metabolic profiles in subjects to whom they are admin
istered. Also disclosed are methods for treating FGF2 1-associated disorders, GLP- 1-associated disorders, and Exendin -4 -associated
disorders, including metabolic conditions.

DUAL FUNCTION PROTEINS FOR TREATING METABOLIC DISORDERS

FIELD OF THE INVENTION
[0001]

The present invention relates to new proteins comprising fibroblast growth

factor 2 1 (FGF21 ) and other metabolic regulators known to improve metabolic profiles in
subjects to whom they are administered.

BACKGROUND OF THE INVENTION
[0002]

The fibroblast growth factor (FGF) family is characterized by 22 genetically

distinct, homologous ligands, which are grouped into seven subfamilies. FGF-21 is
most closely related to, and forms a subfamily with, FGF-19 and FGF-23. This FGF
subfamily regulates diverse physiological processes uncommon to classical FGFs,
namely energy and bile acid homeostasis, glucose and lipid metabolism, and phosphate
as well as vitamin D homeostasis. Moreover, unlike other FGFs, this subfamily acts in
an endocrine fashion (Moore, D.D. (2007) Science 316, 1436-8)(Beenken et al. (2009)

Nature Reviews Drug Discovery 8 , 235).

[0003]

FGF21 is a 209 amino acid polypeptide containing a 28 amino acid leader

sequence (SEQ ID NO:132). Human FGF21 has about 79% amino acid identity to
mouse FGF21 and about 80% amino acid identity to rat FGF21 . Fibroblast growth
factor 2 1 (FGF21 ) has been described as a treatment for ischemic vascular disease,
wound healing, and diseases associated with loss of pulmonary, bronchia or alveolar
cell function (Nishimura et al. (2000) Biochimica et Biophysica Acta, 1492:203-206;

patent publication WO01/36640; and patent publication WO01/18172). Although FGF2 1 activates FGF receptors and downstream signaling molecules, including FRS2a and

ERK, direct interaction of FGFRs and FGF-21 has not been detected. Studies have

identified β-klotho, which is highly expressed in liver, adipocytes and pancreas, as a
determinant of the cellular response to FGF-21 and a cofactor which mediates FGF-21
signaling through FGFRs (Kurosu, H . et al. (2007) J Biol Chem 282, 26687-95). FGF21
is a potent agonist of the FGFR1 (lllc), FGFR2(lllc) and FGFR3(lllc) β-klotho signaling

complexes.

[0004]

FGF-21 has been shown to induce insulin-independent glucose uptake. FGF-

2 1 has also been shown to ameliorate hyperglycemia in a range of diabetic rodent

models. In addition, transgenic mice over-expressing FGF-21 were found to be
resistant to diet-induced metabolic abnormalities, and demonstrated decreased body
weight and fat mass, and enhancements in insulin sensitivity (Badman, M.K. et al.
(2007) Cell Metab 5 , 426-37). Administration of FGF-21 to diabetic non-human primates

caused a decline in fasting plasma glucose, triglycerides, insulin and glucagon levels,
and led to significant improvements in lipoprotein profiles, including a nearly 80%

increase in HDL cholesterol (Kharitonenkov, A . et al. (2007) Endocrinology 148, 7748 1 ) . Recent studies investigating the molecular mechanisms of FGF21 action have

identified FGF21 as an important endocrine hormone that helps to control adaptation to
the fasting state (Badman et al. (2009) Endocrinology 150, 4931)(lnagaki et al. (2007)
Cell Metabolism 5 , 415). This provides a previously missing link downstream of PPARa,

by which the liver communicates with the rest of the body in regulating the biology of
energy homeostasis (Galman et al. (2008) Cell Metabolism 8 , 169)(Lundasen et al.
(2007) Biochemical and Biophysical Research Communications 360, 437).

[0005]

FGF21 regulates adipocyte homeostasis through activation of an

AMPK/SIRT1/PGC1a pathway to inhibit PPARy expression and increase mitochondrial
function (Chau et al. (2010) PNAS 107, 12553). FGF21 also increases glucose uptake
by skeletal muscle as measured in cultured human myotubes and isolated mouse tissue
(Mashili et al. (201 1) Diabetes Metab Res Rev 27, 286-97). FGF21 treatment of rodent
islet cells leads to improved function and survival through activation of ERK1/2 and Akt
pathways (Wente et al. (2006) Diabetes 55, 2470). FGF21 treatment also results in
altered gene expression for lipogenesis and fatty acid oxidation enzymes in rodent
livers, likely through HNF4a and Foxa2 signaling. However, recent studies (Wei et al.
(201 2) PNAS 109, 3 1 43-48) indicate that treatment of diet-induced obese mice with

FGF21 induces bone loss, due to a diminished inactivation of PPARy (via reduced

sumoylation); a shift of mesenchymal stem cell differentiation from osteoblasts to
adipocytes is seen in the presence of increased PPARy activity in the bone following
FGF21 treatment.

[0006]

A difficulty associated with using FGF-21 directly as a biotherapeutic is that its

half-life is very short (Kharitonenkov, A . et al. (2005) Journal of Clinical Investigation
115:1627-1635). In mice, the half-life of human FGF21 is 0.5 to 1 hours, and in
cynomolgus monkeys, the half-life is 2 to 3 hours. FGF21 may be utilized as a multiuse, sterile pharmaceutical formulation. However, it has been determined that

preservatives, e.g., m-cresol, have an adverse effect on its stability under these
conditions.

[0007]

Another potent metabolic regulator already represented in the clinic is

Glucagon-Like Peptide-1 (GLP-1) (Knudsen et al. (2004) Journal of Medicinal Chemistry
47, 4128). GLP-1 is a 36 amino acid incretin secreted by L-cells of the mammalian gut,

acting on both alpha and beta cells to stimulate insulin secretion and inhibit glucagon
release in a glucose-dependent manner (Hare et al. (2010) Diabetes 59, 1765; Meier et

al. (2005) Diabetes-Metabolism Research and Reviews 21, 9 1 ) . GLP-1 binds to and

activates the GLP-1 receptor (GLP-1 R), a seven-transmembrane helix protein of the
class

II

family of G-protein coupled receptors (GPCRs) (Mayo et al. (2003)

Pharmacological Reviews 55:167). As a GLP-1 receptor agonist, GLP-1 has an
important role in decreasing post-prandial blood glucose levels by stimulating insulin
secretion from the pancreas in order to increase glucose absorption in the peripheral
tissues and inhibiting glucagon secretion, resulting in reduced hepatic glucose release.

[0008]

A second clinically important GLP-1 receptor agonist is Exendin-4. Exendin-4

is a 39 residue polypeptide produced in the salivary glands of the Gila Monster lizard

(Goke et al. (1993) Diabetes 46:433-439; Fehmann et al. (1995) Endocrine Rev.
16:390-410). Although it is the product of a uniquely non-mammalian gene and appears
to be expressed only in the salivary gland, Exendin-4 shares a 52% amino acid
sequence homology with GLP-1 , and in mammals interacts with the GLP-1 receptor
(Goke, et al.; Thorens et al. (1993) Diabetes 42:1678-1682).

In vitro, Exendin-4 has

been shown to promote insulin secretion by insulin producing cells and, given in

equimolar quantities, is more potent than GLP-1 at causing insulin release from insulin
producing cells. Furthermore, Exendin-4 potently stimulates insulin release to reduce
plasma glucose levels in both rodents and humans and is longer acting than GLP-1 ;
however, because it does not occur naturally in mammals, Exendin-4 has certain
potential antigenic properties in mammals that GLP-1 lacks.

[0009]

The ability of GLP-1 and Exendin-4 analogues (e.g., Liraglutide and Byetta) to

improve glucose control in humans is established in the clinic (Idris (2010) Diabetes
Obesity & Metabolism 12, 89; Monami et al (2009) European Journal of Endocrinology
160, 909). GLP-1 has also been reported to increase beta cell mass both through

induced proliferation and inhibition of apoptosis (Egan, A et a l (2003) DiabetesMetabolism Research and Reviews 19, 115;Farilla, L . et al. (2003) Endocrinology 144,
5149;Xu, G . et al. (1999) Diabetes 48, 2270). It also acts as an intestinal hormone to
inhibit acid secretion and gastric emptying in the stomach while providing a satiety
signal that decreases appetite (Vilsboll et al. (2009) Best Practice & Research Clinical
Endocrinology & Metabolism 23, 453). These effects likely account for beneficial weight
loss observed with administration of GLP-1 analogues to type 2 diabetes patients. GLP1 has also been shown to be cardioprotective in postischemic rodent hearts (Ossum et
al. (2009) Pharmacological Research 60, 4 1 1; Sonne, D.P. et al. (2008) Regulatory

Peptides 146, 243;Nikolaidis, L . A . et al. (2004) Circulation 109, 962).

[00010]

Additionally, GLP-1 can reduce the differentiation of human mesenchymal

stem cells (hMSCs) to adipocytes by reducing the expression of PPARy, and GLP-1

promotes cellular proliferation and cytoprotection of hMSCs (Sanz et al. (2010) Am J
Physiol Endocrinol Metab 298, E634-E643).

[00011]

In developing an FGF21 protein, including a variant or analogue thereof, for

use as a therapeutic in the treatment of type 1 and type 2 diabetes mellitus and other

metabolic conditions, an increase in half-life and stability would be desirable. FGF21
proteins having enhanced half-life and stability would allow for less frequent dosing of
patients being administered the protein. Clearly, there is a need to develop a stable
aqueous protein formulation for the therapeutic protein FGF21 .

[00012]

Furthermore, a significant challenge in the development of protein

pharmaceuticals, such as metabolic regulators FGF21, GLP-1, and Exendin-4, is to
cope with their physical and chemical instabilities. The compositional variety and
characteristics of proteins define specific behaviors such as folding, conformational
stability, and unfolding/denaturation.

Such characteristics should be addressed when

aiming to stabilize proteins in the course of developing pharmaceutical formulation
conditions utilizing aqueous protein solutions (Wang, W., Int. J . of Pharmaceutics, 18,
(1999)). A desired effect of stabilizing therapeutic proteins of interest, e.g., the proteins
of the present invention, is increasing resistance to proteolysis and enzymatic
degradation, thereby improving protein stability and reducing protein aggregation.

SUMMARY OF THE INVENTION
[00013]

The invention relates to the identification of new proteins, e.g., fusion

proteins, which comprise fibroblast growth factor 2 1 (FGF21 ) and other metabolic
regulators, e.g., GLP-1 and Exendin-4, and which have improved pharmaceutical
properties over the constituent agents under pharmaceutical formulation conditions,
e.g., are more stable, possess the ability to improve metabolic parameters for subjects

to whom they are administered, are less susceptible to proteolysis and enzymatic
degradation, are less likely to aggregate and form complexes and are less likely to be
immunogenic. The proteins of the invention possess both FGF21 receptor agonist and
GLP-1 receptor agonist activity; they comprise truncations and variants of FGF21 , and

further comprise one or more of, e.g., glucagon-like peptide-1 (GLP-1), Exendin-4, or
other metabolic regulators or variants thereof.

[00014]

Also disclosed are methods for treating FGF21 -associated and GLP-1

associated disorders, as well as other metabolic, endocrine, and cardiovascular
disorders, such as obesity, type 1 and type 2 diabetes mellitus, pancreatitis,
dyslipidemia, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis
(NASH), insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia,
metabolic syndrome, acute myocardial infarction, hypertension, cardiovascular disease,

atherosclerosis, peripheral arterial disease, stroke, heart failure, coronary heart disease,
kidney disease, diabetic complications, neuropathy, gastroparesis, disorders associated
with severe inactivating mutations in the insulin receptor, lipodystrophies including HIVassociated lypodistrophy and other metabolic disorders, and in reducing the mortality
and morbidity of critically ill patients.

[00015]

The proteins of the present invention may be used as a regularly

administered (e.g., daily, more preferably weekly, biweekly, or monthly) injectable, either
alone or in combination with oral anti-diabetic agents, which will improve the glycemic
control, body weight and lipid profile of type 1 and type 2 diabetes mellitus patients. The
proteins may also be used for the treatment of obesity or other FGF21- or GLP-1associated conditions.

[00016]

The proteins of the invention, e.g., GLP-1-FGF21 variant and Exendin-4-

FGF21 variant fusion proteins of the invention, overcome the significant hurdles of

physical instabilities associated with protein therapeutics, including, for instance, with
the administration of the wild-type FGF21 , as they are more stable, less susceptible to
proteolysis and enzymatic degradation, less likely to aggregate and form complexes and
less likely to be immunogenic than wild-type FGF21 under pharmaceutical formulation

conditions.

[00017]

In a first aspect, the invention provides Fibroblast Growth Factor 2 1 (FGF21 )

proteins, e.g., fusion proteins, comprising one or more of the sequences listed in Table
1,

and further described herein. The proteins of the invention can further comprise GLP-

1 and/or Exendin-4 proteins, whether wild-type, truncated, or mutated versions, or
variants thereof. The FGF21 sequences listed in Table 1 are variants of the wild-type
FGF21 sequence, e.g., the wild-type FGF21 sequence with NCBI reference number

NP_061 986.1, and found in such issued patents as, e.g., US 6,716,626B1 , assigned to

Chiron Corporation. The GLP-1 and Exendin-4 sequences listed in Table 1 are variants
of the wild-type GLP-1 and Exendin-4 sequences, e.g., those sequences with NCBI
reference numbers NP_002045 and AAB22006.1 , respectively, and can be found in
such patent publications as, e.g., W098/19698 and WO87/06941A, assigned to Eli Lilly
and Co. and the General Hospital Corp., respectively (GLP-1 ) and US 5,424,286,

assigned to Amylin (Exendin-4).

[00018]

Other embodiments are drawn to polynucleotides encoding the dual function

proteins of the invention, a vector containing said polynucleotides and a host cell
carrying said vector.

[00019]

Provided herein are methods used to generate the proteins of the invention,

wherein such methods involve modification of the wild-type FGF21 protein, via, e.g., the
site-specific incorporation of amino acids at positions of interest within the wild-type

FGF21 protein, as well as the fusion between the FGF21 portion of the molecule to

other metabolic regulators, such as glucagon-like peptide-1 (GLP-1) and Exendin-4, or
conjugates with polymers modified with GLP-1 and/or Exendin-4. Said modifications
and fusions enhance the biological properties of the proteins of the invention relative to

the wild-type versions of the proteins (e.g., FGF21 , GLP-1 , and Exendin-4), as well as,
in some cases, serving as points of attachment for, e.g., labels and protein half-life

extension agents, and for purposes of affixing said variants to the surface of a solid
support. Related embodiments of the invention are methods to produce cells capable of
producing said proteins of the invention, and of producing vectors containing DNA
encoding said variants and fusions.

[00020]

In various embodiments, the proteins of the invention can comprise one or

more fragments of the FGF21, Exendin-4, and/or GLP-1 sequences, including
fragments as small as 8-12 amino acid residues in length, wherein the polypeptide is
capable of lowering blood glucose in a mammal. In various embodiments, the proteins
of the invention can comprise one or more variants of the FGF21 , Exendin-4, and/or
GLP-1 sequences, e.g., with one or more amino acid deletions, insertions, additions, or

substitutions relative to the wild-type sequences thereof.

[00021]

In some embodiments, the proteins of the invention can be covalently linked

to one or more polymers, such as polyethylene glycol (PEG) or polysialic acid, whether
at the position of site-specific amino acid modifications made relative to the wild-type
FGF21 , GLP-1 , or Exendin-4, or at the position of amino acids commonly shared with

the wild-type versions of those proteins. The PEG group is attached in such a way so
as enhance, and/or not to interfere with, the biological function of the constituent

portions of the fusion proteins of the invention, e.g., the GLP-1 protein variants or
FGF21 protein variants. In other embodiments, the polypeptides of the invention can be

fused to a heterologous amino acid sequence, optionally via a linker, such as GS,
GGGGSGGGGSGGGGS (SEQ ID NO:8), or SGGGGSGGG (SEQ ID NO:128). The
heterologous amino acid sequence can be an IgG constant domain or fragment thereof
(e.g., the Fc region), Human Serum Albumin (HSA), or albumin-binding polypeptides.

Such fusion proteins disclosed herein can also form multimers.

[00022]

In some embodiments, a heterologous amino acid sequence (e.g., HSA, Fc,

etc.) is fused to the amino-terminal of the proteins of the invention. In other
embodiments, the fusion heterologous amino acid sequence (e.g., HSA, Fc, etc.) is
fused to the carboxyl-terminal of the proteins of the invention. In still other, more
preferred embodiments, the heterologous amino acid sequence (e.g., HSA, Fc, etc.) is
situated in the middle of the dual function proteins of the invention, i.e., between the Cterminal residue of the GLP-1 or Exendin-4 sequence and the N-terminal residue of the

FGF21 sequence. Said preferred embodiment, e.g., leaves a free N-terminus for

maximum GLP-1 (Exendin-4) activity and a free, intact C-terminus for maximum FGF21
activity.

[00023]

In some embodiments, the GLP-1 receptor agonist is fused to the N-terminus

of heavy and light chain of an antibody and FGF21 is simultaneously fused to the Cterminus of heavy and light chain of the same antibody (i.e., a fusobody, as described
herein). Said preferred embodiment leaves a free N-terminus for maximum GLP-1
(Exendin-4) activity and a free, intact C-terminus for maximum FGF21 activity. A
preferred embodiment uses the antibody sequence described in PCT publication
WO20 11/076781 .

[00024]

In some embodiments, the GLP-1 or Exendin-4 peptide is chemically

attached to FGF21 . In some embodiments, said peptides are attached to an FGF21
amino acid residue side chain. In other embodiments, said peptides are attached to the
N-terminus of FGF21 through native chemical ligation or other methods known to the
art. The preferred embodiment leaves a free N-terminus of GLP-1 (Exendin-4) for

maximal activity and a free, intact C-terminus of FGF21 for maximal activity.

[00025]

In some embodiments, the GLP-1 or Exendin-4 peptide is covalently

attached to a polymer molecule that in turn is attached to the FGF21 protein variant. In
a preferred embodiment, the GLP-1 or Exendin-4 peptide is attached to a PEG polymer
that is simultaneously attached to a FGF21 protein variant. Said preferred embodiment
leaves a free N-terminus for maximum GLP-1 (Exendin-4) activity and a free, intact Cterminus for maximum FGF21 activity. In some embodiments of the invention, a GLP-1
receptor agonist peptide is connected to a FGF21 variant through a PEG linker or other
polymer linker that simultaneously provides half-life extension as well as a covalent
connection for the two receptor agonists.

[00026]

Yet another embodiment is drawn to methods of treating a patient exhibiting

one or more FGF21 -associated disorders or GLP-1 -associated disorders, such as
obesity, type 2 diabetes mellitus, type 1 diabetes mellitus, pancreatitis, dyslipidemia,
nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), insulin
resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, metabolic syndrome,
acute myocardial infarction, hypertension, cardiovascular disease, atherosclerosis,
peripheral arterial disease, stroke, heart failure, coronary heart disease, kidney disease,
diabetic complications, neuropathy, gastroparesis, disorders associated with inactivating
mutations in the insulin receptor, lipodystrophies including HlV-associated lipodystrophy
and other metabolic disorders, comprising administering to said patient in need of such

treatment a therapeutically effective amount of one or more proteins of the invention or
a pharmaceutical composition thereof.

[00027]

The invention also provides pharmaceutical compositions comprising the

dual function proteins of the invention disclosed herein and a pharmaceutically

acceptable formulation agent. Such pharmaceutical compositions can be used in a
method for treating a metabolic disorder, and the method comprises administering to a
human patient in need thereof a pharmaceutical composition of the invention. Nonlimiting examples of metabolic disorders that can be treated include type 1 and type 2
diabetes mellitus and obesity.

[00028]

These and other aspects of the invention will be elucidated in the following

detailed description of the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

[00029]

Figures 1A and 1B show the activity of GLP-1-FGF21-PEG fusion proteins

with different N-terminal mutations, and Exendin-4-FGF21-PEG fusion proteins. Figure
1A shows the mutations added to slow processing by DPP-4 protease (GLP-1 peptide

(circles) or dual function proteins with wild-type (V231; open squares), G O (V251; open
circles), A8G (V258; open triangles), A8S (V232; triangles), or E9P (V271 ; squares)
GLP-1 ) . Figure 1B shows Exendin-4 fusions (GLP-1 peptide (squares) or dual function

proteins with Exendin-4 1-39 (V234; triangles), 1-30 (V267; circles) or 1-30/E16G/E17Q
(V268; open triangles)).

[00030]

Figure 2 shows pharmacokinetic properties (PK) of the GLP-1 -FGF21 -PEG

fusion proteins (FGF21-PEG (V294; open squares), GLP-1 (A8S)-PEG (V253; open
circles) or dual function proteins with wild-type GLP-1 (V237; circles) or GLP-1 (A8S)
(V235; triangles) GLP-1). The PK of wild-type non-PEGylated FGF21 injected at 0.25

mg/kg is shown for comparison (squares).

[00031]

Figures 3A-3C show results from using the oral glucose tolerance test

(OGTT) to measure the efficacy of half-life extended GLP-1 -FGF21 -PEG fusion
proteins. Eight week C57BL/6J mice (n=5) were dosed by intraperitoneal (i.p.) injection
with 1 mg/kg compound or vehicle (solid white bars; triangles). Blood glucose was
measured at 1 and 24 hours post dose to assess acute effects of the GLP-1 , which
were similar for the wild-type GLP-1 (V239; hashed bars; squares) and GLP-1 (A8S)
versions (V232; black bars; circles) at 1 hour and retained slightly better by the GLP1(A8S) version at 24 hours. On the third night, the mice were fasted before challenge
with 1.5 g/kg oral glucose at 72 hours post-dose. The mice dosed with the A8S version
showed significantly improved control of blood glucose compared to those with the wildtype GLP-1 version, suggesting that the A8S mutation increased long-term levels of
active GLP-1 .

[00032]

Figure 4 shows efficacy of GLP-1-FGF21-PEG fusion proteins in ob/ob mice.

Ten week old male ob/ob mice (n=8) were dosed i.p. twice weekly with the indicated
compounds for two weeks. Equivalent dosing of FGF21-PEG (V238; diagonal hashed
bars; squares) and GLP-1-FGF21(R154C)-PEG (V239; horizontal hashed bars; open

squares) showed very similar improvements in blood glucose levels, body weight, and
liver health (as measured by serum ALT levels and liver weight) when compared to the
vehicle-treated group (circles). The DPP-4-resistant fusion, 0.2 mg/kg GLP-1 (A8S)FGF21 (R154C)-PEG (V235; vertical hashed bars; open triangles) showed similar

efficacy to other compounds, but equal dosing at 1 mg/kg GLP-1 (A8S)-FGF21(R154C)PEG (V235; black bars; triangles) gave additional lowering of blood glucose, body

weight, alanine aminotransferase (ALT), and liver weight.

[00033]

Figures 5A-5G show a comparison of the GLP-1 (A8S)-FGF21 (R1 54C)-PEG

(V235; black bars; open triangles) fusion protein to co-administration of FGF21(R154C)PEG + GLP-1 (A8S)-PEG (vertical hashed bars; open circles), single administration of
FGF21 (R154C)-PEG (V238; 0.2 mg/kg (light diagonal hashed bars); 1 mg/kg (dark

diagonal hashed bars; squares)), and single administration of GLP-1 (A8S)-PEG (V253;
0.2 mg/kg (light horizontal hashed bars); 1 mg/kg (dark horizontal hashed bars; open

squares)) in ob/ob mice. Nine week old male ob/ob mice (n=8) were dosed i.p. twice
weekly with the indicated compounds or vehicle (solid white bars; circles) for four
weeks. The fusion showed significantly improved efficacy compared to c o
administration of FGF21(R154C)-PEG + GLP-1 (A8S)-PEG. Although only moderate
weight loss was observed with FGF21(R154C)-PEG and GLP-1 (A8S)-FGF21 (R1 54C)PEG, other groups gained a substantial amount of weight, only in part due to differences
in food intake.

[00034]

Figures 6A-6F show efficacy of GLP-1 (A8S)-FGF21-PEG fusion proteins in

ob/ob mice, comparing FGF21 (R154C)-PEG (V235; dark bars) to FGF21(V76)-PEG
(V272; light bars). Nine week old male ob/ob mice (n=8) were dosed i.p. twice weekly

with the indicated compounds or vehicle (solid white bars) for two weeks. Both the
GLP-1 (A8S)-FGF21(R154C)-PEG and the GLP-1 (A8S)-FGF21(V76)-PEG fusions

showed a dose response from 0.05 to 0.2 mg/kg (0.05 diagonal hashed bars; 0.1
horizontal hashed bars; 0.2 vertical hashed bars) for glucose control and body weight.
At 0.2 mg/kg, GLP-1 (A8S)-FGF21(V76)-PEG

was more efficacious than GLP-1 (A8S)-

FGF21 FGF21(R154C)-PEG particularly for lowering of glucose levels, body weight,

serum triglycerides and cholesterol. Figures 6A-6C show levels of basal glucose (AUC),
alanine aminotransferase (ALT), and serum total cholesterol, respectively. Figures 6D6F show levels of D12 body weight, hepatic lipids, and serum triglycerides, respectively.

[00035]

Figures 7A-7B show the ability of GLP-1 (A8S)-FGF21 (V76)-PEG fusion

proteins to improve pancreatic function and increase islet insulin content, relative to the
combination of the individual agents. Db/db mice were dosed twice per week, for four
weeks, with a combination of individual GLP-1 (A8S)-PEG +FGF21(V76)-PEG
(V76+V253; vertical hashed bars), as well as with the GLP-1 (A8S)-FGF21 (V76)-PEG
dual function fusion protein of the invention (V272; diagonal hashed bars; light for 0.5
mg/kg and dark for 1 mg/kg), or vehicle (white bars).

[00036]

Figures 8A-8B show the ability of GLP-1 -FGF21 -PEG fusion proteins to

improve glucose lowering and body weight, relative to the combination of the individual
agents. Db/db mice were dosed twice per week, for two weeks, with vehicle (white bars;
open circles), a combination of individual GLP-1 (A8S)-PEG (V253; 3 mg/kg (light
horizontal hashed bars; open diamonds) and 5 mg/kg (dark horizontal bars; diamonds))
and FGF21 (V76)-PEG (3 mg/kg (V76; light diagonal hashed bars; open squares) and 5

mg/kg (dark diagonal hashed bars; squares)), as well as with the GLP-1 (A8S)FGF21 (V76)-PEG dual function fusion protein of the invention (V272; 0.2 mg/kg

(smalled checked bars; open triangles); 1 mg/kg (large checked bars; triangles)). As
seen in the figure, 0.2 mg/kg of the GLP-1 (7-35; A8S)-FGF21(V76)-PEG dual function
fusion protein (V272) is as effective as 5 mg/kg of FGF21(V76)-PEG. Also as seen in
the figure, 1.0 mg/kg of the GLP-1 (7-35; A8S)-FGF21 (V76)-PEG dual function fusion
protein (V272) is more effective that the maximal effective combination doses of
FGF21 (V76)-PEG + GLP-1 (7-35; A8S)-PEG ( 1 + 1 mg/kg (light horizontal hashed bars;

exes) and 3 + 3 mg/kg (dark horizontal bars; stars), for both glycemic and body weight
endpoints.

[00037]

Figure 9 shows the results of an assay for FGF21 activity. Phosphorylation

of ERK is measured after treatment of HEK293-beta-klotho cells with the indicated
compounds. The activity of GLP-1 (A8S)-V76-PEG (V272) is significantly higher in
magnitude of signal compared to the same FGF21 variant FGF21 (V76)-PEG in the
presence or absence of equimolar Exenatide.

[00038]

Figure 10 presents results of a receptor pharmacology assay used to

measure the activity of fusion proteinscompared to matched single agonist proteins or
peptides. HEK293 cells transfected with GLP-1 R and FGFR1c/beta-klotho (10a and
10b) or with GLP-1 R alone

( 1 0c

and 10d) were assayed for beta-arrestin recruitment to

GLP-1 R after treatment with compounds for 1 hour. Molecules tested in the assay

were: Exendin-4 (squares), GLP-1 (A8S)-FGF21(V76)-PEG (V272; circles), GLP-1 (A8S)PEG (V253; triangles), V253 +FGF21 (V76)-PEG (open diamonds), Exendin-4(1 -39)-FcFGF21 (V103) (V21 1 ; open circles), Exendin-4(1-39)-Fc (V201 ; open triangles), and

V201 + FGF21(V101) (diamonds).

DETAILED DESCRIPTION OF THE INVENTION
[00039]

The proteins of the present invention represent modified versions of the full-

length, wild-type FGF21 polypeptide, as known in the art. FGF21 wild-type sequence
will serve as a reference sequence (SEQ ID NO:1 ) , for instance, when comparisons
between the FGF21 wild-type sequence and the protein variants are necessary. The
FGF21 wild-type sequence has NCBI reference sequence number NP_061986.1, and

can be found in such issued patents as, e.g., US 6,716,626B1, assigned to Chiron

Corporation (SEQ ID NO:1).
Met Asp Ser Asp Glu Thr Gly Phe Glu His Ser Gly Leu Trp Val Ser
1
5
10
15
Val Leu Ala Gly Leu Leu Leu Gly Ala Cys Gin Ala His Pro lie Pro
20
25
30
Asp Ser Ser Pro Leu Leu Gin Phe Gly Gly Gin Val Arg Gin Arg Tyr
35
40
45
Leu Tyr Thr Asp Asp Ala Gin Gin Thr Glu Ala His Leu Glu lie Arg
50
55
60
Glu Asp Gly Thr Val Gly Gly Ala Ala Asp Gin Ser Pro Glu Ser Leu
65
70
75
80
Leu Gin Leu Lys Ala Leu Lys Pro Gly Val lie Gin lie Leu Gly Val
85
90
95
Lys Thr Ser Arg Phe Leu Cys Gin Arg Pro Asp Gly Ala Leu Tyr Gly
100
105
1 10
Ser Leu His Phe Asp Pro Glu Ala Cys Ser Phe Arg Glu Leu Leu Leu
115
120
125
Glu Asp Gly Tyr Asn Val Tyr Gin Ser Glu Ala His Gly Leu Pro Leu
130
135
140
His Leu Pro Gly Asn Lys Ser Pro His Arg Asp Pro Ala Pro Arg Gly
145
150
155
160
Pro Ala Arg Phe Leu Pro Leu Pro Gly Leu Pro Pro Ala Leu Pro Glu
165
170
175
Pro Pro Gly lie Leu Ala Pro Gin Pro Pro Asp Val Gly Ser Ser Asp
180
185
190
Pro Leu Ser Met Val Gly Pro Ser Gin Gly Arg Ser Pro Ser Tyr Ala
195
200
205
Ser
209

[00040]

The corresponding mRNA sequence coding for the full-length FGF21

polypeptide (NCBI reference sequence number NM_0191 13.2) is shown below (SEQ ID
NO:2):

1 ctgtcagctg aggatccagc cgaaagagga gccaggcact caggccacct gagtctactc
61

acctggacaa ctggaatctg gcaccaattc taaaccactc agcttctccg agctcacacc

121 ccggagatca cctgaggacc cgagccattg atggactcgg acgagaccgg gttcgagcac
181 tcaggactgt gggtttctgt gctggctggt cttctgctgg gagcctgcca ggcacacccc

241 atccctgact ccagtcctct cctgcaattc gggggccaag tccggcagcg gtacctctac
301 acagatgatg cccagcagac agaagcccac ctggagatca gggaggatgg gacggtgggg
361 ggcgctgctg accagagccc cgaaagtctc ctgcagctga aagccttgaa gccgggagtt
421 attcaaatct tgggagtcaa gacatccagg ttcctgtgcc agcggccaga tggggccctg
481 tatggatcgc tccactttga ccctgaggcc tgcagcttcc gggagctgct tcttgaggac
541 ggatacaatg tttaccagtc cgaagcccac ggcctcccgc tgcacctgcc agggaacaag
601 tccccacacc gggaccctgc accccgagga ccagctcgct tcctgccact accaggcctg
661 ccccccgcac tcccggagcc acccggaatc ctggcccccc agccccccga tgtgggctcc

721 tcggaccctc tgagcatggt gggaccttcc cagggccgaa gccccagcta cgcttcctga
781 agccagaggc tgtttactat gacatctcct ctttatttat taggttattt atcttattta
841 tttttttatt tttcttactt gagataataa agagttccag aggagaaaaa aaaaaaaaaa
901 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa

[00041]

The mature FGF21 sequence lacks a leader sequence and may also include

other modifications of a polypeptide such as proteolytic processing of the amino
terminus (with or without a leader sequence) and/or the carboxyl terminus, cleavage of a
smaller polypeptide from a larger precursor, N-linked and/or O-linked glycosylation, and
other post-translational modifications understood by those with skill in the art. A
representative example of a mature FGF21 sequence has the following sequence (SEQ
ID NO:3, which represents amino acid positions 29-209 of full-length FGF21 protein

sequence (NCBI reference sequence number NP_061 986.1 )):

His Pro lie Pro Asp
5
Arg Gin Arg Tyr Leu
20
Leu Glu lie Arg Glu
35
Pro Glu Ser Leu Leu
50
lie Leu Gly Val Lys

Ser Ser Pro Leu Leu Gin Phe Gly Gly Gin Val

Tyr Thr Asp Asp
25
Asp Gly Thr Val
40
Gin Leu Lys Ala
55
Thr Ser Arg Phe
65
70
Ala Leu Tyr Gly Ser Leu His Phe Asp
85

Glu Leu Leu Leu
100
Gly Leu Pro Leu
115
Ala Pro Arg Gly
130
Ala Leu Pro Glu
145
Gly Ser Ser Asp

Glu Asp Gly Tyr Asn
105
His Leu Pro Gly Asn
120
Pro Ala Arg Phe Leu
135
Pro Pro Gly
e Leu
150
Pro Leu Ser Met Val
165
Pro Ser Tyr Ala Ser
180

10

15

Ala Gin Gin Thr Glu Ala His
30
Gly Gly Ala Ala Asp Gin Ser
45
e Gin
Leu Lys Pro Gly Val
60

Leu Cys Gin Arg Pro Asp Gly
75
80
Pro Glu Ala Cys Ser Phe Arg
90

Val Tyr Gin Ser Glu
110
Lys Ser Pro His Arg
125
Pro Leu Pro Gly Leu
140
Ala Pro Gin Pro Pro
155
Gly Pro Ser Gin Gly
170

95

Ala His
Asp

Pro

Pro Pro
Asp Val
160
Arg Ser
175

[00042]

The corresponding cDNA sequence coding for the mature FGF21

polypeptide (SEQ ID NO:3) is shown below (SEQ ID NO:4):
1 caccccatcc ctgactccag tcctctcctg caattcgggg gccaagtccg gcagcggtac
6 1 ctctacacag atgatgccca gcagacagaa gcccacctgg agatcaggga ggatgggacg

121 gtggggggcg ctgctgacca gagccccgaa agtctcctgc agctgaaagc cttgaagccg
181 ggagttattc aaatcttggg agtcaagaca tccaggttcc tgtgccagcg gccagatggg

240 gccctgtatg gatcgctcca ctttgaccct gaggcctgca gcttccggga gctgcttctt
301 gaggacggat acaatgttta ccagtccgaa gcccacggcc tcccgctgca cctgccaggg

360 aacaagtccc cacaccggga ccctgcaccc cgaggaccag ctcgcttcct gccactacca
421 ggcctgcccc ccgcactccc ggagccaccc ggaatcctgg ccccccagcc ccccgatgtg
481 ggctcctcgg accctctgag catggtggga ccttcccagg gccgaagccc cagctacgct
541 tcctga

[00043]

The proteins of the invention of the present invention represent modified

versions of the full-length, wild-type GLP-1 polypeptide, as known in the art. GLP-1
wild-type sequence will serve as a reference sequence (SEQ ID NO:5), for instance,
when comparisons between the GLP-1 wild-type sequence and the protein variants are
necessary.

[00044]

The GLP-1 wild-type sequence is post-translationally modified, and

otherwise derived from, preproglucagon wild-type sequence. Preproglucagon sequence
(SEQ ID NO:5) has NCBI reference sequence number NP_002045, and can be found in
such patent publications as, e.g., W098/19698 and WO87/06941A, assigned to Eli Lilly
and Co. and the General Hospital Corp., respectively. As described, for example, in

Goke, et al. (1991) European Journal of Clinical Investigation 21, 135, GLP-1 is a 37mer
that is derived from preproglucagon (GLP-1 constitutes residues 92-138 of
preproglucagon, and is underlined in SEQ ID NO:5, below). GLP-1 is further processed
into an active 31mer, by cleavage of the six N-term residues.

1
61

ΜΚΞ IYFVAGL

FVMLVQGSWQ RSLQDTEEKS RSFSASQADP LSDPDQMNED KRHSQGTFTS

DYSKYLDSRR AQDFVQWLMN TKRNRNNIAK RHDEFERHAE GTFTSDVSSY LEGQAAKEFI

121 AWLVKGRGRR DFPEEVAIVE ELGRRHADGS FSDEMNTILD NLAARDFINW LIQTKITDRK

[00045]

A n example of the processed, wild-type GLP-1 sequence is as follows (SEQ

ID NO:129):

1

[00046]

HDEFERHAEG

TFTSDVSSYL

EGQAAKEFIA

WLVKGRG

A n example of the active GLP-1 sequence is as follows (SEQ ID NO:30):

1

[00047]

HAEGTFTSDV

SSYLEGQAAK

EFIAWLVKGR

G

The corresponding mRNA sequence coding for the preproglucagon GLP-1

wild-type sequence (SEQ ID NO:5) is shown below (SEQ ID NO:6):

1 gcatagaatg cagatgagca aagtgagtgg gagagggaag tcatttgtaa caaaaactca
61

ttatttacag atgagaaatt tatattgtca gcgtaatatc tgtgaggcta aacagagctg

121 gagagtatat aaaagcagtg cgccttggtg cagaagtaca gagcttagga cacagagcac
181 atcaaaagtt cccaaagagg gcttgctctc tcttcacctg ctctgttcta cagcacacta

241 ccagaagaca gcagaaatga aaagcattta ctttgtggct ggattatttg taatgctggt
301 acaaggcagc tggcaacgtt cccttcaaga cacagaggag aaatccagat cattctcagc
361 ttcccaggca gacccactca gtgatcctga tcagatgaac gaggacaagc gccattcaca
421 gggcacattc accagtgact acagcaagta tctggactcc aggcgtgccc aagattttgt
481 gcagtggttg atgaatacca agaggaacag gaataacatt gccaaacgtc acgatgaatt
541 tgagagacat gctgaaggga cctttaccag tgatgtaagt tcttatttgg aaggccaagc
601 tgccaaggaa ttcattgctt ggctggtgaa aggccgagga aggcgagatt tcccagaaga
661 ggtcgccatt gttgaagaac ttggccgcag acatgctgat ggttctttct ctgatgagat

721 gaacaccatt cttgataatc ttgccgccag ggactttata aactggttga ttcagaccaa
781 aatcactgac aggaaataac tatatcacta ttcaagatca tcttcacaac atcacctgct
841 agccacgtgg gatgtttgaa atgttaagtc ctgtaaattt aagaggtgta ttctgaggcc
901 acattgcttt gcatgccaat aaataaattt tcttttagtg ttgtgtagcc aaaaattaca
961 aatggaataa agttttatca aaatattgct aaaatatcag ctttaaaata tgaaagtgct

1021 agattctgtt attttcttct tattttggat gaagtacccc aacctgttta catttagcga
1081 taaaattatt tttctatgat ataatttgta aatgtaaatt attccgatct gacatatctg
1141 cattataata ataggagaat agaagaactg gtagccacag tggtgaaatt ggaaagagaa
1201 ctttcttcct gaaacctttg tcttaaaaat actcagcttt caatgtatca aagatacaat
12 61 taaataaaat

[00048]

tttcaagctt ctttaccaaa aaaaaaaa

The proteins of the invention of the present invention represent modified

versions of the full-length, wild-type Exendin-4 polypeptide, as known in the art.
Exendin-4 wild-type sequence will serve as a reference sequence (SEQ ID NO:7), for
instance, when comparisons between the Exendin-4 wild-type sequence and the protein
variants are necessary.

[00049]

The Exendin-4 wild-type sequence has NCBI reference sequence number

GenBank: AAB22006.1, and can be found in such issued patents as, e.g., US
5,424,286, assigned to Amylin Pharmaceuticals, Inc. and Eli Lilly and Co. A n example
of the wild-type sequence is as follows (SEQ ID NO:7):

1 HGEGTFTSDL

SKQMEEEAVR

LFIEWLKNGG

PSSGAPPPS

[00050]

The proteins of the invention may comprise protein variants or mutants of the

wild-type proteins listed herein, e.g., FGF21 variants, GLP-1 variants, and/or Exendin-4
variants. As used herein, the terms "protein variant," "human variant," "polypeptide or
protein variant," "variant," "mutant," as well as any like terms or specific versions thereof
(e.g., "FGF21 protein variant," "human GLP-1 variant," "Exendin-4 polypeptide or protein

variant," "variant," "FGF21 mutant," etc.) define protein or polypeptide sequences that
comprise modifications, truncations, other variants of naturally occurring (i.e., wild-type)
protein or polypeptide counterparts or corresponding native sequences. "Variant
FGF21" or "FGF21 mutant," for instance, is described relative to the wild-type (i.e.,
naturally occurring) FGF21 protein as described herein.
Representative dual function protein sequences of the invention are listed in Table 1.
The descriptions of said agonists include the individual constituent agonists and, where
applicable a linker. If a variant is used as a constituent agonist, the changes or
substitutions made are numbered relative to their wild-type counterparts. By way of
example, "Dual Function 1- Protein" (SEQ ID NO:9) contains residues 7-35 of the wildtype GLP-1 sequence as described herein (i.e., a GLP-1 receptor agonist), a linker
sequence, and an FGF21 variant (i.e., an FGF21 receptor agonist) with a number of
listed changes to the FGF21 wild-type sequence (SEQ ID NO:1) as described herein.

Table 1. Dual Function Protein and Nucleotides of the invention
SEQ
ID

Variant
NO:

Sequence

V272

HSEGTFTSDV
SGGGGSGGGD
AQETEAHLEI
KALKPGVIQI
LHFDPEACSF
LHLPGNRSPH
LPEPPGILAP
SPSYAS

SSYLEGQAAK
SSPLLQFGGQ
REDGTVGGAA
LGVKTSRFLC
RELLLEDGYN
CDPAPQGPAR
QPPDVGSSDP

EFIAWLVKGG
VRQRYLYTDD
HQSPESLLEL
QKPDGALYGS
VYQSEAHGLP
FLPLPGLPPA
LAMVGPSQGR

CATTCTGAAG
TCTAGCTACC
GAATTCATCG
TCTGGTGGTG
AGCAGCCCGC
GTGCGTCAGC
GCGCAGGAAA
CGTGAAGATG
CATCAGAGCC
AAAGCGCTGA
CTGGGCGTGA
CAGAAACCGG
CTGCATTTTG
CGTGAACTGC
GTGTATCAGA
CTGCATCTGC
TGCGATCCGG
TTTCTGCCGC
CTGCCGGAAC
CAGCCGCCGG
CTGGCGATGG
AGCCCGAGCT
HGEGTFTSDL
SGGGGSGGGG
QVRQRYLYTD
AHQSPESLLE
CQKPDGALYG
NVYQSEAHGL
RFLPLPGLPP
PLAMVGPSQG
RSPSYAS

GCACTTTTAC
TGGAAGGCCA
CGTGGCTGGT
GTGGTTCTGG
TGCTGCAGTT
GTTATCTGTA
CCGAAGCGCA
GCACCGTGGG
CGGAAAGCCT
AACCGGGCGT
AAACCAGCCG
ATGGCGCGCT
ATCCGGAAGC
TGCTGGAAGA
GCGAAGCGCA
CGGGCAACCG
CACCGCAGGG
TGCCGGGTCT
CGCCGGGTAT
ATGTTGGTAG
TGGGTCCGAG
ATGCGAGCTA
SKQMEEEAVR
SGGGGSGGGG
DAQETEAHLE
LKALKPGVIQ
SLHFDPEACS
PLHLPGNRSP
ALPEPPGILA

TAGCGATGTT
GGCTGCGAAA
TAAAGGCGGT
CGGTGGCGAT
TGGCGGCCAG
TACCGATGAT
TCTGGAAATT
CGGTGCGGCG
GCTGGAACTG
GATTCAGATT
TTTTCTGTGC
GTATGGCAGC
GTGCAGCTTT
TGGCTATAAC
TGGCCTGCCG
TAGCCCGCAT
TCCGGCGCGT
GCCGCCGGCA
TCTGGCCCCG
CAGCGATCCG
CCAGGGTCGT
A
LFIEWLKNGG
DSSPLLQFGG
IREDGTVGGA
ILGVKTSRFL
FRELLLEDGY
HCDPAPQGPA
PQPPDVGSSD

Long Name

Short
Name

GLP-1 (735; A8S) GSGGGGSGGGFGF21 (33209;Q5 6ED74H-Q82ER105KK150RR154C-40
kDa
branched
PEG-R159QS195A)
GLP-1 (735; A8S) GSGGGGSGGGFGF21 (33209;Q5 6ED74H-Q82ER105KK150RR154CR159QS195A)

GLP1 (A8S) L10FGF21 (V
76) 4OKPEGb

Exendin4 (130) SGGGGSGGGGS
GGGGSGGGGFGF21 (33209;Q5 6ED74H-Q82ER105KK150RR154C-40
kDa
branched
PEG-R159QS195A)

Ex (130) L20FGF21 (V
76) 4OKPEGb

NO:

9

10

11

V 2 77

GLP1 (A8S) L10FGF21 (V
76)

CATGGTGAGG
TCTAAACAGA
CTGTTCATTG
TCTGGTGGTG
TCTGGCGGCG
GATAGCAGCC
CAGGTGCGTC
GATGCGCAGG
ATTCGTGAAG
GCGCATCAGA
CTGAAAGCGC
ATTCTGGGCG
TGCCAGAAAC
AGCCTGCATT
TTTCGTGAAC
AACGTGTATC
CCGCTGCATC
CATTGCGATC
CGTTTTCTGC
GCACTGCCGG
CCGCAGCCGC
CCGCTGGCGA
CGTAGCCCGA
CTAA
HSEGTFTSDV
SGDSSPLLQF
LEIREDGTVG
IQILGVKTSR
CSFRELLLED
SPHRDPAPRG
LAPQPPDVGS
CATTCTGAAG
TCTAGCTACC
GAATTCATCG
TCTGGTGATA
GGCGGCCAGG
ACCGAT GAT G
CTGGAAATTC
GGTGCGGCGG
CTGCAGCTGA
ATTCAGATTC
TTTCTGTGCC
TATGGCAGCC
TGCAGCTTTC
GGCTATAACG
GGCCTGCCGC
AGCCCGCATC
CCGGCGCGTT
CCGCCGGCAC
CTGGCCCCGC
AGCGATCCGC
CAGGGTCGTA

GTACGTTTAC
TGGAAGAAGA
AATGGCTGAA
GTGGTTCTGG
GTGGTAGCGG
CGCTGCTGCA
AGCGTTATCT
AAACCGAAGC
ATGGCACCGT
GCCCGGAAAG
TGAAACCGGG
TGAAAACCAG
CGGATGGCGC
TTGATCCGGA
TGCTGCTGGA
AGAGCGAAGC
TGCCGGGCAA
CGGCACCGCA
CGCTGCCGGG
AACCGCCGGG
CGGATGTTGG
TGGTGGGTCC
GCTATGCGAG

TTCTGATCTG
AGCTGTTCGC
AAATGGTGGT
CGGTGGCGGT
TGGCGGCGGT
GTTTGGCGGC
GTATACCGAT
GCATCTGGAA
GGGCGGTGCG
CCTGCTGGAA
CGTGATTCAG
CCGTTTTCTG
GCTGTATGGC
AGCGTGCAGC
AGATGGCTAT
GCATGGCCTG
CCGTAGCCCG
GGGTCCGGCG
TCTGCCGCCG
TATTCTGGCC
TAGCAGCGAT
GAGCCAGGGT

Exendin4 (130) SGGGGSGGGGS
GGGGSGGGGFGF21 (33209;Q5 6ED74H-Q82ER105KK150RR154CR159QS195A)

Ex (130) L20FGF21 (V

SSYLEGQAAK
GGQVRQRYLY
GAADQSPESL
FLCQRPDGAL
GYNVYQSEAH
PARFLPLPGL
SDPLSMVGPS
GCACTTTTAC
TGGAAGGCCA
CGTGGCTGGT
GCAGCCCGCT
TGCGTCAGCG
CGCAGCAGAC
GTGAAGATGG
ATCAGAGCCC
AAGCGCTGAA
TGGGCGTGAA
AGCGTCCGGA
TGCATTTTGA
GTGAACTGCT
TGTATCAGAG
TGCATCTGCC
GTGATCCGGC
TTCTGCCGCT
TGCCGGAACC
AGCCGCCGGA
TGTCTATGGT
GCCCGAGCTA

EFIAWLVKGG
TDDAQQTEAH
LQLKALKPGV
YGSLHFDPEA
GLPLHLPGNK
PPALPEPPGI
QGRSPSYAS
TAGCGATGTT
GGCTGCGAAA
TAAAGGCGGT
GCTGCAGTTT
TTATCTGTAT
CGAAGCGCAT
CACCGTGGGC
GGAAAGCCTG
ACCGGGCGTG
AACCAGCCGT
TGGCGCGCTG
TCCGGAAGCG
GCTGGAAGAT
CGAAGCGCAT
GGGCAACAAA
ACCGCGTGGT
GCCGGGTCTG
GCCGGGTATT
TGTTGGTAGC
GGGTCCGAGC
TGCGAGCTAA

GLP-1 (735; A8S) GSGFGF21 (33-

GLP1 (A8S) L3FGF21

76)

209)

GLP-1 (735; A8S) GSGFGF21 (33209)

GLP1 (A8S) L3FGF21

V219

V 2 95

HAEGTFTSDV
SGDSSPLLQF
LEIREDGTVG
IQILGVKTSR
CSFRELLLED
SPHRDPAPRG
LAPQPPDVGS
CATGCGGAAG
TCTAGCTACC
GAATTCATCG
TCTGGTGATA
GGCGGCCAGG
AC C GAT GAT G
CTGGAAATTC
GGTGCGGCGG
CTGCAGCTGA
ATTCAGATTC
TTTCTGTGCC
TATGGCAGCC
TGCAGCTTTC
GGCTATAACG
GGCCTGCCGC
AGCCCGCATC
CCGGCGCGTT
CCGCCGGCAC
CTGGCCCCGC
AGCGATCCGC
CAGGGTCGTA
HGEGTFTSDL
PSSGAPPPSG
TDDAQQTEAH
LQLKALKPGV
YGSLHFDPEA
GLPLHLPGNK
PPALPEPPGI
QGRSPSYAS
CATGGTGAGG
TCTAAACAGA
CTGTTCATTG
CCGTCCTCCG
GGTGGCGACT
GGCGGCCAGG
AC C GAT GAT G
CTGGAAATTC
GGTGCGGCGG
CTGCAGCTGA
ATTCAGATTC
TTTCTGTGCC
TATGGCAGCC
TGCAGCTTTC
GGCTATAACG
GGCCTGCCGC
AGCCCGCATC
CCGGCGCGTT
CCGCCGGCAC

SSYLEGQAAK EFIAWLVKGG
GGQVRQRYLY TDDAQQTEAH
GAADQSPESL LQLKALKPGV
FLCQRPDGAL YGSLHFDPEA
GYNVYQSEAH GLPLHLPGNK
PARFLPLPGL PPALPEPPGI
SDPLSMVGPS QGRSPSYAS
GCACTTTTAC TAGCGATGTT
TGGAAGGCCA GGCTGCGAAA
CGTGGCTGGT TAAAGGCGGT
GCAGCCCGCT GCTGCAGTTT
TGCGTCAGCG TTATCTGTAT
CGCAGCAGAC CGAAGCGCAT
GTGAAGATGG CACCGTGGGC
ATCAGAGCCC GGAAAGCCTG
AAGCGCTGAA ACCGGGCGTG
TGGGCGTGAA AACCAGCCGT
AGCGTCCGGA TGGCGCGCTG
TGCATTTTGA TCCGGAAGCG
GTGAACTGCT GCTGGAAGAT
TGTATCAGAG CGAAGCGCAT
TGCATCTGCC GGGCAACAAA
GTGATCCGGC ACCGCGTGGT
TTCTGCCGCT GCCGGGTCTG
TGCCGGAACC GCCGGGTATT
AGCCGCCGGA TGTTGGTAGC
TGTCTATGGT GGGTCCGAGC
GCCCGAGCTA TGCGAGCTAA
SKQMEEEAVR LFIEWLKNGG
GGDSSPLLQF GGQVRQRYLY
LEIREDGTVG GAADQSPESL
IQILGVKTSR FLCQRPDGAL
CSFRELLLED GYNVYQSEAH
SPHRDPAPRG PARFLPLPGL
LAPQPPDVGS SDPLSMVGPS
GTACGTTTAC
TGGAAGAAGA
AATGGCTGAA
GCGCTCCTCC
CGAGCCCGCT
TGCGTCAGCG
CGCAGCAGAC
GTGAAGATGG
ATCAGAGCCC
AAGCGCTGAA
TGGGCGTGAA
AGCGTCCGGA
TGCATTTTGA
GTGAACTGCT
TGTATCAGAG
TGCATCTGCC
GTGATCCGGC
TTCTGCCGCT
TGCCGGAACC

TTCTGATCTG
AGCTGTTCGC
AAATGGTGGT
GCCTTCTGGT
GCTGCAGTTT
TTATCTGTAT
CGAAGCGCAT
CACCGTGGGC
GGAAAGCCTG
ACCGGGCGTG
AACCAGCCGT
TGGCGCGCTG
TCCGGAAGCG
GCTGGAAGAT
CGAAGCGCAT
GGGCAACAAA
ACCGCGTGGT
GCCGGGTCTG
GCCGGGTATT

GLP-1 (735) -GSGFGF21 (33-

GLP-1L3FGF21

209)

GLP-1 (735) -GSGFGF21 (33-

GLP-1L3FGF21

209)

Exendin4 (139) -GGGFGF21 (33-

Ex (139) -L3FGF21

209)

Exendin4 (139) -GGGFGF21 (33209)

Ex (139) -L3FGF21

V 2 24

V223

CTGGCCCCGC
AGCGATCCGC
CAGGGTCGTA

AGCCGCCGGA
TGTCTATGGT
GCCCGAGCTA

TGTTGGTAGC
GGGTCCGAGC
TGCGAGCTAA

HSEGTFTSDV
SGGGGSGGGD
AQQTEAHLEI
KALKPGVIQI
LHFDPEACSF
LHLPGNKSPH
LPEPPGILAP
SPSYAS
CATTCTGAAG
TCTAGCTACC
GAATTCATCG
TCTGGTGGTG
TCGAGCCCGC
GTGCGTCAGC
GCGCAGCAGA
CGTGAAGATG
GATCAGAGCC
AAAGCGCTGA
CTGGGCGTGA
CAGCGTCCGG
CTGCATTTTG
CGTGAACTGC
GTGTATCAGA
CTGCATCTGC
CGTGATCCGG
TTTCTGCCGC
CTGCCGGAAC
CAGCCGCCGG
CTGTCTATGG
AGCCCGAGCT
HAEGTFTSDV
SGGGGSGGGD
AQQTEAHLEI
KALKPGVIQI
LHFDPEACSF
LHLPGNKSPH
LPEPPGILAP
SPSYAS
CATGCGGAAG
TCTAGCTACC
GAATTCATCG
TCTGGTGGTG
TCGAGCCCGC
GTGCGTCAGC
GCGCAGCAGA
CGTGAAGATG
GATCAGAGCC
AAAGCGCTGA
CTGGGCGTGA
CAGCGTCCGG
CTGCATTTTG

SSYLEGQAAK
SSPLLQFGGQ
REDGTVGGAA
LGVKTSRFLC
RELLLEDGYN
RDPAPRGPAR
QPPDVGSSDP

EFIAWLVKGG
VRQRYLYTDD
DQSPESLLQL
QRPDGALYGS
VYQSEAHGLP
FLPLPGLPPA
LSMVGPSQGR

GLP-1 (735; A8S) GSGGGGSGGGFGF21 (33-

GCACTTTTAC
TGGAAGGCCA
CGTGGCTGGT
GTGGTTCTGG
TGCTGCAGTT
GTTATCTGTA
CCGAAGCGCA
GCACCGTGGG
CGGAAAGCCT
AACCGGGCGT
AAACCAGCCG
ATGGCGCGCT
ATCCGGAAGC
TGCTGGAAGA
GCGAAGCGCA
CGGGCAACAA
CACCGCGTGG
TGCCGGGTCT
CGCCGGGTAT
ATGTTGGTAG
TGGGTCCGAG
ATGCGAGCTA
SSYLEGQAAK
SSPLLQFGGQ
REDGTVGGAA
LGVKTSRFLC
RELLLEDGYN
RDPAPRGPAR
QPPDVGSSDP

TAGCGATGTT
GGCTGCGAAA
TAAAGGCGGT
CGGTGGCGAC
TGGCGGCCAG
TACCGATGAT
TCTGGAAATT
CGGTGCGGCG
GCTGCAGCTG
GATTCAGATT
TTTTCTGTGC
GTATGGCAGC
GTGCAGCTTT
TGGCTATAAC
TGGCCTGCCG
AAGCCCGCAT
TCCGGCGCGT
GCCGCCGGCA
TCTGGCCCCG
CAGCGATCCG
CCAGGGTCGT
A
EFIAWLVKGG
VRQRYLYTDD
DQSPESLLQL
QRPDGALYGS
VYQSEAHGLP
FLPLPGLPPA
LSMVGPSQGR

GLP-1 (735; A8S) GSGGGGSGGGFGF21 (33-

GCACTTTTAC
TGGAAGGCCA
CGTGGCTGGT
GTGGTTCTGG
TGCTGCAGTT
GTTATCTGTA
CCGAAGCGCA
GCACCGTGGG
CGGAAAGCCT
AACCGGGCGT
AAACCAGCCG
ATGGCGCGCT
ATCCGGAAGC

TAGCGATGTT
GGCTGCGAAA
TAAAGGCGGT
CGGTGGCGAC
TGGCGGCCAG
TACCGATGAT
TCTGGAAATT
CGGTGCGGCG
GCTGCAGCTG
GATTCAGATT
TTTTCTGTGC
GTATGGCAGC
GTGCAGCTTT

GLP-1 (735) GSGGGGSGGGFGF21 (33-

GLP1 (A8S) L10FGF21

209)

GLP1 (A8S) L10FGF21

209)

GLP-1 (735) GSGGGGSGGGFGF21 (33-

GLP-1L10FGF21

209)

209)

GLP-1L10FGF21

V234

V193

CGTGAACTGC
GTGTATCAGA
CTGCATCTGC
CGTGATCCGG
TTTCTGCCGC
CTGCCGGAAC
CAGCCGCCGG
CTGTCTATGG
AGCCCGAGCT
HGEGTFTSDL
PSSGAPPPSG
QRYLYTDDAQ
SPESLLQLKA
PDGALYGSLH
QSEAHGLPLH
PLPGLPPALP
MVGPSQGRSP
SYAS
CATGGTGAGG
TCTAAACAGA
CTGTTCATTG
CCGTCCTCCG
GGTGGTGGTT
CCGCTGCTGC
CAGCGTTATC
CAGACCGAAG
GATGGCACCG
AGCCCGGAAA
CTGAAACCGG
GTGAAAACCA
CCGGATGGCG
TTTGATCCGG
CTGCTGCTGG
CAGAGCGAAG
CTGCCGGGCA
CCGGCACCGC
CCGCTGCCGG
GAACCGCCGG
CCGGATGTTG
ATGGTGGGTC
AGCTATGCGA
HSEGTFTSDV
SGGGGSGGGG
AAGGPSVFLF
VDVSHEDPEV
EQYNSTYRW
SNKALPAPIE
SREEMTKNQV
NGQPENNYKT
KSRWQQGNVF
SPGKGGGGSG
VRQRYLYTDD
DQSPESLLQL
QKPDGALYGS
VYQSEAHGLP

TGCTGGAAGA
GCGAAGCGCA
CGGGCAACAA
CACCGCGTGG
TGCCGGGTCT
CGCCGGGTAT
ATGTTGGTAG
TGGGTCCGAG
ATGCGAGCTA
SKQMEEEAVR
GGGSGGGDSS
QTEAHLEIRE
LKPGVIQILG
FDPEACSFRE
LPGNKSPHRD
EPPGILAPQP

TGGCTATAAC
TGGCCTGCCG
AAGCCCGCAT
TCCGGCGCGT
GCCGCCGGCA
TCTGGCCCCG
CAGCGATCCG
CCAGGGTCGT
A
LFIEWLKNGG
PLLQFGGQVR
DGTVGGAADQ
VKTSRFLCQR
LLLEDGYNVY
PAPRGPARFL
PDVGSSDPLS

GTACGTTTAC
TGGAAGAAGA
AATGGCTGAA
GCGCTCCTCC
CTGGCGGTGG
AGTTTGGCGG
TGTATACCGA
CGCATCTGGA
TGGGCGGTGC
GCCTGCTGCA
GCGTGATTCA
GCCGTTTTCT
CGCTGTATGG
AAGCGTGCAG
AAGATGGCTA
CGCATGGCCT
ACAAAAGCCC
GTGGTCCGGC
GTCTGCCGCC
GTATTCTGGC
GTAGCAGCGA
CGAGCCAGGG
GCTAA
SSYLEGQAAK
SGGGGSADKT
PPKPKDTLMI
KFNWYVDGVE
SVLTVLHQDW
KTISKAKGQP
SLTCLVKGFY
TPPVLDSDGS
SCSVMHEALH
GGGSGGGGSD
ACQTEAHLEI
KALKPGVIQI
LHFDPEACSF
LHLPCNRSPH

TTCTGATCTG
AGCTGTTCGC
AAATGGTGGT
GCCTTCTGGT
CGACTCGAGC
CCAGGTGCGT
TGATGCGCAG
AATTCGTGAA
GGCGGATCAG
GCTGAAAGCG
GATTCTGGGC
GTGCCAGCGT
CAGCCTGCAT
CTTTCGTGAA
TAACGTGTAT
GCCGCTGCAT
GCATCGTGAT
GCGTTTTCTG
GGCACTGCCG
CCCGCAGCCG
TCCGCTGTCT
TCGTAGCCCG

Exendin4
(1-39) GGGGSGGGFGF21 (33-

EFIAWLVKGG
HTCPPCPAPE
SRTPEVTCW
VHNAKTKPRE
LNGKEYKCKV
REPQVYTLPP
PSDIAVEWES
FFLYSKLTVD
NHYTQKSLSL
SSPLLQFGGQ
REDGTVGGAA
LGVKTSRFLC
RELLLEDGYN
RDPASRGPAR

GLP-1 (735; A8S) S (GGGGS) 3A Fc- (GGGGS) 3FGF21 (33209;Q55CR105KG148CK150RP158SS195AP199GG202A)

Exendin4
(1-39) GGGGSGGGFGF21 (33-

Ex (139) -L8FGF21

209)

Ex (139) -L8FGF21

209)

GLP1 (A8S) L17-FCL15FGF21 (V
103)

V194

V195

V 296

FLPLPGLPPA
LAMVGGSQAR

LPEPPGILAP
SPSYAS

QPPDVGSSDP

HSEGTFTSDV
SGGGGSGGGG
AAGGPSVFLF
VDVSHEDPEV
EQYNSTYRW
SNKALPAPIE
SREEMTKNQV
NGQPENNYKT
KSRWQQGNVF
SPGKGGGGSG
VRQRYLYTDD
DQSPESLLQL
QKPDGALYGS
VYQSEAHGLP
FLPLPGLPPA
LAMVGPSQAR
HSEGTFTSDV
SGGGGSGGGG
AAGGPSVFLF
VDVSHEDPEV
EQYNSTYRW
SNKALPAPIE
SREEMTKNQV
NGQPENNYKT
KSRWQQGNVF
SPGKGGGGSG
VRQRYLYTDD
DQSPESLLQL
QKPDGALYGS
VYQSEAHGLP
FLPLPGLPPA
LAMVGPSQAR
HGEGTFTSDV
SGGGGSGGGD
AQETEAHLEI
KALKPGVIQI
LHFDPEACSF
LHLPGNRSPH
LPEPPGILAP
SPSYAS

SSYLEGQAAK
SGGGGSADKT
PPKPKDTLMI
KFNWYVDGVE
SVLTVLHQDW
KTISKAKGQP
SLTCLVKGFY
TPPVLDSDGS
SCSVMHEALH
GGGSGGGGSD
ACQTEAHLEI
KALKPGVIQI
LHFDPEACSF
LHLPCNRSPH
LPEPPGILAP
SPSYES
SSYLEGQAAK
SGGGGSADKT
PPKPKDTLMI
KFNWYVDGVE
SVLTVLHQDW
KTISKAKGQP
SLTCLVKGFY
TPPVLDSDGS
SCSVMHEALH
GGGSGGGGSD
ACQTEAHLEI
KALKPGVIQI
LHFDPEACSF
LHLPCNRSPH
LPEPPGILAP
SPSYDS
SSYLEGQAAK
SSPLLQFGGQ
REDGTVGGAA
LGVKTSRFLC
RELLLEDGYN
CDPAPQGPAR
QPPDVGSSDP

EFIAWLVKGG
HTCPPCPAPE
SRTPEVTCW
VHNAKTKPRE
LNGKEYKCKV
REPQVYTLPP
PSDIAVEWES
FFLYSKLTVD
NHYTQKSLSL
SSPLLQFGGQ
REDGTVGGAA
LGVKTSRFLC
RELLLEDGYN
RDPASRGPAR
QPPDVGSSDP

GLP-1 (735; A8S) S (GGGGS) 3A Fc- (GGGGS) 3FGF21 (33209; Q55CR105KG148CK150RP158SS195AG202AA208E)

GLP1 (A8S) L17-FCL15FGF21 (V

EFIAWLVKGG
HTCPPCPAPE
SRTPEVTCW
VHNAKTKPRE
LNGKEYKCKV
REPQVYTLPP
PSDIAVEWES
FFLYSKLTVD
NHYTQKSLSL
SSPLLQFGGQ
REDGTVGGAA
LGVKTSRFLC
RELLLEDGYN
RDPASRGPAR
QPPDVGSSDP

GLP-1 (735; A8S) S (GGGGS) 3A Fc- (GGGGS) 3FGF21 (33209;Q55CR105KG148CP158SK150RS195AG202AA208D)

GLP1 (A8S) L17-FCL15FGF21 (V

EFIAWLVKGG
VRQRYLYTDD
HQSPESLLEL
QKPDGALYGS
VYQSEAHGLP
FLPLPGLPPA
LAMVGPSQGR

GLP1 (A8G) L10FGF21 (V
76) 4OKPEGb

CATGGTGAAG
TCTAGCTACC
GAATTCATCG
TCTGGTGGTG
AGCAGCCCGC
GTGCGTCAGC

GCACTTTTAC
TGGAAGGCCA
CGTGGCTGGT
GTGGTTCTGG
TGCTGCAGTT
GTTATCTGTA

TAGCGATGTT
GGCTGCGAAA
TAAAGGCGGT
CGGTGGCGAT
TGGCGGCCAG
TACCGATGAT

GLP-1 (735; A8G) GSGGGGSGGGFGF21 (33209;Q5 6ED74H-Q82ER105KK150RR154C-40
kDa
branched
PEG-R159QS195A)
GLP-1 (735; A8G) GSGGGGSGGGFGF21 (33209;Q5 6ED74H-Q82E-

194)

195)

GLP1 (A8G) L10FGF21 (V
76)

V294

GCGCAGGAAA
CGTGAAGATG
CATCAGAGCC
AAAGCGCTGA
CTGGGCGTGA
CAGAAACCGG
CTGCATTTTG
CGTGAACTGC
GTGTATCAGA
CTGCATCTGC
TGCGATCCGG
TTTCTGCCGC
CTGCCGGAAC
CAGCCGCCGG
CTGGCGATGG
AGCCCGAGCT
HSEGTFTSDV
SGGGGSGGGD
AQQTEAHLEI
KALKPGVIQI
LHFDPEACSF
LHLPGNKSPH
LPEPPGILAP
SPSYAS

CCGAAGCGCA
GCACCGTGGG
CGGAAAGCCT
AACCGGGCGT
AAACCAGCCG
ATGGCGCGCT
ATCCGGAAGC
TGCTGGAAGA
GCGAAGCGCA
CGGGCAACCG
CACCGCAGGG
TGCCGGGTCT
CGCCGGGTAT
ATGTTGGTAG
TGGGTCCGAG
ATGCGAGCTA
SSYLEGQAAK
SSPLLQFGGQ
REDGTVGGAA
LGVKTSRFLC
RELLLEDGYN
UDPAPRGPAR
QPPDVGSSDP

TCTGGAAATT
CGGTGCGGCG
GCTGGAACTG
GATTCAGATT
TTTTCTGTGC
GTATGGCAGC
GTGCAGCTTT
TGGCTATAAC
TGGCCTGCCG
TAGCCCGCAT
TCCGGCGCGT
GCCGCCGGCA
TCTGGCCCCG
CAGCGATCCG
CCAGGGTCGT
A
EFIAWLVKGG
VRQRYLYTDD
DQSPESLLQL
QRPDGALYGS
VYQSEAHGLP
FLPLPGLPPA
LSMVGPSQGR

GCACTTTTAC
TGGAAGGCCA
CGTGGCTGGT
GTGGTTCTGG
TGCTGCAGTT
GTTATCTGTA
CCGAAGCGCA
GCACCGTGGG
CGGAAAGCCT
AACCGGGCGT
AAACCAGCCG
ATGGCGCGCT
ATCCGGAAGC
TGCTGGAAGA
GCGAAGCGCA
CGGGCAACAA
CACCGCGTGG
TGCCGGGTCT
CGCCGGGTAT
ATGTTGGTAG
TGGGTCCGAG
ATGCGAGCTA
SKQMEEEAVR
GGGSGGGDSS
QTEAHLEIRE
LKPGVIQILG
FDPEACSFRE
LPGNKSPHUD
EPPGILAPQP
SYAS

TAGCGATGTT
GGCTGCGAAA
TAAAGGCGGT
CGGTGGCGAC
TGGCGGCCAG
TACCGATGAT
TCTGGAAATT
CGGTGCGGCG
GCTGCAGCTG
GATTCAGATT
TTTTCTGTGC
GTATGGCAGC
GTGCAGCTTT
TGGCTATAAC
TGGCCTGCCG
AAGCCCGCAT
TCCGGCGCGT
GCCGCCGGCA
TCTGGCCCCG
CAGCGATCCG
CCAGGGTCGT
A
LFIEWLKNGG
PLLQFGGQVR
DGTVGGAADQ
VKTSRFLCQR
LLLEDGYNVY
PAPRGPARFL
PDVGSSDPLS

R105KK150RR154CR159QS195A)

GLP-1 (735; A8S) GSGGGGSGGGFGF21 (3320 9 ;
R154Pcl-40
kDa
branched

GLP1 (A8S) L10FGF21154Pcl4OKPEGb

PEG)

V298

CATTCTGAAG
TCTAGCTACC
GAATTCATCG
TCTGGTGGTG
TCGAGCCCGC
GTGCGTCAGC
GCGCAGCAGA
CGTGAAGATG
GATCAGAGCC
AAAGCGCTGA
CTGGGCGTGA
CAGCGTCCGG
CTGCATTTTG
CGTGAACTGC
GTGTATCAGA
CTGCATCTGC
TAGGATCCGG
TTTCTGCCGC
CTGCCGGAAC
CAGCCGCCGG
CTGTCTATGG
AGCCCGAGCT
HGEGTFTSDL
PSSGAPPPSG
QRYLYTDDAQ
SPESLLQLKA
PDGALYGSLH
QSEAHGLPLH
PLPGLPPALP
MVGPSQGRSP

GLP-1 (735; A8S) GSGGGGSGGGFGF21 (33209;
R154TAG)

GLP1 (A8S) L10FGF21154TAG

Exendin4
(1-39) GGGGSGGGFGF21 (33209;
R154TAG) -40
kDa
branched

Ex (139) -L8FGF21 (1
54Pcl) 4OKPEGb

PEG

CATGGTGAGG
TCTAAACAGA
CTGTTCATTG
CCGTCCTCCG
GGTGGTGGTT
CCGCTGCTGC
CAGCGTTATC
CAGACCGAAG
GATGGCACCG
AGCCCGGAAA
CTGAAACCGG
GTGAAAACCA
CCGGATGGCG
TTTGATCCGG
CTGCTGCTGG
CAGAGCGAAG
CTGCCGGGCA
CCGGCACCGC
CCGCTGCCGG
GAACCGCCGG
CCGGATGTTG
ATGGTGGGTC
AGCTATGCGA
HSEGTFTSDV
SGGGGSGGGD
AQQTEAHLEI
KALKPGVIQI
LHFDPEACSF
LHLPGNKSPH
LPEPPGILAP
SPSYAS

GTACGTTTAC
TGGAAGAAGA
AATGGCTGAA
GCGCTCCTCC
CTGGCGGTGG
AGTTTGGCGG
TGTATACCGA
CGCATCTGGA
TGGGCGGTGC
GCCTGCTGCA
GCGTGATTCA
GCCGTTTTCT
CGCTGTATGG
AAGCGTGCAG
AAGATGGCTA
CGCATGGCCT
ACAAAAGCCC
GTGGTCCGGC
GTCTGCCGCC
GTATTCTGGC
GTAGCAGCGA
CGAGCCAGGG
GCTAA
SSYLEGQAAK
SSPLLQFGGQ
REDGTVGGAA
LGVKTSRFLC
RELLLEDGYN
CDPAPRGPAR
QPPDVGSSDP

TTCTGATCTG
AGCTGTTCGC
AAATGGTGGT
GCCTTCTGGT
CGACTCGAGC
CCAGGTGCGT
TGATGCGCAG
AATTCGTGAA
GGCGGATCAG
GCTGAAAGCG
GATTCTGGGC
GTGCCAGCGT
CAGCCTGCAT
CTTTCGTGAA
TAACGTGTAT
GCCGCTGCAT
GCATTAGGAT
GCGTTTTCTG
GGCACTGCCG
CCCGCAGCCG
TCCGCTGTCT
TCGTAGCCCG

Exendin4
(1-39) GGGGSGGGFGF21 (3320 9 ;
R154TAG)

Ex (139) -L8FGF21 (1
54TAG)

EFIAWLVKGG
VRQRYLYTDD
DQSPESLLQL
QRPDGALYGS
VYQSEAHGLP
FLPLPGLPPA
LSMVGPSQGR

GLP-1 (7-35;
A8S) GSGGGGSGGGFGF21 (33209;R154C40 kDa
branched
PEG)

GLP1 (A8S) L8FGF21 (1
54C) 4OKPEGb

CATTCTGAAG
TCTAGCTACC
GAATTCATCG
TCTGGTGGTG
TCGAGCCCGC
GTGCGTCAGC
GCGCAGCAGA
CGTGAAGATG
GATCAGAGCC
AAAGCGCTGA
CTGGGCGTGA
CAGCGTCCGG
CTGCATTTTG
CGTGAACTGC
GTGTATCAGA
CTGCATCTGC
TGCGATCCGG
TTTCTGCCGC
CTGCCGGAAC
CAGCCGCCGG
CTGTCTATGG
AGCCCGAGCT

GCACTTTTAC
TGGAAGGCCA
CGTGGCTGGT
GTGGTTCTGG
TGCTGCAGTT
GTTATCTGTA
CCGAAGCGCA
GCACCGTGGG
CGGAAAGCCT
AACCGGGCGT
AAACCAGCCG
ATGGCGCGCT
ATCCGGAAGC
TGCTGGAAGA
GCGAAGCGCA
CGGGCAACAA
CACCGCGTGG
TGCCGGGTCT
CGCCGGGTAT
ATGTTGGTAG
TGGGTCCGAG
ATGCGAGCTA

TAGCGATGTT
GGCTGCGAAA
TAAAGGCGGT
CGGTGGCGAC
TGGCGGCCAG
TACCGATGAT
TCTGGAAATT
CGGTGCGGCG
GCTGCAGCTG
GATTCAGATT
TTTTCTGTGC
GTATGGCAGC
GTGCAGCTTT
TGGCTATAAC
TGGCCTGCCG
AAGCCCGCAT
TCCGGCGCGT
GCCGCCGGCA
TCTGGCCCCG
CAGCGATCCG
CCAGGGTCGT
A

GLP-1 (7-35;
A8S) GSGGGGSGGGFGF21 (33209;R154C)

GLP1 (A8S) L8FGF21 (1

HAEGTFTSDV
SGGGGSGGGD
AQQTEAHLEI
KALKPGVIQI
LHFDPEACSF
LHLPGNKSPH
LPEPPGILAP
SPSYAS
CATGCGGAAG
TCTAGCTACC
GAATTCATCG
TCTGGTGGTG
TCGAGCCCGC
GTGCGTCAGC
GCGCAGCAGA
CGTGAAGATG
GATCAGAGCC
AAAGCGCTGA
CTGGGCGTGA
CAGCGTCCGG
CTGCATTTTG
CGTGAACTGC
GTGTATCAGA
CTGCATCTGC
TGCGATCCGG
TTTCTGCCGC
CTGCCGGAAC
CAGCCGCCGG
CTGTCTATGG
AGCCCGAGCT

SSYLEGQAAK
SSPLLQFGGQ
REDGTVGGAA
LGVKTSRFLC
RELLLEDGYN
CDPAPRGPAR
QPPDVGSSDP

EFIAWLVKGG
VRQRYLYTDD
DQSPESLLQL
QRPDGALYGS
VYQSEAHGLP
FLPLPGLPPA
LSMVGPSQGR

GLP-1 (735) GSGGGGSGGGFGF21 (33209;R154C40 kDa
branched

GLP-1L8FGF21 (1
54C) 4OKPEGb

GCACTTTTAC
TGGAAGGCCA
CGTGGCTGGT
GTGGTTCTGG
TGCTGCAGTT
GTTATCTGTA
CCGAAGCGCA
GCACCGTGGG
CGGAAAGCCT
AACCGGGCGT
AAACCAGCCG
ATGGCGCGCT
ATCCGGAAGC
TGCTGGAAGA
GCGAAGCGCA
CGGGCAACAA
CACCGCGTGG
TGCCGGGTCT
CGCCGGGTAT
ATGTTGGTAG
TGGGTCCGAG
ATGCGAGCTA

TAGCGATGTT
GGCTGCGAAA
TAAAGGCGGT
CGGTGGCGAC
TGGCGGCCAG
TACCGATGAT
TCTGGAAATT
CGGTGCGGCG
GCTGCAGCTG
GATTCAGATT
TTTTCTGTGC
GTATGGCAGC
GTGCAGCTTT
TGGCTATAAC
TGGCCTGCCG
AAGCCCGCAT
TCCGGCGCGT
GCCGCCGGCA
TCTGGCCCCG
CAGCGATCCG
CCAGGGTCGT
A

GLP-1 (735) GSGGGGSGGGFGF21 (33209;R154C)

54C)

PEG)

GLP-1L8FGF21 (1
54C)

V 299

V 271

HGEGTFTSDL
PSSGAPPPSG
QRYLYTDDAQ
SPESLLQLKA
PDGALYGSLH
QSEAHGLPLH
PLPGLPPALP
MVGPSQGRSP
CATGGTGAGG
TCTAAACAGA
CTGTTCATTG
CCGTCCTCCG
GGTGGTGGTT
CCGCTGCTGC
CAGCGTTATC
CAGACCGAAG
GATGGCACCG
AGCCCGGAAA
CTGAAACCGG
GTGAAAACCA
CCGGATGGCG
TTTGATCCGG
CTGCTGCTGG
CAGAGCGAAG
CTGCCGGGCA
CCGGCACCGC
CCGCTGCCGG
GAACCGCCGG
CCGGATGTTG
ATGGTGGGTC
AGCTATGCGA
HAPGTFTSDV
SGGGGSGGGD
AQQTEAHLEI
KALKPGVIQI
LHFDPEACSF
LHLPGNKSPH
LPEPPGILAP
SPSYAS
CATGCGCCGG
TCTAGCTACC
GAATTCATCG
TCTGGTGGTG
TCGAGCCCGC
GTGCGTCAGC
GCGCAGCAGA
CGTGAAGATG
GATCAGAGCC
AAAGCGCTGA
CTGGGCGTGA
CAGCGTCCGG
CTGCATTTTG
CGTGAACTGC
GTGTATCAGA
CTGCATCTGC

SKQMEEEAVR
GGGSGGGDSS
QTEAHLEIRE
LKPGVIQILG
FDPEACSFRE
LPGNKSPHCD
EPPGILAPQP
SYAS
GTACGTTTAC
TGGAAGAAGA
AATGGCTGAA
GCGCTCCTCC
CTGGCGGTGG
AGTTTGGCGG
TGTATACCGA
CGCATCTGGA
TGGGCGGTGC
GCCTGCTGCA
GCGTGATTCA
GCCGTTTTCT
CGCTGTATGG
AAGCGTGCAG
AAGATGGCTA
CGCATGGCCT
ACAAAAGCCC
GTGGTCCGGC
GTCTGCCGCC
GTATTCTGGC
GTAGCAGCGA
CGAGCCAGGG
GCTAA
SSYLEGQAAK
SSPLLQFGGQ
REDGTVGGAA
LGVKTSRFLC
RELLLEDGYN
CDPAPRGPAR
QPPDVGSSDP

LFIEWLKNGG
PLLQFGGQVR
DGTVGGAADQ
VKTSRFLCQR
LLLEDGYNVY
PAPRGPARFL
PDVGSSDPLS

Exendin4
(1-39) GGGGSGGGFGF21 (33209;R154C40 kDa
branched

TTCTGATCTG
AGCTGTTCGC
AAATGGTGGT
GCCTTCTGGT
CGACTCGAGC
CCAGGTGCGT
TGATGCGCAG
AATTCGTGAA
GGCGGATCAG
GCTGAAAGCG
GATTCTGGGC
GTGCCAGCGT
CAGCCTGCAT
CTTTCGTGAA
TAACGTGTAT
GCCGCTGCAT
GCATTGCGAT
GCGTTTTCTG
GGCACTGCCG
CCCGCAGCCG
TCCGCTGTCT
TCGTAGCCCG

Exendin4
(1-39) GGGGSGGGFGF21 (33209;R154C)

Ex (139) -L8FGF21

EFIAWLVKGG
VRQRYLYTDD
DQSPESLLQL
QRPDGALYGS
VYQSEAHGLP
FLPLPGLPPA
LSMVGPSQGR

GLP1 (E9P) L10FGF21 (1
54C) 4OKPEGb

GCACTTTTAC
TGGAAGGCCA
CGTGGCTGGT
GTGGTTCTGG
TGCTGCAGTT
GTTATCTGTA
CCGAAGCGCA
GCACCGTGGG
CGGAAAGCCT
AACCGGGCGT
AAACCAGCCG
ATGGCGCGCT
ATCCGGAAGC
TGCTGGAAGA
GCGAAGCGCA
CGGGCAACAA

TAGCGATGTT
GGCTGCGAAA
TAAAGGCGGT
CGGTGGCGAC
TGGCGGCCAG
TACCGATGAT
TCTGGAAATT
CGGTGCGGCG
GCTGCAGCTG
GATTCAGATT
TTTTCTGTGC
GTATGGCAGC
GTGCAGCTTT
TGGCTATAAC
TGGCCTGCCG
AAGCCCGCAT

GLP-1 (7-35;
E9P) GSGGGGSGGGFGF21 (33209;R154C40 kDa
branched
PEG)
GLP-1 (7-35;
E9P) GSGGGGSGGGFGF21 (33209;R154C)

Ex (139) -L8FGF21 (1
54C) 4OKPEGb

PEG)

(154C)

GLP1 (E9P) L10FGF21 (1
54C)

V251

V 2 65

TGCGATCCGG
TTTCTGCCGC
CTGCCGGAAC
CAGCCGCCGG
CTGTCTATGG
AGCCCGAGCT
GHAEGTFTSD
GSGGGGSGGG
DAQQTEAHLE
LKALKPGVIQ
SLHFDPEACS
PLHLPGNKSP
ALPEPPGILA
RSPSYAS
GGTCATGCGG
GTTTCTAGCT
AAAGAATTCA
GGTTCTGGTG
GACTCGAGCC
CAGGTGCGTC
GATGCGCAGC
ATTCGTGAAG
GCGGATCAGA
CTGAAAGCGC
ATTCTGGGCG
TGCCAGCGTC
AGCCTGCATT
TTTCGTGAAC
AACGTGTATC
CCGCTGCATC
CATTGCGATC
CGTTTTCTGC
GCACTGCCGG
CCGCAGCCGC
CCGCTGTCTA
CGTAGCCCGA
HSEGTFTADA
SGGGGSGGGD
AQQTEAHLEI
KALKPGVIQI
LHFDPEACSF
LHLPGNKSPH
LPEPPGILAP
SPSYAS

CACCGCGTGG
TGCCGGGTCT
CGCCGGGTAT
ATGTTGGTAG
TGGGTCCGAG
ATGCGAGCTA
VSSYLEGQAA
DSSPLLQFGG
IREDGTVGGA
ILGVKTSRFL
FRELLLEDGY
HCDPAPRGPA
PQPPDVGSSD

TCCGGCGCGT
GCCGCCGGCA
TCTGGCCCCG
CAGCGATCCG
CCAGGGTCGT
A
KEFIAWLVKG
QVRQRYLYTD
ADQSPESLLQ
CQRPDGALYG
NVYQSEAHGL
RFLPLPGLPP
PLSMVGPSQG

AAGGCACTTT
ACCTGGAAGG
TCGCGTGGCT
GTGGTGGTTC
CGCTGCTGCA
AGCGTTATCT
AGACCGAAGC
ATGGCACCGT
GCCCGGAAAG
TGAAACCGGG
TGAAAACCAG
CGGATGGCGC
TTGATCCGGA
TGCTGCTGGA
AGAGCGAAGC
TGCCGGGCAA
CGGCACCGCG
CGCTGCCGGG
AACCGCCGGG
CGGATGTTGG
TGGTGGGTCC
GCTATGCGAG
SSYLEGQAAK
SSPLLQFGGQ
REDGTVGGAA
LGVKTSRFLC
RELLLEDGYN
CDPAPRGPAR
QPPDVGSSDP

TACTAGCGAT
CCAGGCTGCG
GGTTAAAGGC
TGGCGGTGGC
GTTTGGCGGC
GTATACCGAT
GCATCTGGAA
GGGCGGTGCG
CCTGCTGCAG
CGTGATTCAG
CCGTTTTCTG
GCTGTATGGC
AGCGTGCAGC
AGATGGCTAT
GCATGGCCTG
CAAAAGCCCG
TGGTCCGGCG
TCTGCCGCCG
TATTCTGGCC
TAGCAGCGAT
GAGCCAGGGT
CTAA
EFIAWLVKGG
VRQRYLYTDD
DQSPESLLQL
QRPDGALYGS
VYQSEAHGLP
FLPLPGLPPA
LSMVGPSQGR

GLP-1 (6-35;
6G) GSGGGGSGGGFGF21 (33209;R154C40 kDa
branched

G-GLP1-LlOFGF21 (1
54C) 4OKPEGb

PEG)

GLP-1 (6-35;
6G) GSGGGGSGGGFGF21 (33-

G-GLP1-LlOFGF21 (1
54C)

209)

GLP-1 (7-35;
A8S-S14AV16A) GSGGGGSGGGFGF21 (33209;R154C40 kDa
branched

GLP1 (A8S;
14/16) L10FGF21 (1
54C) 4OKPEGb

PEG)

CATTCTGAAG
TCTAGCTACC
GAATTCATCG
TCTGGTGGTG
TCGAGCCCGC
GTGCGTCAGC
GCGCAGCAGA
CGTGAAGATG
GATCAGAGCC
AAAGCGCTGA

GCACTTTTAC
TGGAAGGCCA
CGTGGCTGGT
GTGGTTCTGG
TGCTGCAGTT
GTTATCTGTA
CCGAAGCGCA
GCACCGTGGG
CGGAAAGCCT
AACCGGGCGT

TGCTGATGCT
GGCTGCGAAA
TAAAGGCGGT
CGGTGGCGAC
TGGCGGCCAG
TACCGATGAT
TCTGGAAATT
CGGTGCGGCG
GCTGCAGCTG
GATTCAGATT

GLP-1 (7-35;
A8S-S14AV16A) GSGGGGSGGGFGF21 (33209;R154C)

GLP1 (A8S;
14/16) L10FGF21 (1
54C)

V 2 70

CTGGGCGTGA
CAGCGTCCGG
CTGCATTTTG
CGTGAACTGC
GTGTATCAGA
CTGCATCTGC
TGCGATCCGG
TTTCTGCCGC
CTGCCGGAAC
CAGCCGCCGG
CTGTCTATGG
AGCCCGAGCT
HSEGTFTSDA
SGGGGSGGGD
AQQTEAHLEI
KALKPGVIQI
LHFDPEACSF
LHLPGNKSPH
LPEPPGILAP
SPSYAS

AAACCAGCCG
ATGGCGCGCT
ATCCGGAAGC
TGCTGGAAGA
GCGAAGCGCA
CGGGCAACAA
CACCGCGTGG
TGCCGGGTCT
CGCCGGGTAT
ATGTTGGTAG
TGGGTCCGAG
ATGCGAGCTA
AAYLEGQAAK
SSPLLQFGGQ
REDGTVGGAA
LGVKTSRFLC
RELLLEDGYN
CDPAPRGPAR
QPPDVGSSDP

TTTTCTGTGC
GTATGGCAGC
GTGCAGCTTT
TGGCTATAAC
TGGCCTGCCG
AAGCCCGCAT
TCCGGCGCGT
GCCGCCGGCA
TCTGGCCCCG
CAGCGATCCG
CCAGGGTCGT
A
EFIAWLVKGG
VRQRYLYTDD
DQSPESLLQL
QRPDGALYGS
VYQSEAHGLP
FLPLPGLPPA
LSMVGPSQGR

GLP-1 (7-35;
A8S-V16AS17A-S18A) GSGGGGSGGGFGF21 (33209;R154C40 kDa
branched

GLP1 (A8S;
16/17/
18) L10FGF21 (1
54C) 4OKPEGb

PEG)

V266

CATTCTGAAG
GCTGCTTACC
GAATTCATCG
TCTGGTGGTG
TCGAGCCCGC
GTGCGTCAGC
GCGCAGCAGA
CGTGAAGATG
GATCAGAGCC
AAAGCGCTGA
CTGGGCGTGA
CAGCGTCCGG
CTGCATTTTG
CGTGAACTGC
GTGTATCAGA
CTGCATCTGC
TGCGATCCGG
TTTCTGCCGC
CTGCCGGAAC
CAGCCGCCGG
CTGTCTATGG
AGCCCGAGCT
HSEGTFTSDV
SGGGGSGGGD
AQQTEAHLEI
KALKPGVIQI
LHFDPEACSF
LHLPGNKSPH
LPEPPGILAP
SPSYAS

GCACTTTTAC
TGGAAGGCCA
CGTGGCTGGT
GTGGTTCTGG
TGCTGCAGTT
GTTATCTGTA
CCGAAGCGCA
GCACCGTGGG
CGGAAAGCCT
AACCGGGCGT
AAACCAGCCG
ATGGCGCGCT
ATCCGGAAGC
TGCTGGAAGA
GCGAAGCGCA
CGGGCAACAA
CACCGCGTGG
TGCCGGGTCT
CGCCGGGTAT
ATGTTGGTAG
TGGGTCCGAG
ATGCGAGCTA
SSYAE GAAAK
SSPLLQFGGQ
REDGTVGGAA
LGVKTSRFLC
RELLLEDGYN
CDPAPRGPAR
QPPDVGSSDP

TAGCGATGCT
GGCTGCGAAA
TAAAGGCGGT
CGGTGGCGAC
TGGCGGCCAG
TACCGATGAT
TCTGGAAATT
CGGTGCGGCG
GCTGCAGCTG
GATTCAGATT
TTTTCTGTGC
GTATGGCAGC
GTGCAGCTTT
TGGCTATAAC
TGGCCTGCCG
AAGCCCGCAT
TCCGGCGCGT
GCCGCCGGCA
TCTGGCCCCG
CAGCGATCCG
CCAGGGTCGT
A
EFIAWLVKGG
VRQRYLYTDD
DQSPESLLQL
QRPDGALYGS
VYQSEAHGLP
FLPLPGLPPA
LSMVGPSQGR

GLP-1 (7-35;
A8S-V16AS17A-S18A) GSGGGGSGGGFGF21 (33209;R154C)

GLP1 (A8S) 16/17/
18) L10FGF21 (1
54C)

GLP-1 (7-35;
A8S-L20AQ23A) GSGGGGSGGGFGF21 (33209;R154C40 kDa
branched
PEG)

GLP1 (A8S;
20/23) L10FGF21 (1
54C) 4OKPEGb

V300

V 2 62

CATTCTGAAG
TCTAGCTACG
GAATTCATCG
TCTGGTGGTG
TCGAGCCCGC
GTGCGTCAGC
GCGCAGCAGA
CGTGAAGATG
GATCAGAGCC
AAAGCGCTGA
CTGGGCGTGA
CAGCGTCCGG
CTGCATTTTG
CGTGAACTGC
GTGTATCAGA
CTGCATCTGC
TGCGATCCGG
TTTCTGCCGC
CTGCCGGAAC
CAGCCGCCGG
CTGTCTATGG
AGCCCGAGCT
HSEGTFTSDS
QQTEAHLEIR
ALKPGVIQIL
HFDPEACSFR
HLPGNKSPHC
PEPPGILAPQ
PSYAS

GCACTTTTAC
CTGAAGGCGC
CGTGGCTGGT
GTGGTTCTGG
TGCTGCAGTT
GTTATCTGTA
CCGAAGCGCA
GCACCGTGGG
CGGAAAGCCT
AACCGGGCGT
AAACCAGCCG
ATGGCGCGCT
ATCCGGAAGC
TGCTGGAAGA
GCGAAGCGCA
CGGGCAACAA
CACCGCGTGG
TGCCGGGTCT
CGCCGGGTAT
ATGTTGGTAG
TGGGTCCGAG
ATGCGAGCTA
SPLLQFGGQV
EDGTVGGAAD
GVKTSRFLCQ
ELLLEDGYNV
DPAPRGPARF
PPDVGSSDPL

TAGCGATGTT
TGCTGCGAAA
TAAAGGCGGT
CGGTGGCGAC
TGGCGGCCAG
TACCGATGAT
TCTGGAAATT
CGGTGCGGCG
GCTGCAGCTG
GATTCAGATT
TTTTCTGTGC
GTATGGCAGC
GTGCAGCTTT
TGGCTATAAC
TGGCCTGCCG
AAGCCCGCAT
TCCGGCGCGT
GCCGCCGGCA
TCTGGCCCCG
CAGCGATCCG
CCAGGGTCGT
A
RQRYLYTDDA
QSPESLLQLK
RPDGALYGSL
YQSEAHGLPL
LPLPGLPPAL
SMVGPSQGRS

GLP-1 (7-35;
A8S-L20AQ23A) GSGGGGSGGGFGF21 (33209;R154C)

GLP1 (A8S;
20/23) L10FGF21 (1

GLP-1 (7-14;
A8S) FGF21 (33209;R154C40 kDa
branched
PEG)

GLP1 (A8S;
7-14) L0FGF21 (1
54C) 4OKPEGb

CATTCTGAAG
AGCCCGCTGC
CGTCAGCGTT
CAGCAGACCG
GAAGATGGCA
CAGAGCCCGG
GCGCTGAAAC
GGCGTGAAAA
CGTCCGGATG
CATTTTGATC
GAACTGCTGC
TATCAGAGCG
CATCTGCCGG
GATCCGGCAC
CTGCCGCTGC
CCGGAACCGC
CCGCCGGATG
TCTATGGTGG
CCGAGCTATG
HSEGTFTSDV
QVRQRYLYTD
ADQSPESLLQ
CQRPDGALYG
NVYQSEAHGL
RFLPLPGLPP

GCACTTTTAC
TGCAGTTTGG
ATCTGTATAC
AAGCGCATCT
CCGTGGGCGG
AAAGCCTGCT
CGGGCGTGAT
CCAGCCGTTT
GCGCGCTGTA
CGGAAGCGTG
TGGAAGATGG
AAGCGCATGG
GCAACAAAAG
CGCGTGGTCC
CGGGTCTGCC
CGGGTATTCT
TTGGTAGCAG
GTCCGAGCCA
CGAGCTAA
SSGGGGSGGG
DAQQTEAHLE
LKALKPGVIQ
SLHFDPEACS
PLHLPGNKSP
ALPEPPGILA

TAGCGATAGC
CGGCCAGGTG
CGATGATGCG
GGAAATTCGT
TGCGGCGGAT
GCAGCTGAAA
TCAGATTCTG
TCTGTGCCAG
TGGCAGCCTG
CAGCTTTCGT
CTATAACGTG
CCTGCCGCTG
CCCGCATTGC
GGCGCGTTTT
GCCGGCACTG
GGCCCCGCAG
CGATCCGCTG
GGGTCGTAGC

GLP-1 (7-14;
A8S) FGF21 (33209;R154C)

GLP1 (A8S; 7
-14) LOFGF21 (1

DSSPLLQFGG
IREDGTVGGA
ILGVKTSRFL
FRELLLEDGY
HCDPAPRGPA
PQPPDVGSSD

GLP-1 (7-18;
A8S) GGGGSGGGFGF21 (33209;R154C40 kDa

54C)

54C)

GLP1 (A8S; 7
-18) L8FGF21 (1
54C) -

PLSMVGPSQG

RSPSYAS

branched

4OKPEGb

PEG)

CATTCTGAAG
TCTTCTGGTG
GACTCGAGCC
CAGGTGCGTC
GATGCGCAGC
ATTCGTGAAG
GCGGATCAGA
CTGAAAGCGC
ATTCTGGGCG
TGCCAGCGTC
AGCCTGCATT
TTTCGTGAAC
AACGTGTATC
CCGCTGCATC
CATTGCGATC
CGTTTTCTGC
GCACTGCCGG
CCGCAGCCGC
CCGCTGTCTA
CGTAGCCCGA
HSEGTFTSDV
QFGGQVRQRY
VGGAADQSPE
SRFLCQRPDG
EDGYNVYQSE
RGPARFLPLP
GSSDPLSMVG

GCACTTTTAC
GTGGTGGTTC
CGCTGCTGCA
AGCGTTATCT
AGACCGAAGC
ATGGCACCGT
GCCCGGAAAG
TGAAACCGGG
TGAAAACCAG
CGGATGGCGC
TTGATCCGGA
TGCTGCTGGA
AGAGCGAAGC
TGCCGGGCAA
CGGCACCGCG
CGCTGCCGGG
AACCGCCGGG
CGGATGTTGG
TGGTGGGTCC
GCTATGCGAG
SSYLESGGGG
LYTDDAQQTE
SLLQLKALKP
ALYGSLHFDP
AHGLPLHLPG
GLPPALPEPP
PSQGRSPSYA

TAGCGATGTT
TGGCGGTGGC
GTTTGGCGGC
GTATACCGAT
GCATCTGGAA
GGGCGGTGCG
CCTGCTGCAG
CGTGATTCAG
CCGTTTTCTG
GCTGTATGGC
AGCGTGCAGC
AGATGGCTAT
GCATGGCCTG
CAAAAGCCCG
TGGTCCGGCG
TCTGCCGCCG
TATTCTGGCC
TAGCAGCGAT
GAGCCAGGGT
CTAA
SGGGDSSPLL
AHLEIREDGT
GVIQILGVKT
EACSFRELLL
NKSPHCDPAP
GILAPQPPDV
S

CATTCTGAAG
TCTAGCTACC
TCTGGCGGTG
CAGTTTGGCG
CTGTATACCG
GCGCATCTGG
GTGGGCGGTG
AGCCTGCTGC
GGCGTGATTC
AGCCGTTTTC
GCGCTGTATG
GAAGCGTGCA
GAAGATGGCT
GCGCATGGCC
AACAAAAGCC
CGTGGTCCGG
GGTCTGCCGC
GGTATTCTGG
GGTAGCAGCG
CCGAGCCAGG
AGCTAA

GCACTTTTAC
TGGAATCTGG
GCGACTCGAG
GCCAGGTGCG
ATGATGCGCA
AAATTCGTGA
CGGCGGATCA
AGCTGAAAGC
AGATTCTGGG
TGTGCCAGCG
GCAGCCTGCA
GCTTTCGTGA
ATAACGTGTA
TGCCGCTGCA
CGCATTGCGA
CGCGTTTTCT
CGGCACTGCC
CCCCGCAGCC
ATCCGCTGTC
GTCGTAGCCC

TAGCGATGTT
TGGTGGTGGT
CCCGCTGCTG
TCAGCGTTAT
GCAGACCGAA
AGATGGCACC
GAGCCCGGAA
GCTGAAACCG
CGTGAAAACC
TCCGGATGGC
TTTTGATCCG
ACTGCTGCTG
TCAGAGCGAA
TCTGCCGGGC
TCCGGCACCG
GCCGCTGCCG
GGAACCGCCG
GCCGGATGTT
TATGGTGGGT
GAGCTATGCG

GLP-1 (7-18;
A8S) GGGGSGGGFGF21 (33209;R154C)

GLP1 (A8S; 7
-18) L8FGF21 (1
54C)

GLP-1 (7-21;
A8S) SGGGGSGGGFGF21 (33209;R154C40 kDa
branched
PEG)
GLP-1 (7-21;
A8S) SGGGGSGGGFGF21 (33209;R154C)

GLP1 (A8S; 7
-21) L9FGF21 (1
54C) 4OKPEGb
GLP1 (A8S; 7
-21) L9FGF21 (1
54C)

V 260

HSEGTFTSDV
GGDSSPLLQF
LEIREDGTVG
IQILGVKTSR
CSFRELLLED
SPHCDPAPRG
LAPQPPDVGS

SSYLEGQAAK
GGQVRQRYLY
GAADQSPESL
FLCQRPDGAL
GYNVYQSEAH
PARFLPLPGL
SDPLSMVGPS

EFISGGGGSG
TDDAQQTEAH
LQLKALKPGV
YGSLHFDPEA
GLPLHLPGNK
PPALPEPPGI
QGRSPSYAS

GLP-1 (7-29;
A8S) SGGGGSGGGFGF21 (33209;R154C40 kDa
branched

CATTCTGAAG
TCTAGCTACC
GAATTCATCT
GGTGGCGACT
GGCGGCCAGG
ACCGAT GAT G
CTGGAAATTC
GGTGCGGCGG
CTGCAGCTGA
ATTCAGATTC
TTTCTGTGCC
TATGGCAGCC
TGCAGCTTTC
GGCTATAACG
GGCCTGCCGC
AGCCCGCATT
CCGGCGCGTT
CCGCCGGCAC
CTGGCCCCGC
AGCGATCCGC
CAGGGTCGTA
HSEGTFTSDV
GSGGGDSSPL
EAHLEIREDG
PGVIQILGVK
PEACSFRELL
GNKSPHCDPA
PGILAPQPPD
AS
CATTCTGAAG
TCTAGCTACC
GAATTCATCG
GGTTCTGGCG
CTGCAGTTTG
TATCTGTATA
GAAGCGCATC
ACCGTGGGCG
GAAAGCCTGC
CCGGGCGTGA
ACCAGCCGTT
GGCGCGCTGT
CCGGAAGCGT
CTGGAAGATG
GAAGCGCATG
GGCAACAAAA
CCGCGTGGTC
CCGGGTCTGC

GCACTTTTAC
TGGAAGGCCA
CTGGTGGTGG
CGAGCCCGCT
TGCGTCAGCG
CGCAGCAGAC
GTGAAGATGG
ATCAGAGCCC
AAGCGCTGAA
TGGGCGTGAA
AGCGTCCGGA
TGCATTTTGA
GTGAACTGCT
TGTATCAGAG
TGCATCTGCC
GCGATCCGGC
TTCTGCCGCT
TGCCGGAACC
AGCCGCCGGA
TGTCTATGGT
GCCCGAGCTA
SSYLEGQAAK
LQFGGQVRQR
TVGGAADQSP
TSRFLCQRPD
LEDGYNVYQS
PRGPARFLPL
VGSSDPLSMV

TAGCGATGTT
GGCTGCGAAA
TGGTTCTGGC
GCTGCAGTTT
TTATCTGTAT
CGAAGCGCAT
CACCGTGGGC
GGAAAGCCTG
ACCGGGCGTG
AACCAGCCGT
TGGCGCGCTG
TCCGGAAGCG
GCTGGAAGAT
CGAAGCGCAT
GGGCAACAAA
ACCGCGTGGT
GCCGGGTCTG
GCCGGGTATT
TGTTGGTAGC
GGGTCCGAGC
TGCGAGCTAA
EFIAWLSGGG
YLYTDDAQQT
ESLLQLKALK
GALYGSLHFD
EAHGLPLHLP
PGLPPALPEP
GPSQGRSPSY

GLP-1 (7-29;
A8S) SGGGGSGGGFGF21 (33-

GCACTTTTAC
TGGAAGGCCA
CGTGGCTGTC
GTGGCGACTC
GCGGCCAGGT
CCGATGATGC
TGGAAATTCG
GTGCGGCGGA
TGCAGCTGAA
TTCAGATTCT
TTCTGTGCCA
ATGGCAGCCT
GCAGCTTTCG
GCTATAACGT
GCCTGCCGCT
GCCCGCATTG
CGGCGCGTTT
CGCCGGCACT

TAGCGATGTT
GGCTGCGAAA
TGGTGGTGGT
GAGCCCGCTG
GCGTCAGCGT
GCAGCAGACC
TGAAGATGGC
TCAGAGCCCG
AGCGCTGAAA
GGGCGTGAAA
GCGTCCGGAT
GCATTTTGAT
TGAACTGCTG
GTATCAGAGC
GCATCTGCCG
CGATCCGGCA
TCTGCCGCTG
GCCGGAACCG

GLP1 (A8S; 7
-29) L9FGF21 (1
54C) 4OKPEGb

PEG)

V259

209)

GLP1 (A8S; 7
-29) L9FGF21 (1
54C)

GLP-1 (7-32;
A8S) SGGGGSGGGFGF21 (33209;R154C40 kDa
branched
PEG)
GLP-1 (7-32;
A8S) SGGGGSGGGFGF21 (33209;R154C)

GLP1 (A8S; 7
-32) L9FGF21 (1
54C) 4OKPEGb
GLP1 (A8S; 7
-32) L9FGF21 (1
54C)

V 2 63

V269

CCGGGTATTC
GTTGGTAGCA
GGTCCGAGCC
GCGAGCTAA

TGGCCCCGCA
GCGATCCGCT
AGGGTCGTAG

GCCGCCGGAT
GTCTATGGTG
CCCGAGCTAT

HSEGTFTSDV
SGGGGSGGGD
AQQTEAHLEI
KALKPGVIQI
LHFDPEACSF
LHLPGNKSPH
LPEPPGILAP
SPSYAS
CATTCTGAAG
TGTAGCTACC
GAATTCATCG
TCTGGTGGTG
TCGAGCCCGC
GTGCGTCAGC
GCGCAGCAGA
CGTGAAGATG
GATCAGAGCC
AAAGCGCTGA
CTGGGCGTGA
CAGCGTCCGG
CTGCATTTTG
CGTGAACTGC
GTGTATCAGA
CTGCATCTGC
CGTGATCCGG
TTTCTGCCGC
CTGCCGGAAC
CAGCCGCCGG
CTGTCTATGG
AGCCCGAGCT
HSEGTFTSDV
SGGGGSGGGD
AQQTEAHLEI
KALKPGVIQI
LHFDPEACSF
LHLPGNKSPH
LPEPPGILAP
SPSYAS
CATTCTGAAG
TCTAGCTACC
GAATTCATCG
TCTGGTGGTG
TCGAGCCCGC
GTGCGTCAGC
GCGCAGCAGA
CGTGAAGATG
GATCAGAGCC
AAAGCGCTGA
CTGGGCGTGA
CAGCGTCCGG
CTGCATTTTG

CSYLEGQAAK
SSPLLQFGGQ
REDGTVGGAA
LGVKTSRFLC
RELLLEDGYN
RDPAPRGPAR
QPPDVGSSDP

EFIAWLVKGG
VRQRYLYTDD
DQSPESLLQL
QRPDGALYGS
VYQSEAHGLP
FLPLPGLPPA
LSMVGPSQGR

GCACTTTTAC
TGGAAGGCCA
CGTGGCTGGT
GTGGTTCTGG
TGCTGCAGTT
GTTATCTGTA
CCGAAGCGCA
GCACCGTGGG
CGGAAAGCCT
AACCGGGCGT
AAACCAGCCG
ATGGCGCGCT
ATCCGGAAGC
TGCTGGAAGA
GCGAAGCGCA
CGGGCAACAA
CACCGCGTGG
TGCCGGGTCT
CGCCGGGTAT
ATGTTGGTAG
TGGGTCCGAG
ATGCGAGCTA
SSYLEGCAAK
SSPLLQFGGQ
REDGTVGGAA
LGVKTSRFLC
RELLLEDGYN
RDPAPRGPAR
QPPDVGSSDP

TAGCGATGTT
GGCTGCGAAA
TAAAGGCGGT
CGGTGGCGAC
TGGCGGCCAG
TACCGATGAT
TCTGGAAATT
CGGTGCGGCG
GCTGCAGCTG
GATTCAGATT
TTTTCTGTGC
GTATGGCAGC
GTGCAGCTTT
TGGCTATAAC
TGGCCTGCCG
AAGCCCGCAT
TCCGGCGCGT
GCCGCCGGCA
TCTGGCCCCG
CAGCGATCCG
CCAGGGTCGT
A
EFIAWLVKGG
VRQRYLYTDD
DQSPESLLQL
QRPDGALYGS
VYQSEAHGLP
FLPLPGLPPA
LSMVGPSQGR

GLP-1 (7-35;
A8S-S17C) GSGGGGSGGGFGF21 (33-

GCACTTTTAC
TGGAAGGCTG
CGTGGCTGGT
GTGGTTCTGG
TGCTGCAGTT
GTTATCTGTA
CCGAAGCGCA
GCACCGTGGG
CGGAAAGCCT
AACCGGGCGT
AAACCAGCCG
ATGGCGCGCT
ATCCGGAAGC

TAGCGATGTT
TGCTGCGAAA
TAAAGGCGGT
CGGTGGCGAC
TGGCGGCCAG
TACCGATGAT
TCTGGAAATT
CGGTGCGGCG
GCTGCAGCTG
GATTCAGATT
TTTTCTGTGC
GTATGGCAGC
GTGCAGCTTT

GLP-1 (7-35;
A8S-Q23C) GSGGGGSGGGFGF21 (33-

GLP-1 (7-35;
A8S-S17C-40
kDa
branched
PEG) GSGGGGSGGGFGF21 (33-

GLP1 (A8SS17C) 4OKPEGb
-L10FGF21

209)

209)

GLP-1 (7-35;
A8S-Q23C-40
kDa
branched
PEG) GSGGGGSGGGFGF21 (33-

GLP1 (A8SS17C) L10FGF21

GLP1 (A8SQ23C) 4OKPEGb
-L10FGF21

209)

209)

GLP1 (A8SQ23C) L10FGF21

V243

V 264

CGTGAACTGC
GTGTATCAGA
CTGCATCTGC
CGTGATCCGG
TTTCTGCCGC
CTGCCGGAAC
CAGCCGCCGG
CTGTCTATGG
AGCCCGAGCT
HSEGTFTSDV
SGGGGSGGGD
AQQTEAHLEI
KALKPGVIQI
LHFDPEACSF
LHLPGNKSPH
LPEPPGILAP
SPSYAS
CATTCTGAAG
TCTAGCTACC
GAATTCATCG
TCTGGTGGTG
TCGAGCCCGC
GTGCGTCAGC
GCGCAGCAGA
CGTGAAGATG
GATCAGAGCC
AAAGCGCTGA
CTGGGCGTGA
CAGCGTCCGG
CTGCATTTTG
CGTGAACTGC
GTGTATCAGA
CTGCATCTGC
CGTGATCCGG
TTTCTGCCGC
CTGCCGGAAC
CAGCCGCCGG
CTGTCTATGG
AGCCCGAGCT
HSEGTFTSDV
SGGGGSGGGD
AQQTEAHLEI
KALKPGVIQI
LHFDPEACSF
LHLPGNKSPH
LPEPPGILAP
SPSYAS
CATTCTGAAG
TCTAGCTACC
TGTTTCATCG
TCTGGTGGTG
TCGAGCCCGC
GTGCGTCAGC
GCGCAGCAGA
CGTGAAGATG

TGCTGGAAGA
GCGAAGCGCA
CGGGCAACAA
CACCGCGTGG
TGCCGGGTCT
CGCCGGGTAT
ATGTTGGTAG
TGGGTCCGAG
ATGCGAGCTA
SSYLEGQAAC
SSPLLQFGGQ
REDGTVGGAA
LGVKTSRFLC
RELLLEDGYN
RDPAPRGPAR
QPPDVGSSDP

TGGCTATAAC
TGGCCTGCCG
AAGCCCGCAT
TCCGGCGCGT
GCCGCCGGCA
TCTGGCCCCG
CAGCGATCCG
CCAGGGTCGT
A
EFIAWLVKGG
VRQRYLYTDD
DQSPESLLQL
QRPDGALYGS
VYQSEAHGLP
FLPLPGLPPA
LSMVGPSQGR

GLP-1 (7-35;
A8S-K26C-40
kDa
branched
PEG) GSGGGGSGGGFGF21 (33-

GLP1 (A8SK26C) L10FGF214OKPEGb

209)

GCACTTTTAC
TGGAAGGCCA
CGTGGCTGGT
GTGGTTCTGG
TGCTGCAGTT
GTTATCTGTA
CCGAAGCGCA
GCACCGTGGG
CGGAAAGCCT
AACCGGGCGT
AAACCAGCCG
ATGGCGCGCT
ATCCGGAAGC
TGCTGGAAGA
GCGAAGCGCA
CGGGCAACAA
CACCGCGTGG
TGCCGGGTCT
CGCCGGGTAT
ATGTTGGTAG
TGGGTCCGAG
ATGCGAGCTA
SSYLEGQAAK
SSPLLQFGGQ
REDGTVGGAA
LGVKTSRFLC
RELLLEDGYN
RDPAPRGPAR
QPPDVGSSDP

TAGCGATGTT
GGCTGCGTGT
TAAAGGCGGT
CGGTGGCGAC
TGGCGGCCAG
TACCGATGAT
TCTGGAAATT
CGGTGCGGCG
GCTGCAGCTG
GATTCAGATT
TTTTCTGTGC
GTATGGCAGC
GTGCAGCTTT
TGGCTATAAC
TGGCCTGCCG
AAGCCCGCAT
TCCGGCGCGT
GCCGCCGGCA
TCTGGCCCCG
CAGCGATCCG
CCAGGGTCGT
A
CFIAWLVKGG
VRQRYLYTDD
DQSPESLLQL
QRPDGALYGS
VYQSEAHGLP
FLPLPGLPPA
LSMVGPSQGR

GLP-1 (7-35;
A8S-K26C) GSGGGGSGGGFGF21 (33-

GCACTTTTAC
TGGAAGGCCA
CGTGGCTGGT
GTGGTTCTGG
TGCTGCAGTT
GTTATCTGTA
CCGAAGCGCA
GCACCGTGGG

TAGCGATGTT
GGCTGCGAAA
TAAAGGCGGT
CGGTGGCGAC
TGGCGGCCAG
TACCGATGAT
TCTGGAAATT
CGGTGCGGCG

GLP-1 (7-35;
A8S-E27C) GSGGGGSGGGFGF21 (33-

209)

GLP-1 (7-35;
A8S-E27C-40
kDa
branched
PEG) GSGGGGSGGGFGF21 (33-

GLP1 (A8SK26C) L10FGF21

GLP1 (A8SE27C) 4OKPEGb
-L10FGF21

209)

209)

GLP1 (A8SE27C) L10FGF21

78

V 2 44

79

80

V250

GATCAGAGCC
AAAGCGCTGA
CTGGGCGTGA
CAGCGTCCGG
CTGCATTTTG
CGTGAACTGC
GTGTATCAGA
CTGCATCTGC
CGTGATCCGG
TTTCTGCCGC
CTGCCGGAAC
CAGCCGCCGG
CTGTCTATGG
AGCCCGAGCT
HSEGTFTSDV
SGGGGSGGGD
AQQTEAHLEI
KALKPGVIQI
LHFDPEACSF
LHLPGNKSPH
LPEPPGILAP
SPSYAS
CATTCTGAAG
TCTAGCTACC
GAATTCATCG
TCTGGTGGTG
TCGAGCCCGC
GTGCGTCAGC
GCGCAGCAGA
CGTGAAGATG
GATCAGAGCC
AAAGCGCTGA
CTGGGCGTGA
CAGCGTCCGG
CTGCATTTTG
CGTGAACTGC
GTGTATCAGA
CTGCATCTGC
CGTGATCCGG
TTTCTGCCGC
CTGCCGGAAC
CAGCCGCCGG
CTGTCTATGG
AGCCCGAGCT
HSEGTFTSDV
SGGGGCGGGD
AQQTEAHLEI
KALKPGVIQI
LHFDPEACSF
LHLPGNKSPH
LPEPPGILAP
SPSYAS

CGGAAAGCCT
AACCGGGCGT
AAACCAGCCG
ATGGCGCGCT
ATCCGGAAGC
TGCTGGAAGA
GCGAAGCGCA
CGGGCAACAA
CACCGCGTGG
TGCCGGGTCT
CGCCGGGTAT
ATGTTGGTAG
TGGGTCCGAG
ATGCGAGCTA
SSYLEGQAAK
SSPLLQFGGQ
REDGTVGGAA
LGVKTSRFLC
RELLLEDGYN
RDPAPRGPAR
QPPDVGSSDP

GCTGCAGCTG
GATTCAGATT
TTTTCTGTGC
GTATGGCAGC
GTGCAGCTTT
TGGCTATAAC
TGGCCTGCCG
AAGCCCGCAT
TCCGGCGCGT
GCCGCCGGCA
TCTGGCCCCG
CAGCGATCCG
CCAGGGTCGT
A
EFIAWLVCGG
VRQRYLYTDD
DQSPESLLQL
QRPDGALYGS
VYQSEAHGLP
FLPLPGLPPA
LSMVGPSQGR

GCACTTTTAC
TGGAAGGCCA
CGTGGCTGGT
GTGGTTCTGG
TGCTGCAGTT
GTTATCTGTA
CCGAAGCGCA
GCACCGTGGG
CGGAAAGCCT
AACCGGGCGT
AAACCAGCCG
ATGGCGCGCT
ATCCGGAAGC
TGCTGGAAGA
GCGAAGCGCA
CGGGCAACAA
CACCGCGTGG
TGCCGGGTCT
CGCCGGGTAT
ATGTTGGTAG
TGGGTCCGAG
ATGCGAGCTA
SSYLEGQAAK
SSPLLQFGGQ
REDGTVGGAA
LGVKTSRFLC
RELLLEDGYN
RDPAPRGPAR
QPPDVGSSDP

TAGCGATGTT
GGCTGCGAAA
TTGTGGCGGT
CGGTGGCGAC
TGGCGGCCAG
TACCGATGAT
TCTGGAAATT
CGGTGCGGCG
GCTGCAGCTG
GATTCAGATT
TTTTCTGTGC
GTATGGCAGC
GTGCAGCTTT
TGGCTATAAC
TGGCCTGCCG
AAGCCCGCAT
TCCGGCGCGT
GCCGCCGGCA
TCTGGCCCCG
CAGCGATCCG
CCAGGGTCGT
A
EFIAWLVKGG
VRQRYLYTDD
DQSPESLLQL
QRPDGALYGS
VYQSEAHGLP
FLPLPGLPPA
LSMVGPSQGR

GLP-1 (7-35;
A8S-K34C-40
kDa
branched
PEG) GSGGGGSGGGFGF21 (33-

GLP1 (A8SK34C) L10FGF214OKPEGb

209)

GLP-1 (7-35;
A8S-K34C) GSGGGGSGGGFGF21 (33209)

GLP-1 (7-35;
A8S) GSGGGGC (40
kDa
branched
PEG) GGGFGF21 (33209)

GLP1 (A8SK34C) L10FGF21

GLP1 (A8S) L10-CFGF2140
KPEGb

CATTCTGAAG
TCTAGCTACC
GAATTCATCG
TCTGGTGGTG
TCGAGCCCGC
GTGCGTCAGC
GCGCAGCAGA
CGTGAAGATG
GATCAGAGCC
AAAGCGCTGA
CTGGGCGTGA
CAGCGTCCGG
CTGCATTTTG
CGTGAACTGC
GTGTATCAGA
CTGCATCTGC
CGTGATCCGG
TTTCTGCCGC
CTGCCGGAAC
CAGCCGCCGG
CTGTCTATGG
AGCCCGAGCT
HAEGTFTSDV
SGGGGSGGGD
AQQTEAHLEI
KALKPGVIQI
LHFDPEACSF
LHLPGNKSPH
LPEPPGILAP
SPSYAS
CATGCGGAAG
TCTAGCTACC
GAATTCATCG
TCTGGTGGTG
TCGAGCCCGC
GTGCGTCAGC
GCGCAGCAGA
CGTGAAGATG
GATCAGAGCC
AAAGCGCTGA
CTGGGCGTGA
CAGCGTCCGG
CTGCATTTTG
CGTGAACTGC
GTGTATCAGA
CTGCATCTGC
CGTGATCCGG
TTTCTGCCGC
CTGCCGGAAC
CAGCCGCCGG
CTGTCTATGG
AGCCCGAGCT

GCACTTTTAC
TGGAAGGCCA
CGTGGCTGGT
GTGGTTGTGG
TGCTGCAGTT
GTTATCTGTA
CCGAAGCGCA
GCACCGTGGG
CGGAAAGCCT
AACCGGGCGT
AAACCAGCCG
ATGGCGCGCT
ATCCGGAAGC
TGCTGGAAGA
GCGAAGCGCA
CGGGCAACAA
CACCGCGTGG
TGCCGGGTCT
CGCCGGGTAT
ATGTTGGTAG
TGGGTCCGAG
ATGCGAGCTA
SSYLEGQAAC
SSPLLQFGGQ
REDGTVGGAA
LGVKTSRFLC
RELLLEDGYN
RDPAPRGPAR
QPPDVGSSDP

TAGCGATGTT
GGCTGCGAAA
TAAAGGCGGT
CGGTGGCGAC
TGGCGGCCAG
TACCGATGAT
TCTGGAAATT
CGGTGCGGCG
GCTGCAGCTG
GATTCAGATT
TTTTCTGTGC
GTATGGCAGC
GTGCAGCTTT
TGGCTATAAC
TGGCCTGCCG
AAGCCCGCAT
TCCGGCGCGT
GCCGCCGGCA
TCTGGCCCCG
CAGCGATCCG
CCAGGGTCGT
A
EFIAWLVKGG
VRQRYLYTDD
DQSPESLLQL
QRPDGALYGS
VYQSEAHGLP
FLPLPGLPPA
LSMVGPSQGR

GLP-1 (7-35;
A8S) GSGGGGCGGGFGF21 (33-

GCACTTTTAC
TGGAAGGCCA
CGTGGCTGGT
GTGGTTCTGG
TGCTGCAGTT
GTTATCTGTA
CCGAAGCGCA
GCACCGTGGG
CGGAAAGCCT
AACCGGGCGT
AAACCAGCCG
ATGGCGCGCT
ATCCGGAAGC
TGCTGGAAGA
GCGAAGCGCA
CGGGCAACAA
CACCGCGTGG
TGCCGGGTCT
CGCCGGGTAT
ATGTTGGTAG
TGGGTCCGAG
ATGCGAGCTA

TAGCGATGTT
GGCTGCGTGT
TAAAGGCGGT
CGGTGGCGAC
TGGCGGCCAG
TACCGATGAT
TCTGGAAATT
CGGTGCGGCG
GCTGCAGCTG
GATTCAGATT
TTTTCTGTGC
GTATGGCAGC
GTGCAGCTTT
TGGCTATAAC
TGGCCTGCCG
AAGCCCGCAT
TCCGGCGCGT
GCCGCCGGCA
TCTGGCCCCG
CAGCGATCCG
CCAGGGTCGT
A

GLP-1 (7-35;
K26C) GSGGGGSGGGFGF21 (33209)

GLP1 (A8S) L10-CFGF21

209)

GLP-1 (7-35;
K26C-40 kDa
branched
PEG) GSGGGGSGGGFGF21 (33-

GLP1 (K26C)
-L10FGF214OKPEGb

209)

GLP1 (K26C)
-L10FGF21

84

V2 1

85

86

87

V242

HAEGTFTSDV
SGGGGSGGGD
AQQTEAHLEI
KALKPGVIQI
LHFDPEACSF
LHLPGNKSPH
LPEPPGILAP
SPSYAS
CATGCGGAAG
TCTAGCTACC
GAATTCATCG
TCTGGTGGTG
TCGAGCCCGC
GTGCGTCAGC
GCGCAGCAGA
CGTGAAGATG
GATCAGAGCC
AAAGCGCTGA
CTGGGCGTGA
CAGCGTCCGG
CTGCATTTTG
CGTGAACTGC
GTGTATCAGA
CTGCATCTGC
CGTGATCCGG
TTTCTGCCGC
CTGCCGGAAC
CAGCCGCCGG
CTGTCTATGG
AGCCCGAGCT
HAEGTFTSDV
SGGGGCGGGD
AQQTEAHLEI
KALKPGVIQI
LHFDPEACSF
LHLPGNKSPH
LPEPPGILAP
SPSYAS
CATGCGGAAG
TCTAGCTACC
GAATTCATCG
TCTGGTGGTG
TCGAGCCCGC
GTGCGTCAGC
GCGCAGCAGA
CGTGAAGATG
GATCAGAGCC
AAAGCGCTGA
CTGGGCGTGA
CAGCGTCCGG
CTGCATTTTG
CGTGAACTGC
GTGTATCAGA
CTGCATCTGC
CGTGATCCGG

SSYLEGQAAK
SSPLLQFGGQ
REDGTVGGAA
LGVKTSRFLC
RELLLEDGYN
RDPAPRGPAR
QPPDVGSSDP

EFIAWLVCGG
VRQRYLYTDD
DQSPESLLQL
QRPDGALYGS
VYQSEAHGLP
FLPLPGLPPA
LSMVGPSQGR

GLP-1 (7-35;
K34C-40 kDa
branched
PEG) GSGGGGSGGGFGF21 (33-

GCACTTTTAC
TGGAAGGCCA
CGTGGCTGGT
GTGGTTCTGG
TGCTGCAGTT
GTTATCTGTA
CCGAAGCGCA
GCACCGTGGG
CGGAAAGCCT
AACCGGGCGT
AAACCAGCCG
ATGGCGCGCT
ATCCGGAAGC
TGCTGGAAGA
GCGAAGCGCA
CGGGCAACAA
CACCGCGTGG
TGCCGGGTCT
CGCCGGGTAT
ATGTTGGTAG
TGGGTCCGAG
ATGCGAGCTA
SSYLEGQAAK
SSPLLQFGGQ
REDGTVGGAA
LGVKTSRFLC
RELLLEDGYN
RDPAPRGPAR
QPPDVGSSDP

TAGCGATGTT
GGCTGCGAAA
TTGTGGCGGT
CGGTGGCGAC
TGGCGGCCAG
TACCGATGAT
TCTGGAAATT
CGGTGCGGCG
GCTGCAGCTG
GATTCAGATT
TTTTCTGTGC
GTATGGCAGC
GTGCAGCTTT
TGGCTATAAC
TGGCCTGCCG
AAGCCCGCAT
TCCGGCGCGT
GCCGCCGGCA
TCTGGCCCCG
CAGCGATCCG
CCAGGGTCGT
A
EFIAWLVKGG
VRQRYLYTDD
DQSPESLLQL
QRPDGALYGS
VYQSEAHGLP
FLPLPGLPPA
LSMVGPSQGR

GLP-1 (7-35;
K34C) GSGGGGSGGGFGF21 (33-

GCACTTTTAC
TGGAAGGCCA
CGTGGCTGGT
GTGGTTGTGG
TGCTGCAGTT
GTTATCTGTA
CCGAAGCGCA
GCACCGTGGG
CGGAAAGCCT
AACCGGGCGT
AAACCAGCCG
ATGGCGCGCT
ATCCGGAAGC
TGCTGGAAGA
GCGAAGCGCA
CGGGCAACAA
CACCGCGTGG

TAGCGATGTT
GGCTGCGAAA
TAAAGGCGGT
CGGTGGCGAC
TGGCGGCCAG
TACCGATGAT
TCTGGAAATT
CGGTGCGGCG
GCTGCAGCTG
GATTCAGATT
TTTTCTGTGC
GTATGGCAGC
GTGCAGCTTT
TGGCTATAAC
TGGCCTGCCG
AAGCCCGCAT
TCCGGCGCGT

GLP-1(K34C) L10FGF214OKPEGb

209)

GLP1 (K34C)
-L10FGF21

209)

GLP-1 (735) GSGGGGC (40
kDa
branched
PEG) GGGFGF21 (33-

GLP-1L10-CFGF214OKPEGb

209)

GLP-1 (735) GSGGGGCGGGFGF21 (33209)

GLP-1L10-CFGF21

V 267

V 268

TTTCTGCCGC
CTGCCGGAAC
CAGCCGCCGG
CTGTCTATGG
AGCCCGAGCT
HGEGTFTSDL
SGGGGSGGGD
AQQTEAHLEI
KALKPGVIQI
LHFDPEACSF
LHLPGNKSPH
LPEPPGILAP
SPSYAS
CATGGTGAGG
TCTAAACAGA
CTGTTCATTG
TCTGGTGGTG
TCGAGCCCGC
GTGCGTCAGC
GCGCAGCAGA
CGTGAAGATG
GATCAGAGCC
AAAGCGCTGA
CTGGGCGTGA
CAGCGTCCGG
CTGCATTTTG
CGTGAACTGC
GTGTATCAGA
CTGCATCTGC
TGCGATCCGG
TTTCTGCCGC
CTGCCGGAAC
CAGCCGCCGG
CTGTCTATGG
AGCCCGAGCT
HGEGTFTSDL
SGGGGSGGGD
AQQTEAHLEI
KALKPGVIQI
LHFDPEACSF
LHLPGNKSPH
LPEPPGILAP
SPSYAS

TGCCGGGTCT GCCGCCGGCA
CGCCGGGTAT TCTGGCCCCG
ATGTTGGTAG CAGCGATCCG
TGGGTCCGAG CCAGGGTCGT
ATGCGAGCTA A
SKQMEEEAVR LFIEWLKNGG
SSPLLQFGGQ VRQRYLYTDD
REDGTVGGAA DQSPESLLQL
LGVKTSRFLC QRPDGALYGS
RELLLEDGYN VYQSEAHGLP
CDPAPRGPAR FLPLPGLPPA
QPPDVGSSDP LSMVGPSQGR

CATGGTGAGG
TCTAAACAGA
CTGTTCATTG
TCTGGTGGTG
TCGAGCCCGC
GTGCGTCAGC
GCGCAGCAGA
CGTGAAGATG
GATCAGAGCC
AAAGCGCTGA
CTGGGCGTGA

GTACGTTTAC
TGGAAGGGCA
AATGGCTGAA
GTGGTTCTGG
TGCTGCAGTT
GTTATCTGTA
CCGAAGCGCA
GCACCGTGGG
CGGAAAGCCT
AACCGGGCGT
AAACCAGCCG

Exendin4 (130) SGGGGSGGGFGF21 (33209;R154C40 kDa
branched

Ex (130) -L9FGF21 (1
54C) 4OKPEGb

PEG)

GTACGTTTAC TTCTGATCTG
TGGAAGAAGA AGCTGTTCGC
AATGGCTGAA AAATGGTGGT
GTGGTTCTGG CGGTGGCGAC
TGCTGCAGTT TGGCGGCCAG
GTTATCTGTA TACCGATGAT
CCGAAGCGCA TCTGGAAATT
GCACCGTGGG CGGTGCGGCG
CGGAAAGCCT GCTGCAGCTG
AACCGGGCGT GATTCAGATT
AAACCAGCCG TTTTCTGTGC
ATGGCGCGCT GTATGGCAGC
ATCCGGAAGC GTGCAGCTTT
TGCTGGAAGA TGGCTATAAC
GCGAAGCGCA TGGCCTGCCG
CGGGCAACAA AAGCCCGCAT
CACCGCGTGG TCCGGCGCGT
TGCCGGGTCT GCCGCCGGCA
CGCCGGGTAT TCTGGCCCCG
ATGTTGGTAG CAGCGATCCG
TGGGTCCGAG CCAGGGTCGT
ATGCGAGCTA A
SKQMEGQAVR LFIEWLKNGG
SSPLLQFGGQ VRQRYLYTDD
REDGTVGGAA DQSPESLLQL
LGVKTSRFLC QRPDGALYGS
RELLLEDGYN VYQSEAHGLP
CDPAPRGPAR FLPLPGLPPA
QPPDVGSSDP LSMVGPSQGR

Exendin4 (130) SGGGGSGGGFGF21 (33209;R154C)

Ex (130) -L9FGF21 (1

Exendin4 (130;E16GE17Q) SGGGGSGGGFGF21 (33209;R154C40 kDa
branched

Ex (130;GQ )L9FGF21 (1
54C) 4OKPEGb

54C)

PEG)

TTCTGATCTG
AGCTGTTCGC
AAATGGTGGT
CGGTGGCGAC
TGGCGGCCAG
TACCGATGAT
TCTGGAAATT
CGGTGCGGCG
GCTGCAGCTG
GATTCAGATT
TTTTCTGTGC

Exendin4 (130;E16GE17Q) SGGGGSGGGFGF21 (33209;R154C)

Ex (130;GQ )L9FGF21 (1
54C)

V301

V302

CAGCGTCCGG
CTGCATTTTG
CGTGAACTGC
GTGTATCAGA
CTGCATCTGC
TGCGATCCGG
TTTCTGCCGC
CTGCCGGAAC
CAGCCGCCGG
CTGTCTATGG
AGCCCGAGCT
HSEGTFTSDV
SGGGGSGGGD
AQQTEAHLEI
KALKPGVIQI
LHFDPEACSF
LHLPGNKSPH
LPEPPGILAP
SPSYAS
CATTCTGAAG
TCTAGCTACC
GAATTCATCG
TCTGGTGGTG
TCGAGCCCGC
GTGCGTCAGC
GCGCAGCAGA
CGTGAAGATG
GATCAGAGCC
AAAGCGCTGA
CTGGGCGTGA
CAGCGTCCGG
CTGCATTTTG
CGTGAACTGC
GTGTATCAGA
CTGCATCTGC
TAGGATCCGG
TTTCTGCCGC
CTGCCGGAAC
CAGCCGCCGG
CTGTCTATGG
AGCCCGAGCT
HAEGTFTSDV
SGGGGSGGGD
AQQTEAHLEI
KALKPGVIQI
LHFDPEACSF
LHLPGNKSPH
LPEPPGILAP
SPSYAS
CATGCGGAAG
TCTAGCTACC
GAATTCATCG
TCTGGTGGTG
TCGAGCCCGC
GTGCGTCAGC

ATGGCGCGCT
ATCCGGAAGC
TGCTGGAAGA
GCGAAGCGCA
CGGGCAACAA
CACCGCGTGG
TGCCGGGTCT
CGCCGGGTAT
ATGTTGGTAG
TGGGTCCGAG
ATGCGAGCTA
SSYLEGQAAK
SSPLLQFGGQ
REDGTVGGAA
LGVKTSRFLC
RELLLEDGYN
UDPAPRGPAR
QPPDVGSSDP

GTATGGCAGC
GTGCAGCTTT
TGGCTATAAC
TGGCCTGCCG
AAGCCCGCAT
TCCGGCGCGT
GCCGCCGGCA
TCTGGCCCCG
CAGCGATCCG
CCAGGGTCGT
A
EFIAWLVCGG
VRQRYLYTDD
DQSPESLLQL
QRPDGALYGS
VYQSEAHGLP
FLPLPGLPPA
LSMVGPSQGR

GCACTTTTAC
TGGAAGGCCA
CGTGGCTGGT
GTGGTTCTGG
TGCTGCAGTT
GTTATCTGTA
CCGAAGCGCA
GCACCGTGGG
CGGAAAGCCT
AACCGGGCGT
AAACCAGCCG
ATGGCGCGCT
ATCCGGAAGC
TGCTGGAAGA
GCGAAGCGCA
CGGGCAACAA
CACCGCGTGG
TGCCGGGTCT
CGCCGGGTAT
ATGTTGGTAG
TGGGTCCGAG
ATGCGAGCTA
SSYLEGQAAK
SSPLLQFGGQ
REDGTVGGAA
LGVKTSRFLC
RELLLEDGYN
UDPAPRGPAR
QPPDVGSSDP
GCACTTTTAC
TGGAAGGCCA
CGTGGCTGGT
GTGGTTCTGG
TGCTGCAGTT
GTTATCTGTA

GLP-1 (7-35;
A8S-K34C) GSGGGGSGGGFGF21 (33209;R154Pcl
)

GLP1 (A8SK34C) FGF21 (1
54Pcl) -

TAGCGATGTT
GGCTGCGAAA
TTGTGGCGGT
CGGTGGCGAC
TGGCGGCCAG
TACCGATGAT
TCTGGAAATT
CGGTGCGGCG
GCTGCAGCTG
GATTCAGATT
TTTTCTGTGC
GTATGGCAGC
GTGCAGCTTT
TGGCTATAAC
TGGCCTGCCG
AAGCCCGCAT
TCCGGCGCGT
GCCGCCGGCA
TCTGGCCCCG
CAGCGATCCG
CCAGGGTCGT
A
EFIAWLVCGG
VRQRYLYTDD
DQSPESLLQL
QRPDGALYGS
VYQSEAHGLP
FLPLPGLPPA
LSMVGPSQGR

GLP-1 (7-35;
A8S-K34C) GSGGGGSGGGFGF21 (33209;R154TAG
)

GLP1 (A8SK34C) L10FGF21 (1
54TAG)

GLP-1 (7-35;
K34C) GSGGGGSGGGFGF21 (33209;R154Pcl
)

GLP1 (K34C)
-L10FGF21 (1
54Pcl)

TAGCGATGTT
GGCTGCGAAA
TTGTGGCGGT
CGGTGGCGAC
TGGCGGCCAG
TACCGATGAT

GLP-1 (7-35;
K34C) GSGGGGSGGGFGF21 (33209;R154TAG
)

GLP1 (K34C)
-L10FGF21 (1
54TAG)

96

V303

97

98

V 281

GCGCAGCAGA
CGTGAAGATG
GATCAGAGCC
AAAGCGCTGA
CTGGGCGTGA
CAGCGTCCGG
CTGCATTTTG
CGTGAACTGC
GTGTATCAGA
CTGCATCTGC
TAGGATCCGG
TTTCTGCCGC
CTGCCGGAAC
CAGCCGCCGG
CTGTCTATGG
AGCCCGAGCT
HSEGTFTSDV
SGGGGSGGGD
AQQTEAHLEI
KALKPGVIQI
LHFDPEACSF
LHLPGNKSPH
LPEPPGILAP
SPSYAS
CATTCTGAAG
TCTAGCTACC
GAATTCATCG
TCTGGTGGTG
TCGAGCCCGC
GTGCGTCAGC
GCGCAGCAGA
CGTGAAGATG
GATCAGAGCC
AAAGCGCTGA
CTGGGCGTGA
CAGCGTCCGG
CTGCATTTTG
CGTGAACTGC
GTGTATCAGA
CTGCATCTGC
TGCGATCCGG
TTTCTGCCGC
CTGCCGGAAC
CAGCCGCCGG
CTGTCTATGG
AGCCCGAGCT
HSEGTFTSDV
SGGGGSGGGD
AQETEAHLEI
KALKPGVIQI
LHFDPEACSF
LHLPGNRSPH
LPEPPGILAP
SPSYAS

CCGAAGCGCA
GCACCGTGGG
CGGAAAGCCT
AACCGGGCGT
AAACCAGCCG
ATGGCGCGCT
ATCCGGAAGC
TGCTGGAAGA
GCGAAGCGCA
CGGGCAACAA
CACCGCGTGG
TGCCGGGTCT
CGCCGGGTAT
ATGTTGGTAG
TGGGTCCGAG
ATGCGAGCTA
SSYLEGQAAK
SSPLLQFGGQ
REDGTVGGAA
LGVKTSRFLC
RELLLEDGYN
CDPAPRGPAR
QPPDVGSSDP

TCTGGAAATT
CGGTGCGGCG
GCTGCAGCTG
GATTCAGATT
TTTTCTGTGC
GTATGGCAGC
GTGCAGCTTT
TGGCTATAAC
TGGCCTGCCG
AAGCCCGCAT
TCCGGCGCGT
GCCGCCGGCA
TCTGGCCCCG
CAGCGATCCG
CCAGGGTCGT
A
EFIAWLVUGG
VRQRYLYTDD
DQSPESLLQL
QRPDGALYGS
VYQSEAHGLP
FLPLPGLPPA
LSMVGPSQGR

GCACTTTTAC
TGGAAGGCCA
CGTGGCTGGT
GTGGTTCTGG
TGCTGCAGTT
GTTATCTGTA
CCGAAGCGCA
GCACCGTGGG
CGGAAAGCCT
AACCGGGCGT
AAACCAGCCG
ATGGCGCGCT
ATCCGGAAGC
TGCTGGAAGA
GCGAAGCGCA
CGGGCAACAA
CACCGCGTGG
TGCCGGGTCT
CGCCGGGTAT
ATGTTGGTAG
TGGGTCCGAG
ATGCGAGCTA
SSYLEGQAAK
SSPLLQFGGQ
REDGTVGGAA
LGVKTSRFLC
RELLLEDGYN
RDPAPQGPAR
QPPDVGSSDP

TAGCGATGTT
GGCTGCGAAA
TTAGGGCGGT
CGGTGGCGAC
TGGCGGCCAG
TACCGATGAT
TCTGGAAATT
CGGTGCGGCG
GCTGCAGCTG
GATTCAGATT
TTTTCTGTGC
GTATGGCAGC
GTGCAGCTTT
TGGCTATAAC
TGGCCTGCCG
AAGCCCGCAT
TCCGGCGCGT
GCCGCCGGCA
TCTGGCCCCG
CAGCGATCCG
CCAGGGTCGT
A
EFIAWLVKGG
VRQRYLYTDD
HQSPESLLEL
QKPDGALYGS
VYQSEAHGLP
FLPLPGLPPA
LAMVGPSQGR

GLP-1 (7-35;
A8SK34Pcl) GSGGGGSGGGFGF21 (33209;R154C)

GLP1 (A8SK34Pcl)
-L10FGF21 (1

GLP-1 (7-35;
A8SK34TAG) GSGGGGSGGGFGF21 (33209;R154C)

GLP1 (A8SK34TAG)
-L10FGF21 (1

GLP-1 (735; A8S) GSGGGGSGGGFGF21 (33209;Q5 6ED74H-Q82ER105KK150RR159Q-

GLP1 (A8S) L10FGF21 (V
76154R)

54C)

54C)

S195A)

99

100

101

V304

CATTCTGAAG
TCTAGCTACC
GAATTCATCG
TCTGGTGGTG
TCGAGCCCGC
GTGCGTCAGC
GCGCAGGAAA
CGTGAAGATG
CATCAGAGCC
AAAGCGCTGA
CTGGGCGTGA
CAGAAACCGG
CTGCATTTTG
CGTGAACTGC
GTGTATCAGA
CTGCATCTGC
CGTGATCCGG
TTTCTGCCGC
CTGCCGGAAC
CAGCCGCCGG
CTGGCGATGG
AGCCCGAGCT
HSEGTFTSDV
SGGGGSGGGD
AQETEAHLEI
KALKPGVIQI
LHFDPEACSF
LHLPGNRSPH
LPEPPGILAP
SPSYAS

GCACTTTTAC
TGGAAGGCCA
CGTGGCTGGT
GTGGTTCTGG
TGCTGCAGTT
GTTATCTGTA
CCGAAGCGCA
GCACCGTGGG
CGGAAAGCCT
AACCGGGCGT
AAACCAGCCG
ATGGCGCGCT
ATCCGGAAGC
TGCTGGAAGA
GCGAAGCGCA
CGGGCAACCG
CACCGCAGGG
TGCCGGGTCT
CGCCGGGTAT
ATGTTGGTAG
TGGGTCCGAG
ATGCGAGCTA
SSYLEGQAAK
SSPLLQFGGQ
REDGTVGGAA
LGVKTSRFLC
RELLLEEGYN
RDPAPQGPAR
QPPDVGSSDP

TAGCGATGTT
GGCTGCGAAA
TAAAGGCGGT
CGGTGGCGAC
TGGCGGCCAG
TACCGATGAT
TCTGGAAATT
CGGTGCGGCG
GCTGGAACTG
GATTCAGATT
TTTTCTGTGC
GTATGGCAGC
GTGCAGCTTT
TGGCTATAAC
TGGCCTGCCG
TAGCCCGCAT
TCCGGCGCGT
GCCGCCGGCA
TCTGGCCCCG
CAGCGATCCG
CCAGGGTCGT
A
EFIAWLVKGG
VRQRYLYTDD
HQSPESLLEL
QKPDGALYGS
VYQSEAHGLP
FLPLPGLPPA
LAMVGPSQGR

CATTCTGAAG
TCTAGCTACC
GAATTCATCG
TCTGGTGGTG
TCGAGCCCGC
GTGCGTCAGC
GCGCAGGAAA
CGTGAAGATG
CATCAGAGCC
AAAGCGCTGA
CTGGGCGTGA
CAGAAACCGG
CTGCATTTTG
CGTGAACTGC
GTGTATCAGA
CTGCATCTGC
CGTGATCCGG
TTTCTGCCGC

GCACTTTTAC
TGGAAGGCCA
CGTGGCTGGT
GTGGTTCTGG
TGCTGCAGTT
GTTATCTGTA
CCGAAGCGCA
GCACCGTGGG
CGGAAAGCCT
AACCGGGCGT
AAACCAGCCG
ATGGCGCGCT
ATCCGGAAGC
TGCTGGAAGA
GCGAAGCGCA
CGGGCAACCG
CACCGCAGGG
TGCCGGGTCT

TAGCGATGTT
GGCTGCGAAA
TAAAGGCGGT
CGGTGGCGAC
TGGCGGCCAG
TACCGATGAT
TCTGGAAATT
CGGTGCGGCG
GCTGGAACTG
GATTCAGATT
TTTTCTGTGC
GTATGGCAGC
GTGCAGCTTT
AGGCTATAAC
TGGCCTGCCG
TAGCCCGCAT
TCCGGCGCGT
GCCGCCGGCA

GLP-1 (735; A8S) GSGGGGSGGGFGF21 (33209;Q5 6ED74H-Q82ER105KK150RR159QS195A)

GLP1 (A8S) L10FGF21 (V
76154R)

GLP-1 (735; A8S) GSGGGGSGGGFGF21 (33209;Q5 6ED74H-Q82ER105KD130EK150RR159QS195A)
GLP-1 (735; A8S) GSGGGGSGGGFGF21 (33209;Q5 6ED74H-Q82ER105KD130EK150RR159QS195A)

GLP1 (A8S) L10FGF21 (V
76154R130E)

GLP1 (A8S) L10FGF21 (V
76154R130E)

V273

V305

CTGCCGGAAC
CAGCCGCCGG
CTGGCGATGG
AGCCCGAGCT

CGCCGGGTAT
ATGTTGGTAG
TGGGTCCGAG
ATGCGAGCTA

TCTGGCCCCG
CAGCGATCCG
CCAGGGTCGT
A

HSEGTFTSDV
SGGGGSGGGD
AQETEAHLEI
KALKPGVIQI
LHFDPEACSF
LHLPGNRSPH
LPEPPGILAP
SPSYAS

SSYLEGQAAK
SSPLLQFGGQ
REDGTVGGAA
LGVKTSRFLC
RELLLEEGYN
RDPAPQGPAR
QPPDVGSSDP

EFIAWLVCGG
VRQRYLYTDD
HQSPESLLEL
QKPDGALYGS
VYQSEAHGLP
FLPLPGLPPA
LAMVGPSQGR

CATTCTGAAG
TCTAGCTACC
GAATTCATCG
TCTGGTGGTG
TCGAGCCCGC
GTGCGTCAGC
GCGCAGGAAA
CGTGAAGATG
CATCAGAGCC
AAAGCGCTGA
CTGGGCGTGA
CAGAAACCGG
CTGCATTTTG
CGTGAACTGC
GTGTATCAGA
CTGCATCTGC
CGTGATCCGG
TTTCTGCCGC
CTGCCGGAAC
CAGCCGCCGG
CTGGCGATGG
AGCCCGAGCT
HSEGTFTSDV
SGGGGSGGGD
AQETEAHLEI
KALKPGVIQI
LHFDPEACSF
LHLPGNRSPH
LPEPPGILAP
SPSYAS

GCACTTTTAC
TGGAAGGCCA
CGTGGCTGGT
GTGGTTCTGG
TGCTGCAGTT
GTTATCTGTA
CCGAAGCGCA
GCACCGTGGG
CGGAAAGCCT
AACCGGGCGT
AAACCAGCCG
ATGGCGCGCT
ATCCGGAAGC
TGCTGGAAGA
GCGAAGCGCA
CGGGCAACCG
CACCGCAGGG
TGCCGGGTCT
CGCCGGGTAT
ATGTTGGTAG
TGGGTCCGAG
ATGCGAGCTA
SSYLEGQAAK
SSPLLQFGGQ
REDGTVGGAA
LGVKTSRFLC
RELLLEDGYN
RDPAPQGPAR
QPPDVGSSDP

TAGCGATGTT
GGCTGCGAAA
TTGTGGCGGT
CGGTGGCGAC
TGGCGGCCAG
TACCGATGAT
TCTGGAAATT
CGGTGCGGCG
GCTGGAACTG
GATTCAGATT
TTTTCTGTGC
GTATGGCAGC
GTGCAGCTTT
AGGCTATAAC
TGGCCTGCCG
TAGCCCGCAT
TCCGGCGCGT
GCCGCCGGCA
TCTGGCCCCG
CAGCGATCCG
CCAGGGTCGT
A
EFIAWLVCGG
VRQRYLYTDD
HQSPESLLEL
QKPDGALYGS
VYQSEAHGLP
FLPLPGLPPA
LAMVGPSQAR

GLP-1 (735; A8SK34C-40 kDa
branched
PEG) GSGGGGSGGGFGF21 (3320 9;Q5 6ED74H-Q82ER105KD130EK150RR159QS195A)
GLP-1 (735; A8SK34C) GSGGGGSGGGFGF21 (33209;Q5 6ED74H-Q82ER105KD130EK150RR159QS195A)

GLP1 (A8SK34C) L10FGF21 (V
76154R) 4OKPEGb

GLP-1 (735; A8SK34C-40 kDa
branched
PEG) GSGGGGSGGGFGF21 (33209;Q5 6ED74H-Q82ER105KK150RR159QS195AG202A)

GLP1 (A8SK34C) L10FGF21 (V
76154R202A) 4OKPEGb

GLP1 (A8SK34C) L10FGF21 (V
76154R)

CATTCTGAAG
TCTAGCTACC
GAATTCATCG
TCTGGTGGTG
TCGAGCCCGC
GTGCGTCAGC
GCGCAGGAAA
CGTGAAGATG
CATCAGAGCC
AAAGCGCTGA
CTGGGCGTGA
CAGAAACCGG
CTGCATTTTG
CGTGAACTGC
GTGTATCAGA
CTGCATCTGC
CGTGATCCGG
TTTCTGCCGC
CTGCCGGAAC
CAGCCGCCGG
CTGGCGATGG
AGCCCGAGCT
HGEGTFTSDL
SGGGGSGGGD
AQETEAHLEI
KALKPGVIQI
LHFDPEACSF
LHLPGNRSPH
LPEPPGILAP
SPSYAS

GCACTTTTAC
TGGAAGGCCA
CGTGGCTGGT
GTGGTTCTGG
TGCTGCAGTT
GTTATCTGTA
CCGAAGCGCA
GCACCGTGGG
CGGAAAGCCT
AACCGGGCGT
AAACCAGCCG
ATGGCGCGCT
ATCCGGAAGC
TGCTGGAAGA
GCGAAGCGCA
CGGGCAACCG
CACCGCAGGG
TGCCGGGTCT
CGCCGGGTAT
ATGTTGGTAG
TGGGTCCGAG
ATGCGAGCTA
SKQMEEEAVR
SSPLLQFGGQ
REDGTVGGAA
LGVKTSRFLC
RELLLEEGYN
RDPAPQGPAR
QPPDVGSSDP

TAGCGATGTT
GGCTGCGAAA
TTGTGGCGGT
CGGTGGCGAC
TGGCGGCCAG
TACCGATGAT
TCTGGAAATT
CGGTGCGGCG
GCTGGAACTG
GATTCAGATT
TTTTCTGTGC
GTATGGCAGC
GTGCAGCTTT
TGGCTATAAC
TGGCCTGCCG
TAGCCCGCAT
TCCGGCGCGT
GCCGCCGGCA
TCTGGCCCCG
CAGCGATCCG
CCAGGCGCGT
A
LFIEWLKNGG
VRQRYLYTDD
HQSPESLLEL
QKPDGALYGS
VYQSEAHGLP
FLPLPGLPPA
LAMVGPSQGR

CATGGTGAGG
TCTAAACAGA
CTGTTCATTG
TCTGGTGGTG
TCGAGCCCGC
GTGCGTCAGC
GCGCAGGAAA
CGTGAAGATG
CATCAGAGCC
AAAGCGCTGA
CTGGGCGTGA
CAGAAACCGG
CTGCATTTTG
CGTGAACTGC
GTGTATCAGA
CTGCATCTGC
CGTGATCCGG
TTTCTGCCGC
CTGCCGGAAC
CAGCCGCCGG
CTGGCGATGG
AGCCCGAGCT

GTACGTTTAC
TGGAAGAAGA
AATGGCTGAA
GTGGTTCTGG
TGCTGCAGTT
GTTATCTGTA
CCGAAGCGCA
GCACCGTGGG
CGGAAAGCCT
AACCGGGCGT
AAACCAGCCG
ATGGCGCGCT
ATCCGGAAGC
TGCTGGAAGA
GCGAAGCGCA
CGGGCAACCG
CACCGCAGGG
TGCCGGGTCT
CGCCGGGTAT
ATGTTGGTAG
TGGGTCCGAG
ATGCGAGCTA

TTCTGATCTG
AGCTGTTCGC
AAATGGTGGT
CGGTGGCGAC
TGGCGGCCAG
TACCGATGAT
TCTGGAAATT
CGGTGCGGCG
GCTGGAACTG
GATTCAGATT
TTTTCTGTGC
GTATGGCAGC
GTGCAGCTTT
AGGCTATAAC
TGGCCTGCCG
TAGCCCGCAT
TCCGGCGCGT
GCCGCCGGCA
TCTGGCCCCG
CAGCGATCCG
CCAGGGTCGT
A

GLP-1 (735; A8SK34C) GSGGGGSGGGFGF21 (3320 9;Q5 6ED74H-Q82ER105KK150RR159QS195AG202A)

GLP1 (A8SK34C) L10FGF21 (V
76154R-

Exendin4 (130) SGGGGSGGGFGF21 (3320 9;Q5 6ED74H-Q82ER105KD130EK150RR159QS195A)
Exendin4 (130) SGGGGSGGGFGF21 (3320 9;Q5 6ED74H-Q82ER105KD130EK150RR159QS195A)

Ex (130) -L9FGF21 (V
76-

202A)

154R)

Ex (130) -L9FGF21 (V
76154R)

V 2 74

V307

HGEGTFTSDL
SGGGGSGGGD
AQETEAHLEI
KALKPGVIQI
LHFDPEACSF
LHLPGNRSPH
LPEPPGILAP
SPSYAS

SKQMEEEAVR
SSPLLQFGGQ
REDGTVGGAA
LGVKTSRFLC
RELLLEEGYN
RDPAPQGPAR
QPPDVGSSDP

LFIEWLCNGG
VRQRYLYTDD
HQSPESLLEL
QKPDGALYGS
VYQSEAHGLP
FLPLPGLPPA
LAMVGPSQGR

CATGGTGAGG
TCTAAACAGA
CTGTTCATTG
TCTGGTGGTG
TCGAGCCCGC
GTGCGTCAGC
GCGCAGGAAA
CGTGAAGATG
CATCAGAGCC
AAAGCGCTGA
CTGGGCGTGA
CAGAAACCGG
CTGCATTTTG
CGTGAACTGC
GTGTATCAGA
CTGCATCTGC
CGTGATCCGG
TTTCTGCCGC
CTGCCGGAAC
CAGCCGCCGG
CTGGCGATGG
AGCCCGAGCT
HGEGTFTSDL
SGGGGSGGGD
AQETEAHLEI
KALKPGVIQI
LHFDPEACSF
LHLPGNRSPH
LPEPPGILAP
SPSYAS

GTACGTTTAC
TGGAAGAAGA
AATGGCTGTG
GTGGTTCTGG
TGCTGCAGTT
GTTATCTGTA
CCGAAGCGCA
GCACCGTGGG
CGGAAAGCCT
AACCGGGCGT
AAACCAGCCG
ATGGCGCGCT
ATCCGGAAGC
TGCTGGAAGA
GCGAAGCGCA
CGGGCAACCG
CACCGCAGGG
TGCCGGGTCT
CGCCGGGTAT
ATGTTGGTAG
TGGGTCCGAG
ATGCGAGCTA
SKQMEEEAVR
SSPLLQFGGQ
REDGTVGGAA
LGVKTSRFLC
RELLLEEGYN
RDPAPQGPAR
QPPDVGSSDP

TTCTGATCTG
AGCTGTTCGC
TAATGGTGGT
CGGTGGCGAC
TGGCGGCCAG
TACCGATGAT
TCTGGAAATT
CGGTGCGGCG
GCTGGAACTG
GATTCAGATT
TTTTCTGTGC
GTATGGCAGC
GTGCAGCTTT
AGGCTATAAC
TGGCCTGCCG
TAGCCCGCAT
TCCGGCGCGT
GCCGCCGGCA
TCTGGCCCCG
CAGCGATCCG
CCAGGGTCGT
A
LFIEWLKCGG
VRQRYLYTDD
HQSPESLLEL
QKPDGALYGS
VYQSEAHGLP
FLPLPGLPPA
LAMVGPSQGR

CATGGTGAGG
TCTAAACAGA
CTGTTCATTG
TCTGGTGGTG
TCGAGCCCGC

GTACGTTTAC
TGGAAGAAGA
AATGGCTGAA
GTGGTTCTGG
TGCTGCAGTT

TTCTGATCTG
AGCTGTTCGC
ATGTGGTGGT
CGGTGGCGAC
TGGCGGCCAG

Exendin4 (130;K27C-40
kDa
branched
PEG) SGGGGSGGGFGF21 (3320 9;Q5 6ED74H-Q82ER105KD130EK150RR159QS195A)
Exendin4 (130;K2 7C) SGGGGSGGGFGF21 (3320 9;Q5 6ED74H-Q82ER105KD130EK150RR159QS195A)

Ex (130;K2 7C
)-L9FGF21 (V
76154R130E) 4OKPEGb

Exendin4 (130;N28C-40
kDa
branched
PEG) SGGGGSGGGFGF21 (3320 9;Q5 6ED74H-Q82ER105KD130EK150RR159QS195A)
Exendin4 (130;N2 8C) SGGGGSGGGFGF21 (3320 9;Q5 6E-

Ex (130;N2 8C
) -L9FGF21 (V
76154R130E) 4OKPEGb

Ex (130;K2 7C
)-L9FGF21 (V
76154R130E)

Ex (130;N2 8C
)-L9FGF21 (V
76-

GTGCGTCAGC
GCGCAGGAAA
CGTGAAGATG
CATCAGAGCC
AAAGCGCTGA
CTGGGCGTGA
CAGAAACCGG
CTGCATTTTG
CGTGAACTGC
GTGTATCAGA
CTGCATCTGC
CGTGATCCGG
TTTCTGCCGC
CTGCCGGAAC
CAGCCGCCGG
CTGGCGATGG
AGCCCGAGCT
HGEGTFTSDL
SGGGGSGGGD
AQETEAHLEI
KALKPGVIQI
LHFDPEACSF
LHLPGNRSPH
LPEPPGILAP
SPSYAS

GTTATCTGTA TACCGATGAT
CCGAAGCGCA TCTGGAAATT
GCACCGTGGG CGGTGCGGCG
CGGAAAGCCT GCTGGAACTG
AACCGGGCGT GATTCAGATT
AAACCAGCCG TTTTCTGTGC
ATGGCGCGCT GTATGGCAGC
ATCCGGAAGC GTGCAGCTTT
TGCTGGAAGA AGGCTATAAC
GCGAAGCGCA TGGCCTGCCG
CGGGCAACCG TAGCCCGCAT
CACCGCAGGG TCCGGCGCGT
TGCCGGGTCT GCCGCCGGCA
CGCCGGGTAT TCTGGCCCCG
ATGTTGGTAG CAGCGATCCG
TGGGTCCGAG CCAGGGTCGT
ATGCGAGCTA A
SKQMEEEAVR LFIEWLCNGG
SSPLLQFGGQ VRQRYLYTDD
REDGTVGGAA HQSPESLLEL
LGVKTSRFLC QKPDGALYGS
RELLLEDGYN VYQSEAHGLP
RDPAPQGPAR FLPLPGLPPA
QPPDVGSSDP LAMVGPSQAR

CATGGTGAGG
TCTAAACAGA
CTGTTCATTG
TCTGGTGGTG
TCGAGCCCGC
GTGCGTCAGC
GCGCAGGAAA
CGTGAAGATG
CATCAGAGCC
AAAGCGCTGA
CTGGGCGTGA
CAGAAACCGG
CTGCATTTTG
CGTGAACTGC
GTGTATCAGA
CTGCATCTGC
CGTGATCCGG
TTTCTGCCGC
CTGCCGGAAC
CAGCCGCCGG
CTGGCGATGG
AGCCCGAGCT

GTACGTTTAC
TGGAAGAAGA
AATGGCTGTG
GTGGTTCTGG
TGCTGCAGTT
GTTATCTGTA
CCGAAGCGCA
GCACCGTGGG
CGGAAAGCCT
AACCGGGCGT
AAACCAGCCG
ATGGCGCGCT
ATCCGGAAGC
TGCTGGAAGA
GCGAAGCGCA
CGGGCAACCG
CACCGCAGGG
TGCCGGGTCT
CGCCGGGTAT
ATGTTGGTAG
TGGGTCCGAG
ATGCGAGCTA

TTCTGATCTG
AGCTGTTCGC
TAATGGTGGT
CGGTGGCGAC
TGGCGGCCAG
TACCGATGAT
TCTGGAAATT
CGGTGCGGCG
GCTGGAACTG
GATTCAGATT
TTTTCTGTGC
GTATGGCAGC
GTGCAGCTTT
TGGCTATAAC
TGGCCTGCCG
TAGCCCGCAT
TCCGGCGCGT
GCCGCCGGCA
TCTGGCCCCG
CAGCGATCCG
CCAGGCGCGT
A

D74H-Q82ER105KD130EK150RR159QS195A)

154R-

Exendin4 (130;K27C-40
kDa
branched
PEG) SGGGGSGGGFGF21 (3320 9;Q5 6ED74H-Q82ER105KK150RR159QS195AG202A)
Exendin4 (130;K2 7C) SGGGGSGGGFGF21 (3320 9;Q5 6ED74H-Q82ER105KK150RR159QS195AG202A)

Ex (130;K2 7C
)--L9FGF21 (V
76154R202A) 4OKPEGb

130E)

Ex (130;K2 7C
)-L9FGF21 (V
76154R202A)

116

V309

117

118

119

V 2 76

HGEGTFTSDL
SGGGGSGGGD
AQETEAHLEI
KALKPGVIQI
LHFDPEACSF
LHLPGNRSPH
LPEPPGILAP
SPSYAS

SKQMEEEAVR
SSPLLQFGGQ
REDGTVGGAA
LGVKTSRFLC
RELLLEDGYN
RDPAPQGPAR
QPPDVGSSDP

LFIEWLKCGG
VRQRYLYTDD
HQSPESLLEL
QKPDGALYGS
VYQSEAHGLP
FLPLPGLPPA
LAMVGPSQAR

CATGGTGAGG
TCTAAACAGA
CTGTTCATTG
TCTGGTGGTG
TCGAGCCCGC
GTGCGTCAGC
GCGCAGGAAA
CGTGAAGATG
CATCAGAGCC
AAAGCGCTGA
CTGGGCGTGA
CAGAAACCGG
CTGCATTTTG
CGTGAACTGC
GTGTATCAGA
CTGCATCTGC
CGTGATCCGG
TTTCTGCCGC
CTGCCGGAAC
CAGCCGCCGG
CTGGCGATGG
AGCCCGAGCT
HSEGTFTSDV
GSGGGGSGGG
QVRQRYLYTD
AHQSPESLLE
CQKPDGALYG
NVYQSEAHGL
RFLPLPGLPP
PLAMVGPSQG

GTACGTTTAC
TGGAAGAAGA
AATGGCTGAA
GTGGTTCTGG
TGCTGCAGTT
GTTATCTGTA
CCGAAGCGCA
GCACCGTGGG
CGGAAAGCCT
AACCGGGCGT
AAACCAGCCG
ATGGCGCGCT
ATCCGGAAGC
TGCTGGAAGA
GCGAAGCGCA
CGGGCAACCG
CACCGCAGGG
TGCCGGGTCT
CGCCGGGTAT
ATGTTGGTAG
TGGGTCCGAG
ATGCGAGCTA
SSYLEGQAAK
GSGGGGSGGG
DAQETEAHLE
LKALKPGVIQ
SLHFDPEACS
PLHLPGNRSP
ALPEPPGILA
RSPSYAS

TTCTGATCTG
AGCTGTTCGC
ATGTGGTGGT
CGGTGGCGAC
TGGCGGCCAG
TACCGATGAT
TCTGGAAATT
CGGTGCGGCG
GCTGGAACTG
GATTCAGATT
TTTTCTGTGC
GTATGGCAGC
GTGCAGCTTT
TGGCTATAAC
TGGCCTGCCG
TAGCCCGCAT
TCCGGCGCGT
GCCGCCGGCA
TCTGGCCCCG
CAGCGATCCG
CCAGGCGCGT
A
EFIAWLVKGG
DSSPLLQFGG
IREDGTVGGA
ILGVKTSRFL
FRELLLEDGY
HCDPAPQGPA
PQPPDVGSSD

CATTCTGAAG
TCTAGCTACC
GAATTCATCG
GGTAGCGGTG
GGTTCTGGCG
GATAGCAGCC

GCACTTTTAC
TGGAAGGCCA
CGTGGCTGGT
GCGGCGGTTC
GTGGCGGTAG
CGCTGCTGCA

TAGCGATGTT
GGCTGCGAAA
TAAAGGCGGT
TGGTGGTGGT
CGGTGGCGGC
GTTTGGCGGC

Exendin4 (130;N28C-40
kDa
branched
PEG) SGGGGSGGGFGF21 (33209;Q5 6ED74H-Q82ER105KK150RR159QS195AG202A)
Exendin4 (130;N2 8C) SGGGGSGGGFGF21 (33209;Q5 6ED74H-Q82ER105KK150RR159QS195AG202A)

Ex (130;N2 8C
)-L9FGF21 (V
76154R202A) 4OKPEGb

GLP-1 (735; A8S) GGS (GGGGS) 3
-FGF21 (33209;Q5 6ED74H-Q82ER105KK150RR154C-40
kDa
branched
PEG-R159QS195A)
GLP-1 (735; A8S) GGS (GGGGS) 3
-FGF21 (33209;Q5 6ED74H-Q82E-

GLP1 (A8S) L20FGF21 (V
76) 4OKPEGb

Ex (130;N2 8C
)-L9FGF21 (V
76154R202A)

GLP1 (A8S) L20FGF21 (V
76)

CAGGTGCGTC
GATGCGCAGG
ATTCGTGAAG
GCGCATCAGA
CTGAAAGCGC
ATTCTGGGCG
TGCCAGAAAC
AGCCTGCATT
TTTCGTGAAC
AACGTGTATC
CCGCTGCATC
CATTGCGATC
CGTTTTCTGC
GCACTGCCGG
CCGCAGCCGC
CCGCTGGCGA
CGTAGCCCGA
HGEGTFTSDL
GGGGSDKTHT
KPKDTLMISR
NWYVDGVEVH
LTVLHQDWLN
ISKAKGQPRE
TCLVKGFYPS
PVLDSDGSFF
SVMHEALHNH
GSGGGGSDSS
QTEAHLEIRE
LKPGVIQILG
FDPEACSFRE
LPCNRSPHRD
EPPGILAPQP
SYAS
HGEGTFTSDL
GGGGSGGGGS
GGPSVFLFPP
VSHEDPEVKF
YNSTYRWSV
KALPAPIEKT
EEMTKNQVSL
QPENNYKTTP
RWQQGNVFSC
GKGGGGSGGG
QRYLYTDDAC
SPESLLQLKA
PDGALYGSLH
QSEAHGLPLH
PLPGLPPALP
MVGGSQARSP
HGEGTFTSDL
PSSGAPPPSG
GPSVFLFPPK
SHEDPEVKFN
NSTYRVVSVL
ALPAPIEKTI

AGCGTTATCT
AAACCGAAGC
ATGGCACCGT
GCCCGGAAAG
TGAAACCGGG
TGAAAACCAG
CGGATGGCGC
TTGATCCGGA
TGCTGCTGGA
AGAGCGAAGC
TGCCGGGCAA
CGGCACCGCA
CGCTGCCGGG
AACCGCCGGG
CGGATGTTGG
TGGTGGGTCC
GCTATGCGAG
SKQMEEEAVR
CPPCPAPEAA
TPEVTCVWD
NAKTKPREEQ
GKEYKCKVSN
PQVYTLPPSR
DIAVEWESNG
LYSKLTVDKS
YTQKSLSLSP
PLLQFGGQVR
DGTVGGAADQ
VKTSRFLCQK
LLLEDGYNVY
PASRGPARFL
PDVGSSDPLA

GTATACCGAT
GCATCTGGAA
GGGCGGTGCG
CCTGCTGGAA
CGTGATTCAG
CCGTTTTCTG
GCTGTATGGC
AGCGTGCAGC
AGATGGCTAT
GCATGGCCTG
CCGTAGCCCG
GGGTCCGGCG
TCTGCCGCCG
TATTCTGGCC
TAGCAGCGAT
GAGCCAGGGT
CTAA
LFIEWLKNGG
GGPSVFLFPP
VSHEDPEVKF
YNSTYRWSV
KALPAPIEKT
EEMTKNQVSL
QPENNYKTTP
RWQQGNVFSC
GKGGGGSGGG
QRYLYTDDAC
SPESLLQLKA
PDGALYGSLH
QSEAHGLPLH
PLPGLPPALP
MVGGSQARSP

R105KK150RR154CR159QS195A)

Exendin4 (130) - (GGGGS)
-Fc- (GGGGS) 3
-FGF21 (33209;Q55CR105KG148CK150RP158SS195AP199GG202A)

Exendin
(1-30) L5-FCL15-

SKQMEEEAVR
GGGGSDKTHT
KPKDTLMISR
NWYVDGVEVH
LTVLHQDWLN
ISKAKGQPRE
TCLVKGFYPS
PVLDSDGSFF
SVMHEALHNH
GSGGGGSDSS
QTEAHLEIRE
LKPGVIQILG
FDPEACSFRE
LPCNRSPHRD
EPPGILAPQP
SYAS
SKQMEEEAVR
GGGSDKTHTC
PKDTLMI SRT
WYVDGVEVHN
TVLHQDWLNG
SKAKGQPREP

LFIEWLKNGG
CPPCPAPEAA
TPEVTCWVD
NAKTKPREEQ
GKEYKCKVSN
PQVYTLPPSR
DIAVEWESNG
LYSKLTVDKS
YTQKSLSLSP
PLLQFGGQVR
DGTVGGAADQ
VKTSRFLCQK
LLLEDGYNVY
PASRGPARFL
PDVGSSDPLA

Exendin4 (130) - (GGGGS) 3
-Fc- (GGGGS) 3
-FGF21 (33209;Q55CR105KG148CK150RP158SS195AP199GG202A)

Ex (130) -L15-

LFIEWLKNGG
PPCPAPEAAG
PEVTCVWDV
AKTKPREEQY
KEYKCKVSNK
QVYTLPPSRE

Exendin4 (139) - (GGGGS)
-Fc- (GGGGS) 3
-FGF21 (33209;Q55CR105K-

Ex

FGF21 (VI
03)

)

FC-L15FGF21 (VI
03)

(1-

39) -L5FC-L15FGF21 (V

103)

123

124

125

V198

V203

V202

EMTKNQVSLT
PENNYKTTPP
WQQGNVFSCS
KGGGGSGGGG
RYLYTDDACQ
PESLLQLKAL
DGALYGSLHF
SEAHGLPLHL
LPGLPPALPE
VGGSQARSPS
HGEGTFTSDL
PSSGAPPPSG
PPCPAPEAAG
PEVTCVWDV
AKTKPREEQY
KEYKCKVSNK
QVYTLPPSRE
IAVEWESNGQ
YSKLTVDKSR
TQKSLSLSPG
LLQFGGQVRQ
GTVGGAADQS
KTSRFLCQKP
LLEDGYNVYQ
ASRGPARFLP
DVGSSDPLAM
HSEGTFTSDV
GGGSDKTHTC
PKDTLMISRT
WYVDGVEVHN
TVLHQDWLNG
SKAKGQPREP
CLVKGFYPSD
VLDSDGSFFL
VMHEALHNHY
SGGGGSDSSP
TEAHLEIRED
KPGVIQILGV
DPEACSFREL
PCNRSPHRDP
PPGILAPQPP
YAS
HSEGTFTSDV
GGGSGGGGSG
GPSVFLFPPK
SHEDPEVKFN
NSTYRVVSVL
ALPAPIEKTI
EMTKNQVSLT
PENNYKTTPP
WQQGNVFSCS
KGGGGSGGGG
RYLYTDDACQ
PESLLQLKAL
DGALYGSLHF

CLVKGFYPSD
VLDSDGSFFL
VMHEALHNHY
SGGGGSDSSP
TEAHLEIRED
KPGVIQILGV
DPEACSFREL
PCNRSPHRDP
PPGILAPQPP
YAS
SKQMEEEAVR
GGGSGGGGSG
GPSVFLFPPK
SHEDPEVKFN
NSTYRVVSVL
ALPAPIEKTI
EMTKNQVSLT
PENNYKTTPP
WQQGNVFSCS
KGGGGSGGGG
RYLYTDDACQ
PESLLQLKAL
DGALYGSLHF
SEAHGLPLHL
LPGLPPALPE
VGGSQARSPS
SSYLEGQAAK
PPCPAPEAAG
PEVTCWVDV
AKTKPREEQY
KEYKCKVSNK
QVYTLPPSRE
IAVEWESNGQ
YSKLTVDKSR
TQKSLSLSPG
LLQFGGQVRQ
GTVGGAADQS
KTSRFLCQKP
LLEDGYNVYQ
ASRGPARFLP
DVGSSDPLAM

IAVEWESNGQ
YSKLTVDKSR
TQKSLSLSPG
LLQFGGQVRQ
GTVGGAADQS
KTSRFLCQKP
LLEDGYNVYQ
ASRGPARFLP
DVGSSDPLAM

G148CK150RP158SS195AP199GG202A)

LFIEWLKNGG
GGGSDKTHTC
PKDTLMISRT
WYVDGVEVHN
TVLHQDWLNG
SKAKGQPREP
CLVKGFYPSD
VLDSDGSFFL
VMHEALHNHY
SGGGGSDSSP
TEAHLEIRED
KPGVIQILGV
DPEACSFREL
PCNRSPHRDP
PPGILAPQPP
YAS
EFIAWLVKGG
GPSVFLFPPK
SHEDPEVKFN
NSTYRVVSVL
ALPAPIEKTI
EMTKNQVSLT
PENNYKTTPP
WQQGNVFSCS
KGGGGSGGGG
RYLYTDDACQ
PESLLQLKAL
DGALYGSLHF
SEAHGLPLHL
LPGLPPALPE
VGGSQARSPS

Exendin4 (139) - (GGGGS) 3
-Fc- (GGGGS) 3
-FGF21 (33209;Q55CR105KG148CK150RP158SS195AP199GG202A)

Ex (139) L15-FCL15FGF21 (V

GLP-1 (7-35;
A8S) (GGGGS) -Fc(GGGGS) 3 "
FGF21 (33209;Q55CR105KG148CK150RP158SS195AP199GG202A)

GLP1 (A8S) L5-FCL15FGF21 (V

SSYLEGQAAK
GGGSDKTHTC
PKDTLMISRT
WYVDGVEVHN
TVLHQDWLNG
SKAKGQPREP
CLVKGFYPSD
VLDSDGSFFL
VMHEALHNHY
SGGGGSDSSP
TEAHLEIRED
KPGVIQILGV
DPEACSFREL

EFIAWLVKGG
PPCPAPEAAG
PEVTCVWDV
AKTKPREEQY
KEYKCKVSNK
QVYTLPPSRE
IAVEWESNGQ
YSKLTVDKSR
TQKSLSLSPG
LLQFGGQVRQ
GTVGGAADQS
KTSRFLCQKP
LLEDGYNVYQ

GLP-1 (7-35;
A8S) (GGGGS) 3 -Fc(GGGGS) 3 FGF21 (33209;Q55CR105KG148CK150RP158SS195AP199GG202A)

GLP1 (A8S) L15-FCL15FGF21 (V

103)

103)

103)

126

V310

127

31

V 2 06

SEAHGLPLHL
LPGLPPALPE
VGGSQARSPS

PCNRSPHRDP
PPGILAPQPP
YAS

ASRGPARFLP
DVGSSDPLAM

HGEGTFTSDL
PSSGAPPPSG
SPLLQFGGQV
EDGTVGGAAH
GVKTSRFLCQ
ELLLEDGYNV
DPAPQGPARF
PPDVGSSDPL

SKQMEEEAVR
GGGSGGGGSG
RQRYLYTDDA
QSPESLLELK
KPDGALYGSL
YQSEAHGLPL
LPLPGLPPAL
AMVGPSQGRS

LFIEWLKNGG
GGGSGGGGDS
QETEAHLEIR
ALKPGVIQIL
HFDPEACSFR
HLPGNRSPHC
PEPPGILAPQ
PSYAS

CATGGTGAGG
TCTAAACAGA
CTGTTCATTG
CCGTCCTCCG
GGTGGTGGTT
GGCGGTGGTA
AGCCCGCTGC
CGTCAGCGTT
CAGGAAACCG
GAAGATGGCA
CAGAGCCCGG
GCGCTGAAAC
GGCGTGAAAA
AAACCGGATG
CATTTTGATC
GAACTGCTGC
TATCAGAGCG
CATCTGCCGG
GATCCGGCAC
CTGCCGCTGC
CCGGAACCGC
CCGCCGGATG
GCGATGGTGG
CCGAGCTATG
HGEGTFTSDL
PSSGAPPPSD
LFPPKPKDTL
EVKFNWYVDG
WSVLTVLHQ
IEKTISKAKG
QVSLTCLVKG
KTTPPVLDSD
VFSCSVMHEA
LLQFGGQVRQ
GTVGGAADQS
KTSRFLCQKP
LLEDGYNVYQ
ASRGPARFLP

GTACGTTTAC
TGGAAGAAGA
AATGGCTGAA
GCGCTCCTCC
CTGGCGGTGG
GCGGTGGCGG
TGCAGTTTGG
ATCTGTATAC
AAGCGCATCT
CCGTGGGCGG
AAAGCCTGCT
CGGGCGTGAT
CCAGCCGTTT
GCGCGCTGTA
CGGAAGCGTG
TGGAAGATGG
AAGCGCATGG
GCAACCGTAG
CGCAGGGTCC
CGGGTCTGCC
CGGGTATTCT
TTGGTAGCAG
GTCCGAGCCA
CGAGCTAA
SKQMEEEAVR
KTHTCPPCPA
MISRTPEVTC
VEVHNAKTKP
DWLNGKEYKC
QPREPQVYTL
FYPSDIAVEW
GSFFLYSKLT
LHNHYTQKSL
RYLYTDDACQ
PESLLQLKAL
DGALYGSLHF
SEAHGLPLHL
LPGLPPALPE

TTCTGATCTG
AGCTGTTCGC
AAATGGTGGT
GCCTTCTGGT
CGGTTCTGGC
CGGTGATAGC
CGGCCAGGTG
CGATGATGCG
GGAAATTCGT
TGCGGCGCAT
GGAACTGAAA
TCAGATTCTG
TCTGTGCCAG
TGGCAGCCTG
CAGCTTTCGT
CTATAACGTG
CCTGCCGCTG
CCCGCATTGC
GGCGCGTTTT
GCCGGCACTG
GGCCCCGCAG
CGATCCGCTG
GGGTCGTAGC
LFIEWLKNGG
PEAAGGPSVF
WVDVSHEDP
REEQYNSTYR
KVSNKALPAP
PPSREEMTKN
ESNGQPENNY
VDKSRWQQGN
SLSPGKDSSP
TEAHLEIRED
KPGVIQILGV
DPEACSFREL
PCNRSPHRDP
PPGILAPQPP

Exendin4 (139) (GGGGS) 3GGGG
-FGF21 (3320 9;Q5 6ED74H-Q82ER105KK150RR154C-40
kDa
branched
PEG- R159QS195A)
Exendin4 (139) (GGGGS) 3GGGG
-FGF21 (3320 9;Q5 6ED74H-Q82ER105KK150RR154CR159QS195A)

Ex (139) L19FGF21 (V
76) 4OKPEGb

Exendin4 (139) -FcFGF21 (33209;Q55CR105KG148CK150RP158SS195AP199GG202A)

Ex (139) -LOFc-LOFGF21 (V

Ex (139) L19FGF21 (V
76)

103)

DVGSSDPLAM VGGSQARSPS

YAS

HGEGTFTSDL
PSSGAPPPSD
LFPPKPKDTL
EVKFNWYVDG
WSVLTVLHQ
IEKTISKAKG
QVSLTCLVKG
KTTPPVLDSD
VFSCSVMHEA
SPLLQFGGQV
EDGTVGGAAD
GVKTSRFLCQ
ELLLEDGYNV
DPASRGPARF
PPDVGSSDPL

SKQMEEEAVR LFIEWLKNGG
KTHTCPPCPA PEAAGGPSVF
MISRTPEVTC WVDVSHEDP
VEVHNAKTKP REEQYNSTYR
DWLNGKEYKC KVSNKALPAP
QPREPQVYTL PPSREEMTKN
FYPSDIAVEW ESNGQPENNY
GSFFLYSKLT VDKSRWQQGN
LHNHYTQKSL SLSPGKGSDS
RQRYLYTDDA CQTEAHLEIR
QSPESLLQLK ALKPGVIQIL
RPDGTLYGSL HFDPEACSFR
YQSEAHGLPL HLPCNRSPHR
LPLPGLPPAL PEPPGILAPQ
AMVGGSQARS PSYAS

Exendin4 (139) -Fc-GSFGF21 (33209;Q55CA109TG148CK150RP158SS195AP199GG202A)

Ex (139) -LO-

CACGGAGAAG
TCGAAGCAGA
CTCTTCATCG
CCCTCAAGCG
AAAACCCATA
CCAGAAGCAG
CTGTTCCCGC
ATGATTTCAC
GTCGTGGTGG
GAGGTCAAAT
GTGGAGGTGC
AGGGAAGAAC
GTCGTGTCCG
GACTGGCTGA
AAAGTGAGCA
ATTGAGAAAA
CAGCCTAGAG
CCGCCCTCAC
CAAGTGTCGC
TTCTACCCCT
GAGTCGAACG
AAGACCACGC
GGATCGTTTT
GTAGATAAGT
GTCTTTAGCT
CTTCACAATC
TCGCTTAGCC
TCGCCCCTGT
AGACAGCGCT
TGCCAGACAG
GAGGACGGTA
CAGAGCCCCG
GCCCTTAAGC
GGAGTAAAGA
CGTCCAGATG

GCACCTTTAC
TGGAGGAAGA
AGTGGCTCAA
GAGCGCCTCC
CATGTCCGCC
CGGGTGGGCC
CAAAACCGAA
GCACACCGGA
ATGTATCGCA
TCAACTGGTA
ACAATGCAAA
AATACAATAG
TCTTGACGGT
ACGGAAAGGA
ATAAGGCCCT
CCATTTCCAA
AACCTCAAGT
GCGAAGAGAT
TTACGTGTCT
CGGACATCGC
GCCAGCCGGA
CCCCTGTCTT
TCCTCTACTC
CCCGATGGCA
GCAGCGTGAT
ATTACACACA
CGGGAAAGGG
TGCAGTTTGG
ACCTTTACAC
AGGCACACCT
CGGTCGGGGG
AGTCGCTTCT
CAGGAGTCAT
CCTCACGGTT
GGACACTGTA

Exendin4 (139) -Fc-GSFGF21 (33209;Q55CA109TG148CK150RP158SS195AP199GG202A)

Ex (139) -L0-

ATCGGACTTG
AGCGGTGAGG
GAATGGAGGA
TCCTTCCGAC
TTGTCCCGCA
CTCGGTGTTC
GGACACACTT
AGTGACTTGC
CGAGGACCCC
TGTCGATGGA
GACCAAGCCG
CACGTACCGA
CCTTCACCAG
GTACAAGTGC
CCCTGCCCCG
GGCCAAAGGT
GTATACTCTT
GACGAAAAAC
TGTCAAAGGT
CGTAGAGTGG
GAACAACTAC
GGATAGCGAC
GAAACTCACA
ACAGGGTAAT
GCACGAGGCG
AAAATCACTG
TTCAGATTCG
TGGACAGGTC
GGATGACGCC
CGAAATCAGA
TGCGGCCGAT
CCAGTTGAAG
CCAGATTTTG
TCTCTGTCAG
CGGCTCATTG

FC-L2-

FGF21 (V
101)

FC-L2-

FGF21 (V
101)

CATTTCGATC
GAGTTGCTGC
TATCAGAGCG
CACCTCCCGT
GATCCGGCCT
CTTCCGTTGC
CCCGAGCCTC
CCTCCTGATG
GCGATGGTAG
CCGAGCTATG
HGEGTFTSDL
PSSGAPPPSG
PPCPAPEAAG
PEVTCVWDV
AKTKPREEQY
KEYKCKVSNK
QVYTLPPSRE
IAVEWESNGQ
YSKLTVDKSR
TQKSLSLSPG
YTDDACQTEA
LLQLKALKPG
LYGSLHFDPE
HGLPLHLPCN
LPPALPEPPG
SQARSPSYAS
CACGGAGAAG
TCGAAGCAGA
CTCTTCATCG
CCCTCAAGCG
GGAGGTGGGT
GGGGGAGGGA
CCGCCTTGTC
GGGCCCTCGG
CCGAAGGACA
CCGGAAGTGA
TCGCACGAGG
TGGTATGTCG
GCAAAGACCA
AATAGCACGT
ACGGTCCTTC
AAGGAGTACA
GCCCTCCCTG
TCCAAGGCCA
CAAGTGTATA
GAGATGACGA
TGTCTTGTCA
ATCGCCGTAG
CCGGAGAACA
GTCTTGGATA
TACTCGAAAC
TGGCAACAGG
GTGATGCACG
ACACAAAAAT
AAGGGTTCAG

CCGAAGCGTG
TTGAGGACGG
AAGCGCATGG
GTAACAGGTC
CGAGGGGTCC
CCGGGTTGCC
CCGGGATCCT
TAGGGTCCTC
GTGGATCACA
CATCA
SKQMEEEAVR
GGGSGGGGSG
GPSVFLFPPK
SHEDPEVKFN
NSTYRWSVL
ALPAPIEKTI
EMTKNQVSLT
PENNYKTTPP
WQQGNVFSCS
KGSDSSPLLQ
HLEIREDGTV
VIQILGVKTS
ACSFRELLLE
RSPHRDPASR
ILAPQPPDVG

CTCGTTCCGG
ATATAACGTC
CCTCCCCCTT
GCCGCATCGG
CGCGAGATTT
TCCCGCGCTG
CGCGCCACAG
GGACCCTTTG
AGCACGGTCC
LFIEWLKNGG
GGGSDKTHTC
PKDTLMISRT
WYVDGVEVHN
TVLHQDWLNG
SKAKGQPREP
CLVKGFYPSD
VLDSDGSFFL
VMHEALHNHY
FGGQVRQRYL
GGAADQSPES
RFLCQRPDGT
DGYNVYQSEA
GPARFLPLPG
SSDPLAMVGG

Exendin4 (139) (GGGGS) 3Fc-GSFGF21 (33209;Q55CA109TG148CK150RP158SS195AP199GG202A)

Ex (139) L15-FCL2FGF21 (V

GCACCTTTAC
TGGAGGAAGA
AGTGGCTCAA
GAGCGCCTCC
CGGGCGGTGG
GCGACAAAAC
CCGCACCAGA
TGTTCCTGTT
CACTTATGAT
CTTGCGTCGT
ACCCCGAGGT
ATGGAGTGGA
AGCCGAGGGA
ACCGAGTCGT
ACCAGGACTG
AGTGCAAAGT
CCCCGATTGA
AAGGTCAGCC
CTCTTCCGCC
AAAACCAAGT
AAGGTTTCTA
AGTGGGAGTC
ACTACAAGAC
GCGACGGATC
TCACAGTAGA
GTAATGTCTT
AGGCGCTTCA
CACTGTCGCT
ATTCGTCGCC

ATCGGACTTG
AGCGGTGAGG
GAATGGAGGA
TCCTTCCGGA
AGGCTCCGGA
CCATACATGT
AGCAGCGGGT
CCCGCCAAAA
TTCACGCACA
GGTGGATGTA
CAAATTCAAC
GGTGCACAAT
AGAACAATAC
GTCCGTCTTG
GCTGAACGGA
GAGCAATAAG
GAAAACCATT
TAGAGAACCT
CTCACGCGAA
GTCGCTTACG
CCCCTCGGAC
GAACGGCCAG
CACGCCCCCT
GTTTTTCCTC
TAAGTCCCGA
TAGCTGCAGC
CAATCATTAC
TAGCCCGGGA
CCTGTTGCAG

Exendin4 (139) (GGGGS) 3Fc-GSFGF21 (33209;Q55CA109TG148CK150RP158SS195AP199GG202A)

Ex (139) L15-FCL2FGF21 (V

101)

101)

TTTGGTGGAC
TACACGGATG
CACCTCGAAA
GGGGGTGCGG
CTTCTCCAGT
GTCATCCAGA
CGGTTTCTCT
CTGTACGGCT
GCGTGCTCGT
GACGGATATA
CATGGCCTCC
AGGTCGCCGC
GGTCCCGCGA
TTGCCTCCCG
ATCCTCGCGC
TCCTCGGACC
TCACAAGCAC
HGEGTFTSDL
PSSGAPPPSD
LFPPKPKDTL
EVKFNWYVDG
WSVLTVLHQ
IEKTISKAKG
QVSLTCLVKG
KTTPPVLDSD
VFSCSVMHEA
SPLLQFGGQV
EDGTVGGAAD
GVKTSRFLCQ
ELLLEDGYNV
DPASRGPARF
PPDVGSSDPL
CACGGAGAAG
TCGAAGCAGA
CTCTTCATCG
CCCTCAAGCG
AAAACCCATA
CCAGAAGCAG
CTGTTCCCGC
ATGATTTCAC
GTCGTGGTGG
GAGGTCAAAT
GTGGAGGTGC
AGGGAAGAAC
GTCGTGTCCG
GACTGGCTGA
AAAGTGAGCA
ATTGAGAAAA
CAGCCTAGAG
CCGCCCTCAC
CAAGTGTCGC
TTCTACCCCT
GAGTCGAACG
AAGACCACGC
GGATCGTTTT

AGGTCAGACA GCGCTACCTT
ACGCCTGCCA GACAGAGGCA
TCAGAGAGGA CGGTACGGTC
CCGATCAGAG CCCCGAGTCG
TGAAGGCCCT TAAGCCAGGA
TTTTGGGAGT AAAGACCTCA
GTCAGCGTCC AGATGGGACA
CATTGCATTT CGATCCCGAA
TCCGGGAGTT GCTGCTTGAG
ACGTCTATCA GAGCGAAGCG
CCCTTCACCT CCCGTGTAAC
ATCGGGATCC GGCCTCGAGG
GATTTCTTCC GTTGCCCGGG
CGCTGCCCGA GCCTCCCGGG
CACAGCCTCC TGATGTAGGG
CTTTGGCGAT GGTAGGTGGA
GGTCCCCGAG CTATGCATCA
SKQMEEEAVR LFIEWLKNGG
KTHTCPPCPA PEAAGGPSVF
MISRTPEVTC WVDVSHEDP
VEVHNAKTKP REEQYNSTYR
DWLNGKEYKC KVSNKALPAP
QPREPQVYTL PPSREEMTKN
FYPSDIAVEW ESNGQPENNY
GSFFLYSKLT VDKSRWQQGN
LHNHYTQKSL SLSPGKGSDS
RQRYLYTDDA CQTEAHLEIR
QSPESLLQLK ALKPGVIQIL
KPDGALYGSL HFDPEACSFR
YQSEAHGLPL HLPCNRSPHR
LPLPGLPPAL PEPPGILAPQ
AMVGGSQARS PSYAS
GCACCTTTAC ATCGGACTTG
TGGAGGAAGA AGCGGTGAGG
AGTGGCTCAA GAATGGAGGA
GAGCGCCTCC TCCTTCCGAC
CATGTCCGCC TTGTCCCGCA
CGGGTGGGCC CTCGGTGTTC
CAAAACCGAA GGACACACTT
GCACACCGGA AGTGACTTGC
ATGTATCGCA CGAGGACCCC
TCAACTGGTA TGTCGATGGA
ACAATGCAAA GACCAAGCCG
AATACAATAG CACGTACCGA
TCTTGACGGT CCTTCACCAG
ACGGAAAGGA GTACAAGTGC
ATAAGGCCCT CCCTGCCCCG
CCATTTCCAA GGCCAAAGGT
AACCTCAAGT GTATACTCTT
GCGAAGAGAT GACGAAAAAC
TTACGTGTCT TGTCAAAGGT
CGGACATCGC CGTAGAGTGG
GCCAGCCGGA GAACAACTAC
CCCCTGTCTT GGATAGCGAC
TCCTCTACTC GAAACTCACA

Exendin4 (139-Fc-GSFGF21 (33209;Q55CR105KG148CK150RP158SS195AP199GG202A)

Ex (139) -LO-

Exendin4 (139-Fc-GSFGF21 (33209;Q55CR105KG148CK150RP158SS195AP199GG202A)

Ex (139) -L0-

FC-L2-

FGF21 (V
103)

FC-L2-

FGF21 (V
103)

GTAGATAAGT
GTCTTTAGCT
CTTCACAATC
TCGCTTAGCC
TCGCCCCTGT
AGACAGCGCT
TGCCAGACAG
GAGGACGGTA
CAGAGCCCCG
GCCCTTAAGC
GGAGTAAAGA
AAACCAGATG
CATTTCGATC
GAGTTGCTGC
TATCAGAGCG
CACCTCCCGT
GATCCGGCCT
CTTCCGTTGC
CCCGAGCCTC
CCTCCTGATG
GCGATGGTAG
CCGAGCTATG
HGEGTFTSDL
PSSGAPPPSG
PPCPAPEAAG
PEVTCVWDV
AKTKPREEQY
KEYKCKVSNK
QVYTLPPSRE
IAVEWESNGQ
YSKLTVDKSR
TQKSLSLSPG
YTDDACQTEA
LLQLKALKPG
LYGSLHFDPE
HGLPLHLPCN
LPPALPEPPG
SQARSPSYAS
CACGGAGAAG
TCGAAGCAGA
CTCTTCATCG
CCCTCAAGCG
GGAGGTGGGT
GGGGGAGGGA
CCGCCTTGTC
GGGCCCTCGG
CCGAAGGACA
CCGGAAGTGA
TCGCACGAGG
TGGTATGTCG
GCAAAGACCA
AATAGCACGT
ACGGTCCTTC
AAGGAGTACA
GCCCTCCCTG

CCCGATGGCA
GCAGCGTGAT
ATTACACACA
CGGGAAAGGG
TGCAGTTTGG
ACCTTTACAC
AGGCACACCT
CGGTCGGGGG
AGTCGCTTCT
CAGGAGTCAT
CCTCACGGTT
GGGCACTGTA
CCGAAGCGTG
TTGAGGACGG
AAGCGCATGG
GTAACAGGTC
CGAGGGGTCC
CCGGGTTGCC
CCGGGATCCT
TAGGGTCCTC
GTGGATCACA
CATCA
SKQMEEEAVR
GGGSGGGGSG
GPSVFLFPPK
SHEDPEVKFN
NSTYRWSVL
ALPAPIEKTI
EMTKNQVSLT
PENNYKTTPP
WQQGNVFSCS
KGSDSSPLLQ
HLEIREDGTV
VIQILGVKTS
ACSFRELLLE
RSPHRDPASR
ILAPQPPDVG

ACAGGGTAAT
GCACGAGGCG
AAAATCACTG
TTCAGATTCG
TGGACAGGTC
GGATGACGCC
CGAAATCAGA
TGCGGCCGAT
CCAGTTGAAG
CCAGATTTTG
TCTCTGTCAG
CGGCTCATTG
CTCGTTCCGG
ATATAACGTC
CCTCCCCCTT
GCCGCATCGG
CGCGAGATTT
TCCCGCGCTG
CGCGCCACAG
GGACCCTTTG
AGCACGGTCC
LFIEWLKNGG
GGGSDKTHTC
PKDTLMISRT
WYVDGVEVHN
TVLHQDWLNG
SKAKGQPREP
CLVKGFYPSD
VLDSDGSFFL
VMHEALHNHY
FGGQVRQRYL
GGAADQSPES
RFLCQKPDGA
DGYNVYQSEA
GPARFLPLPG
SSDPLAMVGG

Exendin4 (139) (GGGGS) 3FcGSFGF21 (33209;Q55CR105KG148CK150RP158SS195AP199GG202A)

Ex (139) L15-FCL2FGF21 (V

GCACCTTTAC
TGGAGGAAGA
AGTGGCTCAA
GAGCGCCTCC
CGGGCGGTGG
GCGACAAAAC
CCGCACCAGA
TGTTCCTGTT
CACTTATGAT
CTTGCGTCGT
ACCCCGAGGT
ATGGAGTGGA
AGCCGAGGGA
ACCGAGTCGT
ACCAGGACTG
AGTGCAAAGT
CCCCGATTGA

ATCGGACTTG
AGCGGTGAGG
GAATGGAGGA
TCCTTCCGGA
AGGCTCCGGA
CCATACATGT
AGCAGCGGGT
CCCGCCAAAA
TTCACGCACA
GGTGGATGTA
CAAATTCAAC
GGTGCACAAT
AGAACAATAC
GTCCGTCTTG
GCTGAACGGA
GAGCAATAAG
GAAAACCATT

Exendin4 (139) (GGGGS) 3FcGSFGF21 (33209;Q55CR105KG148CK150RP158SS195AP199GG202A)

Ex (139) L15-FCL2FGF21 (V

103)

103)

I

TCCAAGGCCA
CAAGTGTATA
GAGATGACGA
TGTCTTGTCA
ATCGCCGTAG
CCGGAGAACA
GTCTTGGATA
TACTCGAAAC
TGGCAACAGG
GTGATGCACG
ACACAAAAAT
AAGGGTTCAG
TTTGGTGGAC
TACACGGATG
CACCTCGAAA
GGGGGTGCGG
CTTCTCCAGT
GTCATCCAGA
CGGTTTCTCT
CTGTACGGCT
GCGTGCTCGT
GACGGATATA
CATGGCCTCC
AGGTCGCCGC
GGTCCCGCGA
TTGCCTCCCG
ATCCTCGCGC
TCCTCGGACC
TCACAAGCAC

AAGGTCAGCC
CTCTTCCGCC
AAAACCAAGT
AAGGTTTCTA
AGTGGGAGTC
ACTACAAGAC
GCGACGGATC
TCACAGTAGA
GTAATGTCTT
AGGCGCTTCA
CACTGTCGCT
ATTCGTCGCC
AGGTCAGACA
ACGCCTGCCA
TCAGAGAGGA
CCGATCAGAG
TGAAGGCCCT
TTTTGGGAGT
GTCAGAAACC
CATTGCATTT
TCCGGGAGTT
ACGTCTATCA
CCCTTCACCT
ATCGGGATCC
GATTTCTTCC
CGCTGCCCGA
CACAGCCTCC
CTTTGGCGAT
GGTCCCCGAG

TAGAGAACCT
CTCACGCGAA
GTCGCTTACG
CCCCTCGGAC
GAACGGCCAG
CACGCCCCCT
GTTTTTCCTC
TAAGTCCCGA
TAGCTGCAGC
CAATCATTAC
TAGCCCGGGA
CCTGTTGCAG
GCGCTACCTT
GACAGAGGCA
CGGTACGGTC
CCCCGAGTCG
TAAGCCAGGA
AAAGACCTCA
AGATGGGGCA
CGATCCCGAA
GCTGCTTGAG
GAGCGAAGCG
CCCGTGTAAC
GGCCTCGAGG
GTTGCCCGGG
GCCTCCCGGG
TGATGTAGGG
GGTAGGTGGA
CTATGCATCA

HSEGTFTSDV
GGGSGGGGSG
GPSVFLFPPK
SHEDPEVKFN
NSTYRVVSVL
ALPAPIEKTI
EMTKNQVSLT
PENNYKTTPP
WQQGNVFSCS
KGSDSSPLLQ
HLEIREDGTV
VIQILGVKTS
ACSFRELLLE
RSPHRDPASR
ILAPQPPDVG
CACTCCGAAG
AGCTCGTATT
GAGTTTATCG
GGAGGTGGGT
GGGGGAGGGA
CCGCCTTGTC
GGGCCCTCGG
CCGAAGGACA
CCGGAAGTGA
TCGCACGAGG

SSYLEGQAAK
GGGSDKTHTC
PKDTLMI SRT
WYVDGVEVHN
TVLHQDWLNG
SKAKGQPREP
CLVKGFYPSD
VLDSDGSFFL
VMHEALHNHY
FGGQVRQRYL
GGAADQSPES
RFLCQRPDGT
DGYNVYQSEA
GPARFLPLPG
SSDPLAMVGG
GAACATTCAC
TGGAAGGGCA
CATGGTTGGT
CGGGCGGTGG
GCGACAAAAC
CCGCACCAGA
TGTTCCTGTT
CACTTATGAT
CTTGCGTCGT
ACCCCGAGGT

EFIAWLVKGG
PPCPAPEAAG
PEVTCVWDV
AKTKPREEQY
KEYKCKVSNK
QVYTLPPSRE
IAVEWESNGQ
YSKLTVDKSR
TQKSLSLSPG
YTDDACQTEA
LLQLKALKPG
LYGSLHFDPE
HGLPLHLPCN
LPPALPEPPG
SQARSPSYAS
TTCCGATGTA
GGCGGCTAAG
CAAAGGTGGT
AGGCTCCGGA
CCATACATGT
AGCAGCGGGT
CCCGCCAAAA
TTCACGCACA
GGTGGATGTA
CAAATTCAAC

GLP-1 (735; A8S) (GGGGS) 3Fc-GSFGF21 (33209;Q55CA109TG148CK150RP158SS195AP199GG202A)

GLP1 (A8S) L15-FCL2FGF21 (V

GLP-1 (735; A8S) (GGGGS) 3Fc-GSFGF21 (33209;Q55CA109TG148CK150RP158S-

GLP1 (A8S) L15-FCL2FGF21 (V

101)

101)

TGGTATGTCG
GCAAAGACCA
AATAGCACGT
ACGGTCCTTC
AAGGAGTACA
GCCCTCCCTG
TCCAAGGCCA
CAAGTGTATA
GAGATGACGA
TGTCTTGTCA
ATCGCCGTAG
CCGGAGAACA
GTCTTGGATA
TACTCGAAAC
TGGCAACAGG
GTGATGCACG
ACACAAAAAT
AAGGGTTCAG
TTTGGTGGAC
TACACGGATG
CACCTCGAAA
GGGGGTGCGG
CTTCTCCAGT
GTCATCCAGA
CGGTTTCTCT
CTGTACGGCT
GCGTGCTCGT
GACGGATATA
CATGGCCTCC
AGGTCGCCGC
GGTCCCGCGA
TTGCCTCCCG
ATCCTCGCGC
TCCTCGGACC
TCACAAGCAC
HSEGTFTSDV
GGGSGGGGSG
GPSVFLFPPK
SHEDPEVKFN
NSTYRVVSVL
ALPAPIEKTI
EMTKNQVSLT
PENNYKTTPP
WQQGNVFSCS
KGSDSSPLLQ
HLEIREDGTV
VIQILGVKTS
ACSFRELLLE
RSPHRDPASR
ILAPQPPDVG
CACTCCGAAG
AGCTCGTATT
GAGTTTATCG
GGAGGTGGGT
GGGGGAGGGA

ATGGAGTGGA
AGCCGAGGGA
ACCGAGTCGT
ACCAGGACTG
AGTGCAAAGT
CCCCGATTGA
AAGGTCAGCC
CTCTTCCGCC
AAAACCAAGT
AAGGTTTCTA
AGTGGGAGTC
ACTACAAGAC
GCGACGGATC
TCACAGTAGA
GTAATGTCTT
AGGCGCTTCA
CACTGTCGCT
ATTCGTCGCC
AGGTCAGACA
ACGCCTGCCA
TCAGAGAGGA
CCGATCAGAG
TGAAGGCCCT
TTTTGGGAGT
GTCAGCGTCC
CATTGCATTT
TCCGGGAGTT
ACGTCTATCA
CCCTTCACCT
ATCGGGATCC
GATTTCTTCC
CGCTGCCCGA
CACAGCCTCC
CTTTGGCGAT
GGTCCCCGAG
SSYLEGQAAK
GGGSDKTHTC
PKDTLMI SRT
WYVDGVEVHN
TVLHQDWLNG
SKAKGQPREP
CLVKGFYPSD
VLDSDGSFFL
VMHEALHNHY
FGGQVRQRYL
GGAADQSPES
RFLCQKPDGA
DGYNVYQSEA
GPARFLPLPG
SSDPLAMVGG
GAACATTCAC
TGGAAGGGCA
CATGGTTGGT
CGGGCGGTGG
GCGACAAAAC

GGTGCACAAT
AGAACAATAC
GTCCGTCTTG
GCTGAACGGA
GAGCAATAAG
GAAAACCATT
TAGAGAACCT
CTCACGCGAA
GTCGCTTACG
CCCCTCGGAC
GAACGGCCAG
CACGCCCCCT
GTTTTTCCTC
TAAGTCCCGA
TAGCTGCAGC
CAATCATTAC
TAGCCCGGGA
CCTGTTGCAG
GCGCTACCTT
GACAGAGGCA
CGGTACGGTC
CCCCGAGTCG
TAAGCCAGGA
AAAGACCTCA
AGATGGGACA
CGATCCCGAA
GCTGCTTGAG
GAGCGAAGCG
CCCGTGTAAC
GGCCTCGAGG
GTTGCCCGGG
GCCTCCCGGG
TGATGTAGGG
GGTAGGTGGA
CTATGCATCA
EFIAWLVKGG
PPCPAPEAAG
PEVTCVWDV
AKTKPREEQY
KEYKCKVSNK
QVYTLPPSRE
IAVEWESNGQ
YSKLTVDKSR
TQKSLSLSPG
YTDDACQTEA
LLQLKALKPG
LYGSLHFDPE
HGLPLHLPCN
LPPALPEPPG
SQARSPSYAS
TTCCGATGTA
GGCGGCTAAG
CAAAGGTGGT
AGGCTCCGGA
CCATACATGT

S195AP199GG202A)

GLP-1 (735; A8S) (GGGGS) 3Fc-GSFGF21 (33209;Q55CR105KG148CK150RP158SS195AP199GG202A)

GLP1 (A8S) L15-FCL2FGF21 (V

GLP-1 (735; A8S) (GGGGS) 3Fc-GSFGF21 (33-

GLP1 (A8S) L15-FCL2FGF21 (V

103)

CCGCCTTGTC
GGGCCCTCGG
CCGAAGGACA
CCGGAAGTGA
TCGCACGAGG
TGGTATGTCG
GCAAAGACCA
AATAGCACGT
ACGGTCCTTC
AAGGAGTACA
GCCCTCCCTG
TCCAAGGCCA
CAAGTGTATA
GAGATGACGA
TGTCTTGTCA
ATCGCCGTAG
CCGGAGAACA
GTCTTGGATA
TACTCGAAAC
TGGCAACAGG
GTGATGCACG
ACACAAAAAT
AAGGGTTCAG
TTTGGTGGAC
TACACGGATG
CACCTCGAAA
GGGGGTGCGG
CTTCTCCAGT
GTCATCCAGA
CGGTTTCTCT
CTGTACGGCT
GCGTGCTCGT
GACGGATATA
CATGGCCTCC
AGGTCGCCGC
GGTCCCGCGA
TTGCCTCCCG
ATCCTCGCGC
TCCTCGGACC
TCACAAGCAC
HSEGTFTSDV
GGGSGGGGSG
GPSVFLFPPK
SHEDPEVKFN
NSTYRVVSVL
ALPAPIEKTI
EMTKNQVSLT
PENNYKTTPP
WQQGNVFSCS
KDSSPLLQFG
EIREDGTVGG
QILGVKTSRF
SFRELLLEDG
PHRDPASRGP
APQPPDVGSS

CCGCACCAGA
TGTTCCTGTT
CACTTATGAT
CTTGCGTCGT
ACCCCGAGGT
ATGGAGTGGA
AGCCGAGGGA
ACCGAGTCGT
ACCAGGACTG
AGTGCAAAGT
CCCCGATTGA
AAGGTCAGCC
CTCTTCCGCC
AAAACCAAGT
AAGGTTTCTA
AGTGGGAGTC
ACTACAAGAC
GCGACGGATC
TCACAGTAGA
GTAATGTCTT
AGGCGCTTCA
CACTGTCGCT
ATTCGTCGCC
AGGTCAGACA
ACGCCTGCCA
TCAGAGAGGA
CCGATCAGAG
TGAAGGCCCT
TTTTGGGAGT
GTCAGAAACC
CATTGCATTT
TCCGGGAGTT
ACGTCTATCA
CCCTTCACCT
ATCGGGATCC
GATTTCTTCC
CGCTGCCCGA
CACAGCCTCC
CTTTGGCGAT
GGTCCCCGAG
SSYLEGQAAK
GGGSDKTHTC
PKDTLMI SRT
WYVDGVEVHN
TVLHQDWLNG
SKAKGQPREP
CLVKGFYPSD
VLDSDGSFFL
VMHEALHNHY
GQVRQRYLYT
AADQSPESLL
LCQKPDGALY
YNVYQSEAHG
ARFLPLPGLP
DPLAMVGGSQ

AGCAGCGGGT
CCCGCCAAAA
TTCACGCACA
GGTGGATGTA
CAAATTCAAC
GGTGCACAAT
AGAACAATAC
GTCCGTCTTG
GCTGAACGGA
GAGCAATAAG
GAAAACCATT
TAGAGAACCT
CTCACGCGAA
GTCGCTTACG
CCCCTCGGAC
GAACGGCCAG
CACGCCCCCT
GTTTTTCCTC
TAAGTCCCGA
TAGCTGCAGC
CAATCATTAC
TAGCCCGGGA
CCTGTTGCAG
GCGCTACCTT
GACAGAGGCA
CGGTACGGTC
CCCCGAGTCG
TAAGCCAGGA
AAAGACCTCA
AGATGGGGCA
CGATCCCGAA
GCTGCTTGAG
GAGCGAAGCG
CCCGTGTAAC
GGCCTCGAGG
GTTGCCCGGG
GCCTCCCGGG
TGATGTAGGG
GGTAGGTGGA
CTATGCATCA
EFIAWLVKGG
PPCPAPEAAG
PEVTCVWDV
AKTKPREEQY
KEYKCKVSNK
QVYTLPPSRE
IAVEWESNGQ
YSKLTVDKSR
TQKSLSLSPG
DDACQTEAHL
QLKALKPGVI
GSLHFDPEAC
LPLHLPCNRS
PALPEPPGIL
ARSPSYAS

209;Q55CR105KG148CK150RP158SS195AP199GG202A)

103)

GLP-1 (735; A8S) (GGGGS) 3 -FcFGF21 (33209;Q55CR105KG148CK150RP158SS195AP199GG202A)

GLP1 (A8S) L15-FCL0FGF21 (V
103)

CACTCCGAAG
AGCTCGTATT
GAGTTTATCG
GGAGGTGGGT
GGGGGAGGGA
CCGCCTTGTC
GGGCCCTCGG
CCGAAGGACA
CCGGAAGTGA
TCGCACGAGG
TGGTATGTCG
GCAAAGACCA
AATAGCACGT
ACGGTCCTTC
AAGGAGTACA
GCCCTCCCTG
TCCAAGGCCA
CAAGTGTATA
GAGATGACGA
TGTCTTGTCA
ATCGCCGTAG
CCGGAGAACA
GTCTTGGATA
TACTCGAAAC
TGGCAACAGG
GTGATGCACG
ACACAAAAAT
AAGGATTCGT
GGACAGGTCA
GATGACGCCT
GAAATCAGAG
GCGGCCGATC
CAGTTGAAGG
CAGATTTTGG
CTCTGTCAGA
GGCTCATTGC
TCGTTCCGGG
TATAACGTCT
CTCCCCCTTC
CCGCATCGGG
GCGAGATTTC
CCCGCGCTGC
GCGCCACAGC
GACCCTTTGG
GCACGGTCCC
HGEGTFTSDL
PSSGAPPPSG
PPCPAPEAAG
PEVTCVWDV
AKTKPREEQY
KEYKCKVSNK
QVYTLPPSRE
IAVEWESNGQ
YSKLTVDKSR
TQKSLSLSPG

GAACATTCAC
TGGAAGGGCA
CATGGTTGGT
CGGGCGGTGG
GCGACAAAAC
CCGCACCAGA
TGTTCCTGTT
CACTTATGAT
CTTGCGTCGT
ACCCCGAGGT
ATGGAGTGGA
AGCCGAGGGA
ACCGAGTCGT
ACCAGGACTG
AGTGCAAAGT
CCCCGATTGA
AAGGTCAGCC
CTCTTCCGCC
AAAACCAAGT
AAGGTTTCTA
AGTGGGAGTC
ACTACAAGAC
GCGACGGATC
TCACAGTAGA
GTAATGTCTT
AGGCGCTTCA
CACTGTCGCT
CGCCCCTGTT
GACAGCGCTA
GCCAGACAGA
AGGACGGTAC
AGAGCCCCGA
CCCTTAAGCC
GAGTAAAGAC
AACCAGATGG
ATTTCGATCC
AGTTGCTGCT
ATCAGAGCGA
ACCTCCCGTG
ATCCGGCCTC
TTCCGTTGCC
CCGAGCCTCC
CTCCTGATGT
CGATGGTAGG
CGAGCTATGC
SKQMEEEAVR
GGGSGGGGSG
GPSVFLFPPK
SHEDPEVKFN
NSTYRWSVL
ALPAPIEKTI
EMTKNQVSLT
PENNYKTTPP
WQQGNVFSCS
K

TTCCGATGTA
GGCGGCTAAG
CAAAGGTGGT
AGGCTCCGGA
CCATACATGT
AGCAGCGGGT
CCCGCCAAAA
TTCACGCACA
GGTGGATGTA
CAAATTCAAC
GGTGCACAAT
AGAACAATAC
GTCCGTCTTG
GCTGAACGGA
GAGCAATAAG
GAAAACCATT
TAGAGAACCT
CTCACGCGAA
GTCGCTTACG
CCCCTCGGAC
GAACGGCCAG
CACGCCCCCT
GTTTTTCCTC
TAAGTCCCGA
TAGCTGCAGC
CAATCATTAC
TAGCCCGGGA
GCAGTTTGGT
CCTTTACACG
GGCACACCTC
GGTCGGGGGT
GTCGCTTCTC
AGGAGTCATC
CTCACGGTTT
GGCACTGTAC
CGAAGCGTGC
TGAGGACGGA
AGCGCATGGC
TAACAGGTCG
GAGGGGTCCC
CGGGTTGCCT
CGGGATCCTC
AGGGTCCTCG
TGGATCACAA
ATCA
LFIEWLKNGG
GGGSDKTHTC
PKDTLMISRT
WYVDGVEVHN
TVLHQDWLNG
SKAKGQPREP
CLVKGFYPSD
VLDSDGSFFL
VMHEALHNHY

GLP-1 (735; A8S) (GGGGS) 3 -FcFGF21 (33209;Q55CR105KG148CK150RP158SS195AP199GG202A)

GLP1 (A8S) L15-FCL0FGF21 (V

Exendin4 (139) (GGGGS) 3 -Fc

Ex (139) L15-FC

103)

V 201

V 207

V212

V213

HGEGTFTSDL
PSSGAPPPSG
GPSVFLFPPK
SHEDPEVKFN
NSTYRVVSVL
ALPAPIEKTI
EMTKNQVSLT
PENNYKTTPP
WQQGNVFSCS
K
HGEGTFTSDL
PSSGAPPPSD
LFPPKPKDTL
EVKFNWYVDG
WSVLTVLHQ
IEKTISKAKG
QVSLTCLVKG
KTTPPVLDSD
VFSCSVMHEA
SGGGGSGGGG
DDACQTEAHL
QLKALKPGVI
GSLHFDPEAC
LPLHLPCNRS
PALPEPPGIL
ARSPSYAS
HSEGTFTSDV
THTCPPCPAP
ISRTPEVTCV
EVHNAKTKPR
WLNGKEYKCK
PREPQVYTLP
YPSDIAVEWE
SFFLYSKLTV
HNHYTQKSLS
DSSPLLQFGG
IREDGTVGGA
ILGVKTSRFL
FRELLLEDGY
HRDPASRGPA
PQPPDVGSSD
HSEGTFTSDV
THTCPPCPAP
ISRTPEVTCV
EVHNAKTKPR
WLNGKEYKCK
PREPQVYTLP
YPSDIAVEWE
SFFLYSKLTV
HNHYTQKSLS
QRYLYTDDAC
SPESLLQLKA
PDGTLYGSLH
QSEAHGLPLH
PLPGLPPALP

SKQMEEEAVR
GGGSDKTHTC
PKDTLMI SRT
WYVDGVEVHN
TVLHQDWLNG
SKAKGQPREP
CLVKGFYPSD
VLDSDGSFFL
VMHEALHNHY

LFIEWLKNGG
PPCPAPEAAG
PEVTCVWDV
AKTKPREEQY
KEYKCKVSNK
QVYTLPPSRE
IAVEWESNGQ
YSKLTVDKSR
TQKSLSLSPG

Exendin4 (139) -GGGGSFc

Ex (139) -L5Fc

SKQMEEEAVR
KTHTCPPCPA
MISRTPEVTC
VEVHNAKTKP
DWLNGKEYKC
QPREPQVYTL
FYPSDIAVEW
GSFFLYSKLT
LHNHYTQKSL
SDSSPLLQFG
EIREDGTVGG
QILGVKTSRF
SFRELLLEDG
PHRDPASRGP
APQPPDVGSS

LFIEWLKNGG
PEAAGGPSVF
WVDVSHEDP
REEQYNSTYR
KVSNKALPAP
PPSREEMTKN
ESNGQPENNY
VDKSRWQQGN
SLSPGKGGGG
GQVRQRYLYT
AADQSPESLL
LCQKPDGALY
YNVYQSEAHG
ARFLPLPGLP
DPLAMVGGSQ

Exendin4 (139) -Fc-

Ex (139) -L0-

(GGGGS)

FC-L15-

FGF21 (33209;Q55CR105KG148CK150RP158SS195AP199GG202A)

FGF21 (V

SSYLEGQAAK
EAAGGPSVFL
VVDVSHEDPE
EEQYNSTYRV
VSNKALPAPI
PSREEMTKNQ
SNGQPENNYK
DKSRWQQGNV
LSPGKGGGGS
QVRQRYLYTD
ADQSPESLLQ
CQKPDGALYG
NVYQSEAHGL
RFLPLPGLPP
PLAMVGGSQA
SSYLEGQAAK
EAAGGPSVFL
VVDVSHEDPE
EEQYNSTYRV
VSNKALPAPI
PSREEMTKNQ
SNGQPENNYK
DKSRWQQGNV
LSPGKGSDSS
QTEAHLEIRE
LKPGVIQILG
FDPEACSFRE
LPCNRSPHRD
EPPGILAPQP

EFIAWLVKDK
FPPKPKDTLM
VKFNWYVDGV
VSVLTVLHQD
EKTISKAKGQ
VSLTCLVKGF
TTPPVLDSDG
FSCSVMHEAL
GGGGSGGGGS
DACQTEAHLE
LKALKPGVIQ
SLHFDPEACS
PLHLPCNRSP
ALPEPPGILA
RSPSYAS
EFIAWLVKDK
FPPKPKDTLM
VKFNWYVDGV
VSVLTVLHQD
EKTISKAKGQ
VSLTCLVKGF
TTPPVLDSDG
FSCSVMHEAL
PLLQFGGQVR
DGTVGGAADQ
VKTSRFLCQR
LLLEDGYNVY
PASRGPARFL
PDVGSSDPLA

GLP-1 (735; A8S) -Fc-

GLP1 (A8S) LO-FcL15FGF21 (V

(GGGGS)

3-

3"

FGF21 (33209;Q55CR105KG148CK150RP158SS195AP199GG202A)

GLP-1 (735; A8S) -FcGSFGF21 (33209;Q55CA109TG148CK150RP158SS195AP199GG202A)

103)

103)

GLP1 (A8S) LO-FcL2FGF21 (V
101)

V215

V217

V 2 78

MVGGSQARSP

SYAS

HSEGTFTSDV
THTCPPCPAP
ISRTPEVTCV
EVHNAKTKPR
WLNGKEYKCK
PREPQVYTLP
YPSDIAVEWE
SFFLYSKLTV
HNHYTQKSLS
QRYLYTDDAC
SPESLLQLKA
PDGALYGSLH
QSEAHGLPLH
PLPGLPPALP
MVGGSQARSP
HGEGTFTSDL
PSSGAPPPSG
V LLL V PGS
VRLFIEWLKN
SGGGGSDKTH
PKPKDTLMIS
FNWYVDGVEV
VLTVLHQDWL
TISKAKGQPR
LTCLVKGFYP
PPVLDSDGSF
CSVMHEALHN
LQFGGQVRQR
TVGGAADQSP
TSRFLCQKPD
LEDGYNVYQS
SRGPARFLPL
VGSSDPLAMV
HSEGTFTSDV
SGGGGSGGGD
AQETEAHLEI
KALKPGVIQI
LHFDPEACSF
LHLPGNRSPH
LPEPPGILAP
SPSYAS

SSYLEGQAAK
EAAGGPSVFL
VVDVSHEDPE
EEQYNSTYRV
VSNKALPAPI
PSREEMTKNQ
SNGQPENNYK
DKSRWQQGNV
LSPGKGSDSS
QTEAHLEIRE
LKPGVIQILG
FDPEACSFRE
LPCNRSPHRD
EPPGILAPQP
SYAS
SKQMEEEAVR
GGGSGGGGSG
TGHGEGTFTS
GGPSSGAPPP
TCPPCPAPEA
RTPEVTCWV
HNAKTKPREE
NGKEYKCKVS
EPQVYTLPPS
SDIAVEWESN
FLYSKLTVDK
HYTQKSLSLS
YLYTDDACQT
ESLLQLKALK
GALYGSLHFD
EAHGLPLHLP
PGLPPALPEP
GGSQARSPSY
SSYLEGQAAK
SSPLLQFGGQ
REDGTVGGAA
LGVKTSRFLC
RELLLEDGYN
CDPAPQGPAR
QPPDVGSSDP

EFIAWLVKDK
FPPKPKDTLM
VKFNWYVDGV
VSVLTVLHQD
EKTISKAKGQ
VSLTCLVKGF
TTPPVLDSDG
FSCSVMHEAL
PLLQFGGQVR
DGTVGGAADQ
VKTSRFLCQK
LLLEDGYNVY
PASRGPARFL
PDVGSSDPLA

GLP-1 (735; A8S) -FcGSFGF21 (33209;Q55CR105KG148CK150RP158SS195AP199GG202A)

GLP1 (A8S) LO-FcL2FGF21 (V

LFIEWLKNGG
GGGSTDTLLL
DLSKQMEEEA
SGGGGSGGGG
AGGPSVFLFP
DVSHEDPEVK
QYNSTYRVVS
NKALPAPIEK
REEMTKNQVS
GQPENNYKTT
SRWQQGNVFS
PGKGSDSSPL
EAHLEIREDG
PGVIQILGVK
PEACSFRELL
CNRSPHRDPA
PGILAPQPPD
AS
EFIAWLVKGG
VRQRYLYTDD
HQSPESLLEL
QKPDGALYGS
VYQSEAHGLP
FLPLPGLPPA
LAMVGPSQGR

Exendin4 (139) (GGGGS) 3Exendin4 (139) (GGGGS) 3 -FcGSFGF21 (33209;Q55CR105KG148CK150RP158SS195AP199GG202A)

Ex (139) L15Ex (139) L15-FCL2FGF21 (V

GLP-1 (735; A8S) GSGGGGSGGGFGF21 (33209;Q5 6ED74H-Q82ER105KK150RR154C-bismaleimide
dimer 40
kDa
branched
PEG-R159QS195A)

GLP1 (A8S) L10FGF21 (V

103)

103)

76)

Dimer4OKPEGb

HSEGTFTSDV
SGGGGSGGGD
AQETEAHLEI
KALKPGVIQI
LHFDPEACSF
LHLPGNRSPH
LPEPPGILAP
SPSYAS

SSYLEGQAAK
SSPLLQFGGQ
REDGTVGGAA
LGVKTSRFLC
RELLLEDGYN
CDPAPQGPAR
QPPDVGSSDP

EFIAWLVKGG
VRQRYLYTDD
HQSPESLLEL
QKPDGALYGS
VYQSEAHGLP
FLPLPGLPPA
LAMVGPSQGR

HSEGTFTSDV
SGGGGSGGGD
AQETEAHLEI
KALKPGVIQI
LHFDPEACSF
LHLPGNRSPH
LPEPPGILAP
SPSYAS

SSYLEGQAAK
SSPLLQFGGQ
REDGTVGGAA
LGVKTSRFLC
RELLLEDGYN
CDPAPQGPAR
QPPDVGSSDP

EFIAWLVKGG
VRQRYLYTDD
HQSPESLLEL
QKPDGALYGS
VYQSEAHGLP
FLPLPGLPPA
LAMVGPSQGR

HGEGTFTSDL
SGGGGSGGGG
QVRQRYLYTD
AHQSPESLLE
CQKPDGALYG
NVYQSEAHGL
RFLPLPGLPP
PLAMVGPSQG

SKQMEEEAVR
SGGGGSGGGG
DAQETEAHLE
LKALKPGVIQ
SLHFDPEACS
PLHLPGNRSP
ALPEPPGILA
RSPSYAS

LFIEWLKNGG
DSSPLLQFGG
IREDGTVGGA
ILGVKTSRFL
FRELLLEDGY
HCDPAPQGPA
PQPPDVGSSD

HGEGTFTSDL
SGGGGSGGGG
QVRQRYLYTD
AHQSPESLLE
CQKPDGALYG
NVYQSEAHGL
RFLPLPGLPP
PLS

SKQMEEEAVR
SGGGGSGGGG
DAQETEAHLE
LKALKPGVIQ
SLHFDPEACS
PLHLPGNRSP
ALPEPPGILA

LFIEWLKNGG
DSSPLLQFGG
IREDGTVGGA
ILGVKTSRFL
FRELLLEDGY
HCDPAPQGPA
PQPPDVGSSD

DLSKQMEEEA
GGSGGGGSGG
TDDAQETEAH
LELKALKPGV
YGSLHFDPEA
GLPLHLPGNR

VRLFIEWLKN
GGDSSPLLQF
LEIREDGTVG
IQILGVKTSR
CSFRELLLED
SPHCDPAPQG

GGSGGGGSGG
GGQVRQRYLY
GAAHQSPESL
FLCQKPDGAL
GYNVYQSEAH
PARFLPLPGL

GLP-1 (735; A8S) GSGGGGSGGGFGF21 (33209;Q5 6ED74H-Q82ER105KK150RR154C-bismaleimide
dimer 20
kDa
branched
PEG-R159QS195A)
GLP-1 (735; A8S) GSGGGGSGGGFGF21 (33209;Q5 6ED74H-Q82ER105KK150RR154CR159QS195A)
Exendin4 (130) S (GGGGS) 3GGG
G-FGF21 (33209;Q5 6ED74H-Q82ER105KK150RR154CR159QS195A)
Exendin4 (130) S (GGGGS) 3GGG
G-FGF21 (33195;Q56ED74H-Q82ER105KK150RR154C-40
kDa
branched
PEG-R159Q)
Exendin4 (930) S (GGGGS) 3GGG
G-FGF21 (33209;Q5 6ED74H-Q82E-

GLP1 (A8S) L10FGF21 (V
76)

Dimer2OKPEGb

GLP1 (A8S) L10FGF21 (V
76)

Ex (130 L20FGF21 (V
76)

Ex (130) L20FGF21 (V
76;CA14
)4OKPEGb

Ex (930) L20FGF21 (V
76) 4OKPEGb

PPALPEPPGI
QGRSPSYAS

LAPQPPDVGS

SDPLAMVGPS

V 2 89

GGQVRQRYLY
GAAHQSPESL
FLCQKPDGAL
GYNVYQSEAH
PARFLPLPGL
SDPLAMVGPS

TDDAQETEAH
LELKALKPGV
YGSLHFDPEA
GLPLHLPGNR
PPALPEPPGI
QGRSPSYAS

LEIREDGTVG
IQILGVKTSR
CSFRELLLED
SPHCDPAPQG
LAPQPPDVGS

V290

HSEGTFTSDV
SGGGGSGGGG
IREDGTVGGA
ILGVKTSRFL
FRELLLEDGY
HCDPAPQGPA
PQPPDVGSSD

SSYLEGQAAK
QVRQRYLYTD
AHQSPESLLE
CQKPDGALYG
NVYQSEAHGL
RFLPLPGLPP
PLAMVGPSQG

EFIAWLVKGG
DAQETEAHLE
LKALKPGVIQ
SLHFDPEACS
PLHLPGNRSP
ALPEPPGILA
RSPSYAS

V291

GVSTSEAKFE
SGGGGSGGGD
AQETEAHLEI
KALKPGVIQI
LHFDPEACSF
LHLPGNRSPH
LPEPPGILAP
SPSYAS

QDSAILWYGV
SSPLLQFGGQ
REDGTVGGAA
LGVKTSRFLC
RELLLEDGYN
CDPAPQGPAR
QPPDVGSSDP

EFAKLHTSGG
VRQRYLYTDD
HQSPESLLEL
QKPDGALYGS
VYQSEAHGLP
FLPLPGLPPA
LAMVGPSQGR

V311

HSEGTFTSDV
SGGGGSGGGD
AQETEAHLEI
KALKPGVIQI
LHFDPEACSF
LHLPGNRSPH
LPEPPGILAP
SPSYAS

SSYLEGQAAK
SSPLLQFGGQ
REDGTVGGAA
LGVKTSRFLC
RELLLEDGYN
CDPAPQGPAR
QPPDVGSSDP

EFIAWLVKGG
VRQRYLYTDD
HQSPESLLEL
QKPDGALYGS
VYQSEAHGLP
FLPLPGLPPA
LAMVGGSQGR

R105KK150RR154C-40
kDa
branched
PEG-R159QS195A)
FGF21 (4220 9 ; Q 5 6ED74H-Q82ER105KK150RR154C-40
kDa
branched
PEG-R159QS195A)
GLP-1 (735; A8S) GSGGGGSGGGFGF21 (42209;Q5 6ED74H-Q82ER105KK150RR154C-40
kDa
branched
PEG-R159QS195A)
GLP-1 (735; A8S
scramble) GSGGGGSGGGFGF21 (33209;Q5 6ED74H-Q82ER105KK150RR154C-40
kDa
branched
PEG-R159QS195A)
GLP-1 (735; A8S) GSGGGGSGGGFGF21 (33209;Q5 6ED74H-Q82ER105KK150RR154C-40
kDa
branched

FGF21 (V
7 6 ; Ν∆ 9 )
4OKPEGb

GLP1 (A8S) L10FGF21 (V
7 6 ; Ν∆ 9 )
4OKPEGb

GLP1 (A8S; s
cramble
)-L10FGF21 (V
76) 4OKPEGb

GLP1 (A8S) L10FGF21 (V
76P199G) 4OKPEGb

PEG-R159QS195AP199G)

155

156

157

V312

CATTCTGAAG
TCTAGCTACC
GAATTCATCG
TCTGGTGGTG
TCGAGCCCGC
GTGCGTCAGC
GCGCAGGAAA
CGTGAAGATG
CATCAGAGCC
AAAGCGCTGA
CTGGGCGTGA
CAGAAACCGG
CTGCATTTTG
CGTGAACTGC
GTGTATCAGA
CTGCATCTGC
TGCGATCCGG
TTTCTGCCGC
CTGCCGGAAC
CAGCCGCCGG
CTGGCGATGG
AGCCCGAGCT

GCACTTTTAC
TGGAAGGCCA
CGTGGCTGGT
GTGGTTCTGG
TGCTGCAATT
GTTATCTGTA
CCGAAGCGCA
GCACCGTGGG
CGGAAAGCCT
AACCGGGCGT
AAACCAGCCG
ATGGCGCGCT
ATCCGGAAGC
TGCTGGAAGA
GCGAAGCGCA
CGGGCAACCG
CACCGCAGGG
TGCCGGGTCT
CGCCGGGTAT
ATGTTGGTAG
TGGGTGGTAG
ATGCGAGC

TAGCGATGTT
GGCTGCGAAA
TAAAGGCGGT
CGGTGGCGAC
TGGCGGCCAG
TACCGATGAT
TCTGGAAATT
CGGTGCGGCG
GCTGGAACTG
GATTCAGATT
TTTTCTGTGC
GTATGGCAGC
GTGCAGCTTT
TGGCTATAAC
TGGCCTGCCG
TAGCCCGCAT
TCCGGCGCGT
GCCGCCGGCA
TCTGGCCCCG
CAGCGATCCG
CCAGGGTCGT

GLP-1 (735; A8S) GSGGGGSGGGFGF21 (33209;Q5 6ED74H-Q82ER105KK150RR154C-40
kDa
branched
PEG-R159QS195AP199G)

GLP1 (A8S) L10FGF21 (V
76P199G) 4OKPEGb

HGEGTFTSDL
SGGGGSGGGG
QVRQRYLYTD
AHQSPESLLE
CQKPDGALYG
NVYQSEAHGL
RFLPLPGLPP
PLAMVGGSQG

SKQMEEEAVR
SGGGGSGGGG
DAQETEAHLE
LKALKPGVIQ
SLHFDPEACS
PLHLPGNRSP
ALPEPPGILA
RSPSYAS

LFIEWLKNGG
DSSPLLQFGG
IREDGTVGGA
ILGVKTSRFL
FRELLLEDGY
HCDPAPQGPA
PQPPDVGSSD

Ex (130) L20FGF21 (V
76P199G) 4OKPEGb

CATGGTGAGG
TCTAAACAGA
CTGTTCATTG
TCTGGTGGTG
TCTGGCGGCG
GACTCGAGCC
CAGGTGCGTC
GATGCGCAGG
ATTCGTGAAG
GCGCATCAGA
CTGAAAGCGC
ATTCTGGGCG
TGCCAGAAAC

GTACGTTTAC
TGGAAGAAGA
AATGGCTGAA
GTGGTTCTGG
GTGGTAGCGG
CGCTGCTGCA
AGCGTTATCT
AAACCGAAGC
ATGGCACCGT
GCCCGGAAAG
TGAAACCGGG
TGAAAACCAG
CGGATGGCGC

TTCTGATCTG
AGCTGTTCGC
AAATGGTGGT
CGGTGGCGGT
TGGCGGCGGT
GTTTGGCGGC
GTATACCGAT
GCATCTGGAA
GGGCGGTGCG
CCTGCTGGAA
CGTGATTCAG
CCGTTTTCTG
GCTGTATGGC

Exendin4 (130) S (GGGGS) 3
GGGGFGF21 (33209;Q5 6ED74H-Q82ER105KK150RR154C-40
kDa
branched
PEG-R159QS195AP199G)
Exendin4 (130) S (GGGGS) 3
GGGGFGF21 (33209;Q5 6ED74H-Q82ER105KK150RR154C-40
kDa
branched
PEG-R159Q-

Ex (130) L20FGF21 (V
76P199G) 4OKPEGb

158

V313

159

V314

160

V315

AGCCTGCATT
TTTCGTGAAC
AACGTGTATC
CCGCTGCATC
CATTGCGATC
CGTTTTCTGC
GCACTGCCGG
CCGCAGCCGC
CCGCTGGCGA
CGTAGCCCGA
HGEGTFTSDL
PSSGAPPPSG
PPCPAPEAAG
PEVTCVWDV
AKTKPREEQY
KEYKCKVSNK
QVYTLPPSRE
IAVEWESNGQ
YSKLTVDKSR
TQKSLSLSPG
YTDDACQTEA
LLQLKALKPG
LYGSLHFDPE
HGLPLHLPCN
LPPALPEPPG
SQARSPSYA
HGEGTFTSDL
PSSGAPPPSG
PPCPAPEAAG
PEVTCVWDV
AKTKPREEQY
KEYKCKVSNK
QVYTLPPSRE
IAVEWESNGQ
YSKLTVDKSR
TQKSLSLSPG
YTDDACQTEA
LLQLKALKPG
LYGSLHFDPE
HGLPLHLPCN
LPPALPEPPG
SQARSPSY
HGEGTFTSDL
PSSGAPPPSG
PPCPAPEAAG
PEVTCVWDV
AKTKPREEQY
KEYKCKVSNK
QVYTLPPSRE
IAVEWESNGQ
YSKLTVDKSR
TQKSLSLSPG
YTDDACQTEA
LLQLKALKPG
LYGSLHFDPE

TTGATCCGGA
TGCTGCTGGA
AGAGCGAAGC
TGCCGGGCAA
CGGCACCGCA
CGCTGCCGGG
AACCGCCGGG
CGGATGTTGG
TGGTGGGTGG
GCTATGCGAG
SKQMEEEAVR
GGGSGGGGSG
GPSVFLFPPK
SHEDPEVKFN
NSTYRWSVL
ALPAPIEKTI
EMTKNQVSLT
PENNYKTTPP
WQQGNVFSCS
KGSDSSPLLQ
HLEIREDGTV
VIQILGVKTS
ACSFRELLLE
RSPHRDPASR
ILAPQPPDVG

AGCGTGCAGC
AGATGGCTAT
GCATGGCCTG
CCGTAGCCCG
GGGTCCGGCG
TCTGCCGCCG
TATTCTGGCC
TAGCAGCGAT
TAGCCAGGGT
C
LFIEWLKNGG
GGGSDKTHTC
PKDTLMISRT
WYVDGVEVHN
TVLHQDWLNG
SKAKGQPREP
CLVKGFYPSD
VLDSDGSFFL
VMHEALHNHY
FGGQVRQRYL
GGAADQSPES
RFLCQKPDGA
DGYNVYQSEA
GPARFLPLPG
SSDPLAMVGG

SKQMEEEAVR
GGGSGGGGSG
GPSVFLFPPK
SHEDPEVKFN
NSTYRWSVL
ALPAPIEKTI
EMTKNQVSLT
PENNYKTTPP
WQQGNVFSCS
KGSDSSPLLQ
HLEIREDGTV
VIQILGVKTS
ACSFRELLLE
RSPHRDPASR
ILAPQPPDVG
SKQMEEEAVR
GGGSGGGGSG
GPSVFLFPPK
SHEDPEVKFN
NSTYRWSVL
ALPAPIEKTI
EMTKNQVSLT
PENNYKTTPP
WQQGNVFSCS
KGSDSSPLLQ
HLEIREDGTV
VIQILGVKTS
ACSFRELLLE

S195AP199G)

Exendin4 (139) (GGGGS) 3 -FcGS-FGF21
(33-208;
Q55C-R105KG148CK150RP158SP174LS195AP199GG202A)

Ex (139) L15-FCL2FGF21 (V
103;CA1
)

LFIEWLKNGG
GGGSDKTHTC
PKDTLMISRT
WYVDGVEVHN
TVLHQDWLNG
SKAKGQPREP
CLVKGFYPSD
VLDSDGSFFL
VMHEALHNHY
FGGQVRQRYL
GGAADQSPES
RFLCQKPDGA
DGYNVYQSEA
GPARFLPLPG
SSDPLAMVGG

Exendin4 (139) (GGGGS) 3 -FcGS-FGF21
(33-207;
Q55C-R105KG148CK150RP158SP174LS195AP199GG202A)

Ex (139) L15-FCL2FGF21 (V
103;CA2
)

LFIEWLKNGG
GGGSDKTHTC
PKDTLMISRT
WYVDGVEVHN
TVLHQDWLNG
SKAKGQPREP
CLVKGFYPSD
VLDSDGSFFL
VMHEALHNHY
FGGQVRQRYL
GGAADQSPES
RFLCQKPDGA
DGYNVYQSEA

Exendin4 (139) (GGGGS) 3 -FcGS-FGF21
(33-206;
Q55C-R105KG148CK150RP158SP174LS195AP199GG202A)

Ex (139) L15-FCL2FGF21 (V
103;CA3
)

HGLPLHLPCN
LPPALPEPPG
SQARSPS

161

V316

162

V317

163

V225

164

165

V226

V229

RSPHRDPASR
ILAPQPPDVG

GPARFLPLPG
SSDPLAMVGG

HGEGTFTSDL SKQMEEEAVR LFIEWLKNGG
PSSGAPPPSG GGGSGGGGSG GGGSDKTHTC
PPCPAPEAAG GPSVFLFPPK PKDTLMISRT
PEVTCVWDV
SHEDPEVKFN WYVDGVEVHN
AKTKPREEQY NSTYRWSVL
TVLHQDWLNG
KEYKCKVSNK ALPAPIEKTI SKAKGQPREP
QVYTLPPSRE EMTKNQVSLT CLVKGFYPSD
IAVEWESNGQ PENNYKTTPP VLDSDGSFFL
YSKLTVDKSR WQQGNVFSCS VMHEALHNHY
TQKSLSLSPG KGSDSSPLLQ FGGQVRQRYL
YTDDACQTEA HLEIREDGTV GGAADQSPES
LLQLKALKPG VIQILGVKTS RFLCQKPDGA
LYGSLHFDPE ACSFRELLLE DGYNVYQSEA
HGLPLHLPCN RSPHRDPASR GPARFLPLPG
LPPALPEPPG ILAPQPPDVG SSDPLAMVGG
SQARSPSYAS P
HGEGTFTSDL SKQMEEEAVR LFIEWLKNGG
PSSGAPPPSG GGGSGGGGSG GGGSDKTHTC
PPCPAPEAAG GPSVFLFPPK PKDTLMISRT
PEVTCVWDV
SHEDPEVKFN WYVDGVEVHN
AKTKPREEQY NSTYRWSVL
TVLHQDWLNG
KEYKCKVSNK ALPAPIEKTI SKAKGQPREP
QVYTLPPSRE EMTKNQVSLT CLVKGFYPSD
IAVEWESNGQ PENNYKTTPP VLDSDGSFFL
YSKLTVDKSR WQQGNVFSCS VMHEALHNHY
TQKSLSLSPG KGSDSSPLLQ FGGQVRQRYL
YTDDACQTEA HLEIREDGTV GGAADQSPES
LLQLKALKPG VIQILGVKTS RFLCQKPDGA
LYGSLHFDPE ACSFRELLLE DGYNVYQSEA
HGLPLHLPCN RSPHRDPASR GPARFLPLPG
LPPALPEPPG ILAPQPPDVG SSDPLAMVGG
SQARSPSYAA P
HAEGTFTSDVSSYLEGQAAKEFIAWLVKGGSG
DSSPLLQFGGQVRQRYLYTDDAQQTEAHLEIR
EDGTVGGAADQSPESLLQLKALKPGVIQILGV
KTSRFLCQRPDGALYGSLHFDPEACSFRELLL
EDGYNVYQSEAHGLPLHLPGNKSPHCDPAPRG
PARFLPLPGLPPALPEPPGILAPQPPDVGSSD
PLSMVGPSQGRSPSYAS
HSEGTFTSDVSSYLEGQAAKEFIAWLVKGGSG
DSSPLLQFGGQVRQRYLYTDDAQQTEAHLEIR
EDGTVGGAADQSPESLLQLKALKPGVIQILGV
KTSRFLCQRPDGALYGSLHFDPEACSFRELLL
EDGYNVYQSEAHGLPLHLPGNKSPHCDPAPRG
PARFLPLPGLPPALPEPPGILAPQPPDVGSSD
PLSMVGPSQGRSPSYAS
HAEGTFTSDVSSYLEGQAAKEFIAWLVKGGSG
DSSPLLQFGGQVRQRYLYTDDAQQTEAHLEIR
EDGTVGGAADQSPESLLQLKALKPGVIQILGV
KTSRFLCQRPDGALYGSLHFDPEACSFRELLL

Exendin4 (139) (GGGGS) 3 -FcGS-FGF21
(33-209;
Q55C-R105KG148CK150RP158SP174LS195AP199GG202A) -P

Ex (139) L15-FCL2FGF21 (V
103) +P2

Exendin4 (139) (GGGGS) 3 -FcGS-FGF21
(33-209;
Q55C-R105KG148CK150RP158SP174LS195AP199GG202AS209A) -p

Ex (139) L15-FCL2FGF21 (V
103S209A
)+P210

GLP-1 (735) -SGFGF21 (33209;R154C)

GLP-1L2FGF21 (1

GLP-1 (7-35;
A8S) -SGFGF21 (33209;R154C)

GLP1 (A8S) L2FGF21 (1

10

54C)

54C)

GLP-1 (735) -SGFGF21 (33209;R154C-

GLP-1L2FGF21 (1
54C) -

V230

V231

V232

V237

V238

V253

V258

EDGYNVYQSEAHGLPLHLPGNKSPHCDPAPRG
PARFLPLPGLPPALPEPPGILAPQPPDVGSSD
PLSMVGPSQGRSPSYAS

40 kDa
linear PEG)

40KPEG1

HSEGTFTSDVSSYLEGQAAKEFIAWLVKGGSG
DSSPLLQFGGQVRQRYLYTDDAQQTEAHLEIR
EDGTVGGAADQSPESLLQLKALKPGVIQILGV
KTSRFLCQRPDGALYGSLHFDPEACSFRELLL
EDGYNVYQSEAHGLPLHLPGNKSPHCDPAPRG
PARFLPLPGLPPALPEPPGILAPQPPDVGSSD
PLSMVGPSQGRSPSYAS
HAEGTFTSDVSSYLEGQAAKEFIAWLVKGGSG
GGGSGGGDSSPLLQFGGQVRQRYLYTDDAQQT
EAHLEIREDGTVGGAADQSPESLLQLKALKPG
VIQILGVKTSRFLCQRPDGALYGSLHFDPEAC
SFRELLLEDGYNVYQSEAHGLPLHLPGNKSPH
CDPAPRGPARFLPLPGLPPALPEPPGILAPQP
PDVGSSDPLSMVGPSQGRSPSYAS
HSEGTFTSDVSSYLEGQAAKEFIAWLVKGGSG
GGGSGGGDSSPLLQFGGQVRQRYLYTDDAQQT
EAHLEIREDGTVGGAADQSPESLLQLKALKPG
VIQILGVKTSRFLCQRPDGALYGSLHFDPEAC
SFRELLLEDGYNVYQSEAHGLPLHLPGNKSPH
CDPAPRGPARFLPLPGLPPALPEPPGILAPQP
PDVGSSDPLSMVGPSQGRSPSYAS
HAEGTFTSDVSSYLEGQAAKEFIAWLVKGGSG
DSSPLLQFGGQVRQRYLYTDDAQQTEAHLEIR
EDGTVGGAADQSPESLLQLKALKPGVIQILGV
KTSRFLCQRPDGALYGSLHFDPEACSFRELLL
EDGYNVYQSEAHGLPLHLPGNKSPHCDPAPRG
PARFLPLPGLPPALPEPPGILAPQPPDVGSSD
PLSMVGPSQGRSPSYAS
GDSSPLLQFGGQVRQRYLYTDDAQQTEAHLEI
REDGTVGGAADQSPESLLQLKALKPGVIQILG
VKTSRFLCQRPDGALYGSLHFDPEACSFRELL
LEDGYNVYQSEAHGLPLHLPGNKSPHCDPAPR
GPARFLPLPGLPPALPEPPGILAPQPPDVGSS
DPLSMVGPSQGRSPSYAS
HSEGTFTSDVSSYLEGQAAKEFIAWLVKGGSG
GGGSGGGDSSPLLQFGGQVRQRYLYTDDAQQT
EAHLEIREDGTVGGAADQSPESLLQLKALKPG
VIQILGVKTSRFLCQRPDGALYGSLHFDPEAC
SFRELLLEDGYNVYQSEAHGLPLHLPGNKSPH
CDPAPRGPARFLPLPGLPPALPEPPGILAPQP
PDVGSSDPLS

GLP-1 (7-35;
A8S) -SGFGF21 (33209;R154C40 kDa
linear PEG)

GLP1 (A8S) L2FGF21 (1
54C) 40KPEG1

GLP-1 (735) SGGGGSGGGFGF21 (33209;R154C40 kDa
linear PEG)
GLP-1 (7-35;
A8S) SGGGGSGGGFGF21 (33209;R154C40 kDa
linear PEG)
GLP-1 (735) -SGFGF21 (33209;R154C40 kDa
branched

GLP-1L8FGF21 (1
54C) 40KPEG1

HGEGTFTSDVSSYLEGQAAKEFIAWLVKGGSG
GGGSGGGDSSPLLQFGGQVRQRYLYTDDAQQT
EAHLEIREDGTVGGAADQSPESLLQLKALKPG
VIQILGVKTSRFLCQRPDGALYGSLHFDPEAC
SFRELLLEDGYNVYQSEAHGLPLHLPGNKSPH
CDPAPRGPARFLPLPGLPPALPEPPGILAPQP
PDVGSSDPLSMVGPSQGRSPSYAS

GLP1 (A8S) L8FGF21 (1
54C) 40KPEG1
GLP-1L2FGF21 (1
54C) 4OKPEGb

PEG)

G-FGF21 (33209;R154C40 kDa
branched

FGF21 (R
154C) 4OKPEGb

PEG)

GLP-1 (7-35;
A8S) SGGGGSGGGFGF21 (33194;R154C40 kDa
branched
PEG)
GLP-1 (7-35;
A8G) SGGGGSGGGFGF21 (33209;R154C40 kDa
branched
PEG)

GLP1 (A8S) L8FGF21(CA14; 1
54C) 4OKPEGb
GLP1 (A8G) L8FGF21 (1
54C) 4OKPEGb

[00051]

The variants or mutants used in the proteins of the invention, e.g., variants of

wild-type FGF21, GLP-1, and/or Exendin-4 feature at least one substituted, added,
and/or removed amino acid relative to the wild-type protein. Additionally, the variants
may include N-and/or C-terminal truncations relative to the wild-type proteins. Generally
speaking, a variant possesses some modified property, structural or functional, of the

wild-type protein. For example, the variant may have enhanced or improved physical
stability in concentrated solutions (e.g., less hydrophobic mediated aggregation),
enhanced or improved plasma stability when incubated with blood plasma or reduced
risk for immunogenicity or enhanced or improved bioactivity while maintaining a

favorable bioactivity profile.
[00052]

Acceptable amino acid substitutions and modifications which constitute

differences between the portions of the proteins of the invention and their wild-type
comparator proteins include, but are not limited to, one or more amino acid
substitutions, including substitutions with pyrrolysine, pyrroline-carbyoxy-lysine (Pel) and
non-naturally occurring amino acid analogs, and truncations. Thus, the proteins of the
invention (e.g., the fusion proteins of the invention) include, but are not limited to, sitedirected mutants, truncated polypeptides, proteolysis-resistant mutants, aggregationreducing mutants, combination mutants, and fusion proteins, as described herein.
[00053]

One skilled in the art of expression of proteins will recognize that methionine

or methionine-arginine sequence can be introduced at the N-terminus of any of the
proteins of the invention, for expression in E . coli, and are contemplated within the
context of this invention.
[00054]

One skilled in the art of expression of proteins will recognize that additional

tags or fusion domains for the purposes of modulating expression levels, purification, or
stabilization can be introduced to the N-terminus of any of the proteins of the invention,
with or without an additional peptide to target digestion by a specific protease for later
removal of that tag or fusion domain, for expression in any host cell, and are
contemplated within the context of this invention.
[00055]

One skilled in the art of expression of proteins will recognize that leader

peptides targeting the expressed protein to the periplasm or extracellular space can be
introduced at the N-terminus of any of the proteins of the invention, for expression in E .
coli or other bacterial hosts, and are contemplated within the context of this invention.

[00056]

One skilled in the art of expression of proteins will recognize that leader

peptides targeting the expressed protein to the ER, secretory vesicles, or extracellular
space can be introduced at the N-terminus of any of the proteins of the invention, for

expression in eukaryotic host cells, and are contemplated within the context of this
invention.

[00057]

The proteins of the invention may possess increased compatibility with

pharmaceutical preservatives (e.g., m-cresol, phenol, benzyl alcohol), thus enabling the
preparation of a preserved pharmaceutical formulation that maintains the
physiochemical properties and biological activity of the protein during storage.
Accordingly, variants with enhanced pharmaceutical stability relative to wild-type, have
improved physical stability in concentrated solutions under both physiological and
preserved pharmaceutical formulation conditions, while maintaining biological potency.
By way of non-limiting example, the proteins of the invention may be more resistant to

proteolysis and enzymatic degradation; may have improved stability; and may be less
likely to aggregate, than their wild-type counterparts or corresponding native sequence.
As used herein, these terms are not mutually exclusive or limiting, it being entirely
possible that a given variant has one or more modified properties of the wild-type
protein.

[00058]

The invention also encompasses nucleic acid molecules encoding the

proteins of the invention, comprising, for example, an FGF21 amino acid sequence that
is at least about 95% identical to the amino acid sequence of SEQ ID NO:3, but wherein

specific residues conferring a desirable property to the FGF21 protein variant, e.g.,
improved potency to FGF21 -receptors, proteolysis-resistance, increased half-life or
aggregation-reducing properties and combinations thereof have not been further
modified. In other words, with the exception of residues in the FGF21 mutant sequence
that have been modified in order to confer proteolysis-resistance, aggregation-reducing,
or other properties, about 5% (alternately 4%, alternately 3%, alternately 2%, alternately
1%) of all other amino acid residues in the FGF21 mutant sequence can be modified.

Such FGF21 mutants possess at least one activity of the wild-type FGF21 polypeptide.

[00059]

Similarly, the invention also comprises nucleic acid molecules encoding the

GLP-1 and Exendin-4 portions of the molecule, whose amino acid sequences are at

least about 85%, identical, and more preferably at least about 90 to 95% identical, to the
amino acid sequence of SEQ ID NO:30 and 7 , respectively, but wherein specific
residues conferring a desirable property to the dual function protein variant, e.g.,
proteolysis-resistance, increased half-life or aggregation-reducing properties and
combinations thereof have not been further modified.

[00060]

The invention also encompasses a nucleic acid molecule comprising a

nucleotide sequence that is at least about 85%, identical, and more preferably, at least
about 90 to 95% identical to the nucleotide sequence of SEQ ID NO:2, SEQ ID NO:4,
SEQ ID NO:6, and the cDNA sequence encoding wild-type Exendin-4, but wherein the

nucleotides encoding amino acid residues conferring the encoded protein's proteolysisresistance, aggregation-reducing or other properties have not been further modified. In
other words, with the exception of nucleotides that encode residues in the FGF21 , GLP1,

or Exendin-4 mutant sequences that have been modified in order to confer

proteolysis-resistance, aggregation-reducing, or other properties, about 15%, and more
preferably about 10 to 5% of all other nucleotides in the mutant sequence can be
modified. Such nucleic acid molecules encode proteins possessing at least one activity
of their wild-type counterparts.

[00061]

Provided herein are methods used to generate the proteins of the invention,

wherein such methods involve site-specific modification and non-site-specific
modification of the wild-type versions of the proteins (e.g., the FGF21 wild-type protein
as described herein), e.g., truncations of the wild-type proteins, and the site-specific

incorporation of amino acids at positions of interest within the wild-type proteins. Said
modifications enhance the biological properties of the proteins of the invention relative
to the wild-type proteins, as well as, in some cases, serving as points of attachment for,
e.g., labels and protein half-life extension agents, and for purposes of affixing said

variants to the surface of a solid support. Related embodiments of the invention are
methods of producing cells capable of producing said dual function proteins of the
invention, and of producing vectors containing DNA encoding said variants.

[00062]

In certain embodiments, such modifications, e.g., site-specific modifications,

are used to attach conjugates, e.g., PEG groups to proteins, polypeptides, and/or
peptides of the invention, for purposes of, e.g., extending half-life or otherwise improving
the biological properties of said proteins, polypeptides, and/or peptides. Said
techniques are described further herein.

[00063]

In other embodiments, such modifications, e.g., site-specific modifications

are used to attach other polymers, small molecules and recombinant protein sequences
that extend half-life of the protein of the invention. One such embodiment includes the
attachment of fatty acids or specific albumin binding compounds to proteins,
polypeptides, and/or peptides. In other embodiments, the modifications are made at a
particular amino acid type and may be attached at one or more sites on the protein.

[00064]

In other embodiments, such modifications, e.g., site-specific modifications

are used as means of attachment for the production of wild-type and/or variant
multimers, e.g., dimers (homodimers or heterodimers) or trimers or tetramers. These
multimeric protein molecules may additionally have groups such as PEG, sugars, and/or
PEG-cholesterol conjugates attached or be fused either amino-terminally or carboxyterminally to other proteins such as Fc, Human Serum Albumin (HSA), etc.

[00065]

In other embodiments, such site-specific modifications are used to produce

proteins, polypeptides and/or peptides wherein the position of the site-specifically
incorporated pyrrolysine, pyrroline-carboxy-lysine, or pyrrolysine analogue or nonnaturally occurring amino acids (para-acetyl-Phe, para-azido-Phe) allows for controlled
orientation and attachment of such proteins, polypeptides and/or peptides onto a
surface of a solid support or to have groups such as PEG, sugars and/or PEGcholesterol conjugates attached.

[00066]

In other embodiments, such site-specific modifications are used to site-

specifically cross-link proteins, polypeptides and/or peptides thereby forming heterooligomers including, but not limited to, heterodimers and heterotrimers. In other
embodiments, such site-specific modifications are used to site-specifically cross-link
proteins, polypeptides and/or peptides thereby forming protein-protein conjugates,
protein-polypeptide conjugates, protein-peptide conjugates, polypeptide-polypeptide
conjugates, polypeptide-peptide conjugates or peptide-peptide conjugates. In other
embodiments, a site specific modification may include a branching point to allow more
than one type of molecule to be attached at a single site of a protein, polypeptide or
peptide.

[00067]

In other embodiments, the modifications listed herein can be done in a non-

site-specific manner and result in protein-protein conjugates, protein-polypeptide
conjugates, protein-peptide conjugates, polypeptide-polypeptide conjugates,
polypeptide-peptide conjugates or peptide-peptide conjugates of the invention.

Definitions
[00068]

Various definitions are used throughout this document. Most words have the

meaning that would be attributed to those words by one skilled in the art. Words
specifically defined either below or elsewhere in this document have the meaning
provided in the context of the present invention as a whole and as are typically
understood by those skilled in the art.

[00069]

As used herein, the term "FGF21 " refers to a member of the fibroblast growth

factor (FGF) protein family. An amino acid sequence of FGF21 (GenBank Accession
No. NP_061 986.1 ) is set forth as SEQ ID NO:1 , the corresponding polynucleotide

sequence of which is set forth as SEQ ID NO:2 (NCBI reference sequence number
NM_0191 13.2). "FGF21 variant," "FGF21 mutant," and similar terms describe modified

version of the FGF21 protein, e.g., with constituent amino acid residues deleted, added,
modified, or substituted.

[00070]

As used herein, the term "FGF21 receptor" refers to a receptor for FGF21

(Kharitonenkov,A,

et al. (2008) Journal of Cellular Physiology 215:1-7; Kurosu,Het al.

(2007) JBC 282:26687-26695; Ogawa, Yet al. (2007) PNAS 104:7432-7437).

[00071]

The term "FGF21 polypeptide" refers to a naturally-occurring polypeptide

expressed in humans. For purposes of this disclosure, the term "FGF21 polypeptide"
can be used interchangeably to refer to any full-length FGF21 polypeptide, e.g., SEQ ID
NO:1 , which consists of 209 amino acid residues and which is encoded by the

nucleotide sequence of SEQ ID NO:2; any mature form of the polypeptide, which
consists of 181 amino acid residues, and in which the 28 amino acid residues at the
amino-terminal end of the full-length FGF21 polypeptide (i.e., which constitute the signal
peptide) have been removed.

[00072]

"Variant 76," or "V76," as used herein, is an FGF21 protein variant, featuring

a 40 kDa branched PEG linked through Cys154, and eight point mutations relative to
the 177 amino acid wild-type protein. Synthesis of the variant is described in greater
detail herein.

[00073]

"Variant 101 ," or "V101," as used herein, is an FGF21 protein variant,

featuring an engineered disulfide bridge, and eight point mutations relative to the 177
amino acid wild-type protein, expressed as a fusion to human lgG1 Fc-domain with a
GS linker. Synthesis of the variant is described in greater detail herein.

[00074]

"Variant 103," or "V103," as used herein, is an FGF21 protein variant,

featuring an engineered disulfide bridge, and eight point mutations relative to the 177
amino acid wild-type protein, expressed as a fusion to human lgG1 Fc-domain with a
GS linker. Synthesis of the variant is described in greater detail herein.

[00075]

"Variant 188," or "V188," as used herein, is an FGF21 protein variant,

featuring an engineered disulfide bridge, and eight point mutations relative to the 177
amino acid wild-type protein, expressed as a fusion to human lgG1 Fc-domain with a
(SGGGG) 3 linker. Synthesis of the variant is described in greater detail herein

[00076]

"GLP-1-FGF21-PEG dual agonists," "dual function proteins," "dual function

fusion proteins," "dual activity proteins," "fusion products," "dual FGF21 receptor agonist
and GLP-1 receptor agonist," "dual FGF21 receptor agonist and GLP-1 receptor agonist

proteins of the invention," "GLP-1-FGF21 fusion proteins," "fusion proteins of the
invention," "fusions of the invention," and similar terms define protein or polypeptide
fusions comprising at least an FGF21 polypeptide or protein variant, mutant, or
truncated version, fused or linked to another metabolic regulator such as GLP-1 or
Exendin-4. They comprise a single molecule with dual activity or dual function vis-a-vis
the receptors of their respective constituents, i.e., they show the ability to agonize the
FGF21 receptor and the GLP-1 receptor. The constituent sequences of said fusion

proteins may comprise modifications, truncations, other variants of naturally occurring
(i.e., wild-type) protein or polypeptide counterparts, and may employ any number of

various other modifications, e.g., PEG groups for half-life extension.

[00077]

A particularly preferred embodiment of the GLP-1 -FGF21 -PEG fusion protein

of the invention incorporates V76 (as defined herein) as the FGF21 variant. Said
preferred embodiment is also referred to herein as "GLP-1 (A8S)-FGF21-PEG" and
features a substitution from alanine to serine at position 8 relative to the wild-type GLP-1
sequence (SEQ ID NO:5129) and substitution from arginine to cysteine at position 154
relative to the wild-type FGF21 sequence (SEQ ID:1). The sequence of GLP-1 (A8S)FGF21 (V76)-PEG is as follows (SEQ ID NO:9).

1

HSEGTFTSDV SSYLEGQAAK EFIAWLVKGG SGGGGSGGGD SSPLLQFGGQ VRQRYLYTDD

61

AQETEAHLEI REDGTVGGAA HQSPESLLEL KALKPGVIQI LGVKTSRFLC QKPDGALYGS

121 LHFDPEACSF RELLLEDGYN VYQSEAHGLP LHLPGNRSPH CDPAPQGPAR FLPLPGLPPA
181 LPEPPGILAP QPPDVGSSDP LAMVGPSQGR SPSYAS

[00078]

The term "isolated nucleic acid molecule" refers to a nucleic acid molecule of

the present invention that (1) has been separated from at least about 50 percent of
proteins, lipids, carbohydrates, or other materials with which it is naturally found when
total nucleic acid is isolated from the source cells, (2) is not linked to all or a portion of a
polynucleotide to which the "isolated nucleic acid molecule" is linked in nature, (3) is
operably linked to a polynucleotide which it is not linked to in nature, or (4) does not
occur in nature as part of a larger polynucleotide sequence. Preferably, the isolated
nucleic acid molecule of the present invention is substantially free from any other
contaminating nucleic acid molecules or other contaminants that are found in its natural
environment that would interfere with its use in polypeptide production or its therapeutic,
diagnostic, prophylactic or research use.

[00079]

The term "vector" is used to refer to any molecule (e.g., nucleic acid,

plasmid, or virus) used to transfer coding information to a host cell.

[00080]

The term "expression vector" refers to a vector that is suitable for

transformation of a host cell and contains nucleic acid sequences that direct and/or
control the expression of inserted heterologous nucleic acid sequences. Expression
includes, but is not limited to, processes such as transcription, translation, and RNA
splicing, if introns are present.

[00081]

The term "operably linked" is used herein to refer to an arrangement of

flanking sequences wherein the flanking sequences so described are configured or
assembled so as to perform their usual function. Elements of fusions proteins may be

operably linked to one another so as to allow the fusion protein to function as if it were a
naturally occurring, endogenous protein, and/or to combine disparate elements of said
fusion proteins in a synergistic fashion.

[00082]

On a nucleotide level, a flanking sequence operably linked to a coding

sequence may be capable of effecting the replication, transcription and/or translation of
the coding sequence. For example, a coding sequence is operably linked to a promoter
when the promoter is capable of directing transcription of that coding sequence. A
flanking sequence need not be contiguous with the coding sequence, so long as it
functions correctly. Thus, for example, intervening untranslated yet transcribed
sequences can be present between a promoter sequence and the coding sequence and
the promoter sequence can still be considered "operably linked" to the coding sequence.

[00083]

The term "host cell" is used to refer to a cell which has been transformed, or

is capable of being transformed with a nucleic acid sequence and then of expressing a

selected gene of interest. The term includes the progeny of the parent cell, whether or
not the progeny is identical in morphology or in genetic make-up to the original parent,
so long as the selected gene is present.

[00084]

The term "amino acid," as used herein, refers to naturally occurring amino

acids, unnatural amino acids, amino acid analogues and amino acid mimetics that

function in a manner similar to the naturally occurring amino acids, all in their D and L
stereoisomers if their structure allows such stereoisomeric forms. Amino acids are
referred to herein by either their name, their commonly known three letter symbols or by
the one-letter symbols recommended by the lUPAC-IUB Biochemical Nomenclature
Commission.

[00085]

The term "naturally occurring" when used in connection with biological

materials such as nucleic acid molecules, polypeptides, host cells, and the like, refers to
materials which are found in nature and are not manipulated by man. Similarly, "nonnaturally occurring" as used herein refers to a material that is not found in nature or that
has been structurally modified or synthesized by man. When used in connection with

nucleotides, the term "naturally occurring" refers to the bases adenine (A), cytosine (C),
guanine (G), thymine (T), and uracil (U). When used in connection with amino acids,
the term "naturally occurring" refers to the 20 conventional amino acids (i.e., alanine (A),
cysteine (C), aspartic acid (D), glutamic acid (E), phenylalanine (F), glycine (G), histidine
(H), isoleucine (I), lysine (K), leucine (L), methionine (M), asparagine (N), proline (P),

glutamine (Q), arginine (R), serine (S), threonine (T), valine (V), tryptophan (W), and
tyrosine (Y)), as well as selenocysteine, pyrrolysine (Pyl, or O), and pyrroline-carboxylysine (Pel, or Z).

[00086]

Pyrrolysine (Pyl) is an amino acid naturally found within methylamine

methyltransferases of methanogenic archaea of the family Methanosarcina. Pyrrolysine
is a lysine analogue co-translationally incorporated at in-frame UAG codons in the

respective mRNA, and it is considered the 22nd natural amino acid.

[00087]

As described at least in PCT patent publication WO201 0/48582 (applicant

IRM, LLC), attempts to biosynthesize pyrrolysine (Pyl) in E . coli resulted in the formation

of a "demethylated pyrrolysine," referred to herein as pyrroline-carboxy-lysine, or Pel.
"Pel," as used herein, refers to either Pcl-A or Pcl-B.

[00088]

The terms "non-natural amino acid" and "unnatural amino acid," as used

herein, are interchangeably intended to represent amino acid structures that cannot be

generated biosynthetically in any organism using unmodified or modified genes from
any organism, whether the same or different. The terms refer to an amino acid residue
that is not present in the naturally occurring (wild-type) FGF21 protein sequence or the
sequences of the present invention. These include, but are not limited to, modified
amino acids and/or amino acid analogues that are not one of the 20 naturally occurring
amino acids, selenocysteine, pyrrolysine (Pyl), or pyrroline-carboxy-lysine (Pel, e.g., as
described in PCT patent publication WO20 10/48582). Such non-natural amino acid
residues can be introduced by substitution of naturally occurring amino acids, and/or by
insertion of non-natural amino acids into the naturally occurring (wild-type) FGF21
protein sequence or the sequences of the invention. The non-natural amino acid
residue also can be incorporated such that a desired functionality is imparted to the
FGF21 molecule, for example, the ability to link a functional moiety (e.g., PEG). When

used in connection with amino acids, the symbol "U" shall mean "non-natural amino

acid" and "unnatural amino acid," as used herein.

[00089]

In addition, it is understood that such "unnatural amino acids" typically

require a modified tRNA and a modified tRNA synthetase (RS) for incorporation into a
protein. These "selected" orthogonal tRNA/RS pairs are generated by a selection
process as developed by Schultz et al. or by random or targeted mutation. As way of
example, pyrroline-carboxy-lysine is a "natural amino acid" as it is generated
biosynthetically by genes transferred from one organism into the host cells and as it is
incorporated into proteins by using natural tRNA and tRNA synthetase genes, while paminophenylalanine (See, Generation of a bacterium with a 2 1 amino acid genetic code,
Mehl RA, Anderson JC, Santoro SW, Wang L , Martin AB, King DS, Horn DM, Schultz
PG. J A m Chem Soc. 2003 Jan 29;125(4):935-9) is an "unnatural amino acid" because,

although generated biosynthetically, it is incorporated into proteins by a "selected" (i.e.
not "naturally-occurring") orthogonal tRNA/tRNA synthetase pair.

[00090]

Modified encoded amino acids include, but are not limited to, hydroxyproline,

γ -carboxyglutamate, O-phosphoserine, azetidinecarboxylic acid, 2-aminoadipic acid, 3-

aminoadipic acid, beta-alanine, aminopropionic acid, 2-aminobutyric acid, 4aminobutyric acid, 6-aminocaproic acid, 2-aminoheptanoic acid, 2-aminoisobutyric acid,
3-aminoisobutyric acid, 2-aminopimelic acid, tertiary-butylglycine, 2,4-diaminoisobutyric
acid, desmosine, 2,2'-diaminopimelic acid, 2,3-diaminoproprionic acid, N-ethylglycine,

N-methylglycine, N-ethylasparagine, homoproline, hydroxylysine, allo-hydroxylysine, 3hydroxyproline, 4-hydroxyproline, isodesmosine, allo-isoleucine, N-methylalanine, Nmethylglycine, N-methylisoleucine, N-methylpentylglycine, N-methylvaline,
naphthalanine, norvaline, norleucine, ornithine, pentylglycine, pipecolic acid and
thioproline. The term "amino acid" also includes naturally occurring amino acids that are
metabolites in certain organisms but are not encoded by the genetic code for
incorporation into proteins. Such amino acids include, but are not limited to, ornithine,
D-ornithine, and D-arginine.

[00091]

The term "amino acid analogue," as used herein, refers to compounds that

have the same basic chemical structure as a naturally occurring amino acid, by way of
example only, an a-carbon that is bound to a hydrogen, a carboxyl group, an amino
group, and an R group. Amino acid analogues include the natural and unnatural amino
acids which are chemically blocked, reversibly or irreversibly, or their C-terminal carboxy
group, their N-terminal amino group and/or their side-chain functional groups are
chemically modified. Such analogues include, but are not limited to, methionine
sulfoxide, methionine sulfone, S-(carboxymethyl)-cysteine, S-(carboxymethyl)-cysteine
sulfoxide, S-(carboxymethyl)-cysteine sulfone, aspartic acid-(beta-methyl ester), Nethylglycine, alanine carboxamide, homoserine, norleucine, and methionine methyl
sulfonium.

[00092]

The term "amino acid mimetics," as used herein, refers to chemical

compounds that have a structure that is different from the general chemical structure of
an amino acid, but functions in a manner similar to a naturally occurring amino acid.

[00093]

The term "biologically active variant" refers to any polypeptide variant used in

the dual function proteins of the invention, e.g., as a constituent protein of the fusions,
that possesses an activity of its wild-type (e.g., naturally-occurring) protein or
polypeptide counterpart, such as the ability to modulate blood glucose, HbA1c, insulin,
triglyceride, or cholesterol levels; increase pancreatic function; reduce lipid levels in
liver; reduce body weight; and to improve glucose tolerance, energy expenditure, or

insulin sensitivity, regardless of the type or number of modifications that have been

introduced into the polypeptide variant. Polypeptide variants possessing a somewhat

decreased level of activity relative to their wild-type versions can nonetheless be
considered to be biologically active polypeptide variants. A non-limiting representative
example of a biologically active polypeptide variant of the invention is an FGF21 variant,
which is modified after, and possesses similar or enhanced biological properties relative
to, wild-type FGF21 .

[00094]

The terms "effective amount" and "therapeutically effective amount" each

refer to the amount of a fusion protein of the invention used to support an observable
level of one or more biological activities of the wild-type polypeptide or protein
counterparts, such as the ability to lower blood glucose, insulin, triglyceride or
cholesterol levels; reduce liver triglyceride or lipid levels; reduce body weight; or improve
glucose tolerance, energy expenditure, or insulin sensitivity. For example, a
"therapeutically-effective amount" administered to a patient exhibiting, suffering, or
prone to suffer from FGF21 -associated disorders or GLP-1 -associated disorders (such
as type 1 or type 2 diabetes mellitus, obesity, or metabolic syndrome), is such an

amount which induces, ameliorates or otherwise causes an improvement in the
pathological symptoms, disease progression, physiological conditions associated with or
resistance to succumbing to the afore mentioned disorders. For the purposes of the
present invention a "subject" or "patient" is preferably a human, but can also be an
animal, more specifically, a companion animal (e.g., dogs, cats, and the like), farm
animals (e.g., cows, sheep, pigs, horses, and the like) and laboratory animals (e.g., rats,
mice, guinea pigs, and the like).

[00095]

The term "pharmaceutically acceptable carrier" or "physiologically acceptable

carrier" as used herein refers to one or more formulation materials suitable for
accomplishing or enhancing the delivery of a fusion protein of the invention.

[00096]

The term "antigen" refers to a molecule or a portion of a molecule that is

capable of being bound by an antibody, and additionally that is capable of being used in
an animal to produce antibodies that are capable of binding to an epitope of that

antigen. An antigen may have one or more epitopes.

[00097]

The term "native Fc" refers to molecule or sequence comprising the

sequence of a non-antigen-binding fragment resulting from digestion of whole antibody
or produced by other means, whether in monomeric or multimeric form, and can contain
the hinge region. The original immunoglobulin source of the native Fc is preferably of
human origin and can be any of the immunoglobulins, although lgG1 and lgG2 are
preferred. Native Fc molecules are made up of monomeric polypeptides that can be
linked into dimeric or multimeric forms by covalent (i.e., disulfide bonds) and noncovalent association. The number of intermolecular disulfide bonds between monomeric
subunits of native Fc molecules ranges from 1 to 4 depending on class (e.g., IgG, IgA,

and IgE) or subclass (e.g., lgG1 , lgG2, lgG3, lgA1 , and lgGA2). One example of a

native Fc is a disulfide-bonded dimer resulting from papain digestion of an IgG (see
Ellison et al., 1982, Nucleic Acids Res. 10: 4071-9). The term "native Fc" as used herein
is generic to the monomeric, dimeric, and multimeric forms. The term "Fc variant" refers

to a molecule or sequence that is modified from a native Fc but still comprises a binding
site for the salvage receptor, FcRn (neonatal Fc receptor). International Publication Nos.
WO 97/34631 and WO 96/32478 describe exemplary Fc variants, as well as interaction
with the salvage receptor, and are hereby incorporated by reference. Thus, the term "Fc
variant" can comprise a molecule or sequence that is humanized from a non-human
native Fc. Furthermore, a native Fc comprises regions that can be removed because
they provide structural features or biological activity that are not required for the fusion
molecules of the Proteins of the invention. Thus, the term "Fc variant" comprises a
molecule or sequence that lacks one or more native Fc sites or residues, or in which
one or more Fc sites or residues has be modified, that affect or are involved in:

(1)

disulfide bond formation, (2) incompatibility with a selected host cell, (3) N-terminal
heterogeneity upon expression in a selected host cell, (4) glycosylation, (5) interaction
with complement, (6) binding to an Fc receptor other than a salvage receptor, or (7)
antibody-dependent cellular cytotoxicity (ADCC). Fc variants are described in further
detail hereinafter.

[00098]

The term "Fc domain" encompasses native Fc and Fc variants and

sequences as defined above. As with Fc variants and native Fc molecules, the term "Fc
domain" includes molecules in monomeric or multimeric form, whether digested from
whole antibody or produced by other means. In some embodiments of the present
invention, an Fc domain can be fused to FGF21 or a FGF21 mutant (including a
truncated form of FGF21 or a FGF21 mutant) via, for example, a covalent bond between
the Fc domain and the FGF21 sequence. Such fusion proteins can form multimers via
the association of the Fc domains and both these fusion proteins and their multimers are
an aspect of the present invention.

[00099]

As used in the present text, the term "fusobody" refers to an antibody-like

soluble protein comprising two heterodimers, each heterodimer consisting of one heavy
and one light chains of amino acids, stably associated together, for example, via one or

more disulfide bond(s). Each heavy or light chain comprises constant regions of an
antibody, referred hereafter respectively as the heavy and light chain constant regions
of the fusobody. The heavy chain constant region comprises at least C H1 region of an
antibody and may further comprise C H2 and CH3 regions, including the hinge region.
The light chain constant region comprises CL region of an antibody. In a fusobody, the
variable regions of an antibody are replaced by heterologous soluble binding domains.

By way of non-limiting example, a fusobody of the invention can comprise a dual

function fusion protein of the invention, wherein the GLP-1 receptor agonist is fused to
the N-terminus of heavy and light chain of an antibody and FGF21 is simultaneously
fused to the C-terminus of heavy and light chain of the same antibody.

[000100]

The term "heterologous" means that these domains are not naturally found

associated with constant regions of an antibody. In particular, such heterologous
binding domains do not have the typical structure of an antibody variable domain
consisting of 4 framework regions, FR1 , FR2, FR3 and FR4 and the 3 complementarity
determining regions (CDRs) in-between. Each arm of the fusobody therefore comprises
a first single chain polypeptides comprising a first binding domain covalently linked at
the N-terminal part of a constant CH1 heavy chain region of an antibody, and a second
single chain polypeptide comprising a second binding domain covalently linked at the Nterminal part of a constant C L light chain of an antibody. The covalent linkage may be
direct, for example via peptidic bound or indirect, via a linker, for example a peptidic
linker. The two heterodimers of the fusobody are covalently linked, for example, by at
least one disulfide bridge at their hinge region, like an antibody structure. Examples of
molecules with a fusobody structure have been described in the art, in particular,
fusobodies comprising ligand binding region of heterodimeric receptor (see for example
international patent publications WO01/46261 and W01 1/076781).

[000101]

The term "polyethylene glycol" or "PEG" refers to a polyalkylene glycol

compound or a derivative thereof, with or without coupling agents or derviatization with
coupling or activating moieties.

[000102]

The term "Exenatide" indicates a synthetic version of exendin-4, Exenatide,

marketed as Byetta and Bydureon, is a glucagon-like peptide-1 agonist (GLP-1 agonist)
medication approved in April 2005 for the treatment of diabetes mellitus type 2 . It
belongs to the group of incretin mimetics and is manufactured by Amylin
Pharmaceuticals.

[000103]

Exendin-4 is a 39 residue polypeptide produced in the salivary glands of the

Gila Monster lizard (Goke et al. (1993) Diabetes 46:433-439; Fehmann et al. (1995)

Endocrine Rev. 16:390-410). Although it is the product of a uniquely non-mammalian
gene and appears to be expressed only in the salivary gland, Exendin-4 shares a 52%
amino acid sequence homology with GLP-1 and in mammals interacts with the GLP-1
receptor (Goke, et al.; Thorens et al. (1993) Diabetes 42:1678-1682).

[000104]

The term "FGF21-associated disorders," "GLP-1 -associated disorders,"

"Exendin-4-associated disorders," and terms similarly used herein, includes obesity,
type 1 and type 2 diabetes mellitus, pancreatitis, dyslipidemia, nonalcoholic fatty liver
disease (NAFLD), nonalcoholic steatohepatitis (NASH), insulin resistance,

hyperinsulinemia, glucose intolerance, hyperglycemia, metabolic syndrome, acute
myocardial infarction, hypertension, cardiovascular disease, atherosclerosis, peripheral
arterial disease, stroke, heart failure, coronary heart disease, kidney disease, diabetic

complications, neuropathy, gastroparesis, disorders associated with severe inactivating
mutations in the insulin receptor, lipodystrophies including HlV-associated lipodystrophy,
and other metabolic disorders.

[000105]

The term "disorders associated with severe inactivating mutations in the

insulin receptor," and terms similarly used herein, describe conditions in subjects

afflicted with mutations in the insulin receptor (or possible proteins directly downstream
from it) which cause severe insulin resistance but are often (though not always) seen
without the obesity common in Type 2 diabetes mellitus. In many ways, subjects
afflicted with these conditions manifest hybrid symptoms of Type 1 diabetes mellitus and
Type 2 diabetes mellitus. Subjects thereby afflicted fall into several categories of
roughly increasing severity, including: Type A Insulin Resistance, Type C Insulin
Resistance (AKA HAIR-AN Syndrome), Rabson-Mendenhall Syndrome and finally
Donohue's Syndrome or Leprechaunism. These disorders are associated with very high
endogenous insulin levels, and very often, hyperglycemia. Subjects thereby afflicted
also present with various clinical features associated with "insulin toxicity," including
hyperandrogenism, polycystic ovarian syndrome (PCOS), hirsuitism, and acanthosis
nigricans (excessive growth and pigmentation) in the folds of the skin.
[000106]

"Lipodystrophies, including HlV-associated lipodystrophy" are disorders of

adipose tissue characterized by a selective loss of body fat. Patients with lipodystrophy
have a tendency to develop insulin resistance, hyperinsulinemia, hyperglycemia,
hypertriglyceridemia and fatty liver. There are numerous forms of lipodystrophy that are
inherited (genetic) or acquired. The genetic forms of lipodystrophy include congenital

generalized lipodystrophy (the Berardinelli-Seip syndrome) and several types of familial
partial lipodystrophy (the Dunnigan type, the Kobberling type, the mandibuloacral

dysplasis type). The acquired forms of lipodystrophy include acquired generalized
lipodystrophy (the Lawrence syndrome), acquired partial lipodystrophy (the BarraquerSimons syndrome), and lipodystrophy induced by protease inhibitors and nucleoside
reverse transcriptase inhibitors used to treat HIV.
[000107]

"Type 2 diabetes mellitus" is a condition characterized by excess glucose

production in spite of the availability of insulin, and circulating glucose levels remain
excessively high as a result of inadequate glucose clearance.
[000108]

"Type 1 diabetes mellitus" is a condition characterized by high blood glucose

levels caused by total lack of insulin. This occurs when the body's immune system

attacks the insulin-producing beta cells in the pancreas and destroys them. The
pancreas then produces little or no insulin.

[000109]

"Glucose intolerance" or Impaired Glucose Tolerance (IGT) is a pre-diabetic

state of dysglycemia that is associated with increased risk of cardiovascular pathology.
The pre-diabetic condition prevents a subject from moving glucose into cells efficiently
and utilizing it as an efficient fuel source, leading to elevated glucose levels in blood and
some degree of insulin resistance.

[000110]

"Hyperglycemia" is defined as an excess of sugar (glucose) in the blood.

[00011 1]

"Hypoglycemia", also called low blood sugar, occurs when your blood

glucose level drops too low to provide enough energy for your body's activities.

[000112]

"Hyperinsulinemia" is defined as a higher-than-normal level of insulin in the

blood.

[000113]

"Insulin resistance" is defined as a state in which a normal amount of insulin

produces a subnormal biologic response.

[000114]

"Obesity," in terms of the human subject, can be defined as that body weight

over 20 percent above the ideal body weight for a given population (R. H . Williams,
Textbook of Endocrinology, 1974, p. 904-916).

[000115]

"Diabetic complications" are problems, caused by high blood glucose levels,

with other body functions such as kidneys, nerves (neuropathies), feet (foot ulcers and
poor circulation) and eyes (e.g. retinopathies). Diabetes also increases the risk for heart
disease and bone and joint disorders. Other long-term complications of diabetes include
skin problems, digestive problems, sexual dysfunction and problems with teeth and
gums.
[0001 16]

"Metabolic syndrome" can be defined as a cluster of at least three of the

following signs: abdominal fat-in most men, a 40-inch waist or greater; high blood
sugar-at least 110 milligrams per deciliter (mg/dl) after fasting; high triglycerides—at
least 150 mg/dL in the bloodstream; low HDL— less than 40 mg/dl; and, blood pressure
of 130/85 mmHg or higher.
[0001 17]

[000118]

"Pancreatitis" is inflammation of the pancreas.
"Dyslipidemia" is a disorder of lipoprotein metabolism, including lipoprotein

overproduction or deficiency. Dyslipidemias may be manifested by elevation of the total
cholesterol, low-density lipoprotein (LDL) cholesterol and triglyceride concentrations,
and a decrease in high-density lipoprotein (HDL) cholesterol concentration in the blood.
[0001 19]

"Nonalcoholic fatty liver disease (NAFLD)" is a liver disease, not associated

with alcohol consumption, characterized by fatty change of hepatocytes.

[000120]

"Nonalcoholic steatohepatitis (NASH)" is a liver disease, not associated with

alcohol consumption, characterized by fatty change of hepatocytes, accompanied by
intralobular inflammation and fibrosis.

[000121]

"Hypertension" or high blood pressure that is a transitory or sustained

elevation of systemic arterial blood pressure to a level likely to induce cardiovascular
damage or other adverse consequences. Hypertension has been arbitrarily defined as a
systolic blood pressure above 140 mmHg or a diastolic blood pressure above 90 mmHg.

[000122]

"Cardiovascular diseases" are diseases related to the heart or blood vessels.

[000123]

"Acute myocardial infarction" occurs when there is interruption of the blood

supply to a part of the heart. The resulting ischemia and oxygen shortage, if left
untreated for a sufficient period of time, can cause damage or death (infarction) of the
heart muscle tissue (myocardium).

[000124]

"Peripheral arterial disease" occurs when plaque builds up in the arteries that

carry blood to the head, organs and limbs. Over time, plaque can harden and narrow
the arteries which limits the flow of oxygen-rich blood to organs and other parts of the
body.

[000125]

"Atherosclerosis" is a vascular disease characterized by irregularly

distributed lipid deposits in the intima of large and medium-sized arteries, causing
narrowing of arterial lumens and proceeding eventually to fibrosis and calcification.
Lesions are usually focal and progress slowly and intermittently. Limitation of blood flow
accounts for most clinical manifestations, which vary with the distribution and severity of
lesions.

[000126]

"Stroke" is any acute clinical event, related to impairment of cerebral

circulation, that lasts longer than 24 hours. A stroke involves irreversible brain damage,
the type and severity of symptoms depending on the location and extent of brain tissue
whose circulation has been compromised.

[000127]

"Heart failure", also called congestive heart failure, is a condition in which the

heart can no longer pump enough blood to the rest of the body.

[000128]

"Coronary heart disease", also called coronary artery disease, is a narrowing

of the small blood vessels that supply blood and oxygen to the heart.

[000129]

"Kidney disease" or nephropathy is any disease of the kidney. Diabetic

nephropathy is a major cause of morbidity and mortality in people with type 1 or type 2
diabetes mellitus.

[000130]

"Neuropathies" are any diseases involving the cranial nerves or the

peripheral or autonomic nervous system.

[000131]

"Gastroparesis" is weakness of gastric peristalsis, which results in delayed

emptying of the bowels.

[000132]

"Click chemistry" is a term that was introduced by K . B . Sharpless in 2001

to describe reactions that are high yielding, wide in scope, create only byproducts that
can be removed without chromatography, are stereospecific, simple to perform, and can
be conducted in easily removable or benign solvents.

[000133]

The critically ill patients encompassed by the present invention generally

experience an unstable hypermetabolic state. This unstable metabolic state is due to
changes in substrate metabolism, which may lead to relative deficiencies in some
nutrients. Generally there is an increased oxidation of both fat and muscle.

[000134]

Moreover, critically ill patients are preferably patients that experience

systemic inflammatory response syndrome or respiratory distress. A reduction in
morbidity means reducing the likelihood that a critically ill patient will develop additional
illnesses, conditions, or symptoms or reducing the severity of additional illnesses,
conditions, or symptoms. For example reducing morbidity may correspond to a
decrease in the incidence of bacteremia or sepsis or complications associated with
multiple organ failure.

[000135] As used herein, the singular forms "a," "an" and "the" include plural
references unless the content clearly dictates otherwise. Thus, for example, reference
to "an antibody" includes a mixture of two or more such antibodies.

[000136] As used herein, the term "about" refers to +/- 20%, more preferably, +/- 10%,
or still more preferably, +/- 5% of a value.

[000137]

The terms "polypeptide" and "protein", are used interchangeably and refer to

a polymeric form of amino acids of any length, which can include coded and non-coded
amino acids, naturally and non-naturally occurring amino acids, chemically or
biochemically modified or derivatized amino acids, and polypeptides having modified
peptide backbones. The term includes fusion proteins, including, but not limited to,
fusion proteins with a heterologous amino acid sequence, fusions with heterologous and
homologous leader sequences, with or without N-terminal methionine residues;
immunologically tagged proteins; and the like.

[000138]

The terms "individual", "subject", "host" and "patient" are used

interchangeably and refer to any subject for whom diagnosis, treatment, or therapy is
desired, particularly humans. Other subjects may include cattle, dogs, cats, guinea
pigs, rabbits, rats, mice, horses, and the like. In some preferred embodiments the

subject is a human.

[000139] As used herein, the term "sample" refers to biological material from a patient.
The sample assayed by the present invention is not limited to any particular type.
Samples include, as non-limiting examples, single cells, multiple cells, tissues, tumors,
biological fluids, biological molecules, or supernatants or extracts of any of the

foregoing. Examples include tissue removed for biopsy, tissue removed during
resection, blood, urine, lymph tissue, lymph fluid, cerebrospinal fluid, mucous, and stool
samples. The sample used will vary based on the assay format, the detection method
and the nature of the tumors, tissues, cells or extracts to be assayed. Methods for

preparing samples are well known in the art and can be readily adapted in order to
obtain a sample that is compatible with the method utilized.

[000140] As used herein, the term "biological molecule" includes, but is not limited to,
polypeptides, nucleic acids, and saccharides.

[000141] As used herein, the term "modulating" refers to a change in the quality or
quantity of a gene, protein, or any molecule that is inside, outside, or on the surface of a
cell. The change can be an increase or decrease in expression or level of the molecule.

The term "modulates" also includes changing the quality or quantity of a biological
function/activity including, without limitation, the ability to lower blood glucose, insulin,
triglyceride, or cholesterol levels; to reduce liver lipid or liver triglyceride levels; to reduce
body weight; and to improve glucose tolerance, energy expenditure, or insulin
sensitivity.

[000142] As used herein, the term "modulator" refers to a composition that modulates
one or more physiological or biochemical events associated with an FGF21 -associated
disorder, such as type 1 or type 2 diabetes mellitus or a metabolic condition like obesity.
Said events include but are not limited to the ability to lower blood glucose, insulin,

triglyceride, or cholesterol levels; to reduce liver lipid or liver triglyceride levels; to reduce
body weight; and to improve glucose tolerance, energy expenditure, or insulin
sensitivity.

[000143] A "gene product" is a biopolymeric product that is expressed or produced by
a gene. A gene product may be, for example, an unspliced RNA, an mRNA, a splice
variant mRNA, a polypeptide, a post-translationally modified polypeptide, a splice
variant polypeptide etc. Also encompassed by this term are biopolymeric products that
are made using an RNA gene product as a template (i.e. cDNA of the RNA). A gene
product may be made enzymatically, recombinantly, chemically, or within a cell to which
the gene is native. In some embodiments, if the gene product is proteinaceous, it
exhibits a biological activity. In some embodiments, if the gene product is a nucleic acid,
it can be translated into a proteinaceous gene product that exhibits a biological activity.

[000144]

"Modulation of FGF21 activity," "Modulation of GLP-1 activity," and

"Modulation of Exendin-4 activity," as used herein, refers to an increase or decrease in
FGF21 , GLP-1 , or Exendin-4 activity, respectively, that can be a result of, for example,

interaction of an agent with an FGF21 , GLP-1, or Exendin-4 polynucleotide or
polypeptide, inhibition of FGF21 , GLP-1 , or Exendin-4 transcription and/or translation

(e.g., through antisense or siRNA interaction with the FGF21, GLP-1, or Exendin-4 gene

or FGF21, GLP-1, or Exendin-4 transcript, through modulation of transcription factors
that facilitate FGF21, GLP-1, or Exendin-4 expression), and the like. For example,
modulation of a biological activity refers to an increase or a decrease in a biological
activity. FGF21 , GLP-1 , or Exendin-4 activity can be assessed by means including,
without limitation, assaying blood glucose, insulin, triglyceride, or cholesterol levels in a
subject, assessing FGF21, GLP-1, or Exendin-4 polypeptide levels, or by assessing
FGF21 , GLP-1 , or Exendin-4 transcription levels.

[000145]

Comparisons of FGF21, GLP-1, or Exendin-4 activity can also be

accomplished by, e.g., measuring levels of an FGF21, GLP-1, or Exendin-4 downstream
biomarker, and measuring increases in FGF21 , GLP-1 , or Exendin-4 signaling. FGF21 ,
GLP-1, or Exendin-4 activity can also be assessed by measuring: cell signaling; kinase

activity; glucose uptake into adipocytes; blood insulin, triglyceride, or cholesterol level
fluctuations; liver lipid or liver triglyceride level changes; interactions between FGF21,
GLP-1 , or Exendin-4 and a receptor; or phosphorylation of an FGF21 , GLP-1 , or

Exendin-4 receptor. In some embodiments phosphorylation of an FGF21, GLP-1, or
Exendin-4 receptor can be tyrosine phosphorylation. In some embodiments modulation
of FGF21 , GLP-1 , or Exendin-4 activity can cause modulation of an FGF21 , GLP-1 , or
Exendin-4-related phenotype.

[000146] A "FGF21, GLP-1, or Exendin-4 downstream biomarker," as used herein, is a
gene or gene product, or measurable indicia of a gene or gene product. In some
embodiments, a gene or activity that is a downstream marker of FGF21 , GLP-1 , or
Exendin-4 exhibits an altered level of expression. In some embodiments, an activity of
the downstream marker is altered in the presence of an FGF21 , GLP-1 , or Exendin-4
modulator. In some embodiments, the downstream markers exhibit altered levels of
expression when FGF21, GLP-1, or Exendin-4 signaling is perturbed with dual function
protein of the present invention. For example, FGF21 downstream markers include,
without limitation, glucose or 2-deoxy-glucose uptake, pERK and other phosphorylated
or acetylated proteins or NAD levels.

[000147] As used herein, the term "up-regulates" refers to an increase, activation or
stimulation of an activity or quantity. For example, FGF21, GLP-1, or Exendin-4
modulators, such as the dual function proteins of the invention, may increase or agonize
the activity of an FGF21, GLP-1, or Exendin-4 receptor. In one embodiment, one or
more of FGFR-1 (lllc), FGFR-2(lllc), or FGFR-3(lllc) and/or β-klotho may be upregulated in response to a dual function protein of the invention. Up-regulation can also
refer to an FGF21, GLP-1, or Exendin-4-related activity, such as e.g., the ability to lower
blood glucose, insulin, triglyceride, or cholesterol levels; to reduce liver lipid or

triglyceride levels; to reduce body weight; to improve glucose tolerance, energy
expenditure, or insulin sensitivity; or to cause phosphorylation of an FGF21 , GLP-1 , or
Exendin-4 receptor; or to increase an FGF21 , GLP-1 , or Exendin-4 downstream marker.
For example, the FGFR21 receptor can be one or more of FGFR-1 (lllc), FGFR-2(lllc),
or FGFR-3(lllc) and/or β-klotho. Up-regulation may range anywhere from 25% to 500%
as compared to a control.

[000148] As used herein, the term "N-terminus" refers to at least the first 20 amino
acids of a protein.

[000149] As used herein, the terms "N-terminal domain" and "N-terminal region" are
used interchangeably and refer to a fragment of a protein that begins at the first amino
acid of the protein and ends at any amino acid in the N-terminal half of the protein. For
example, the N-terminal domain of FGF21 is from amino acid 1 of SEQ ID NO:1 to any
amino acid between about amino acids 10 and 105 of SEQ ID NO:1 .

[000150] As used herein, the term "C-terminus" refers to at least the last 20 amino
acids of a protein.

[000151] As used herein, the terms "C-terminal domain" and "C-terminal region" are
used interchangeably and refer to a fragment of a protein that begins at any amino acid
in the C-terminal half of the protein and ends at the last amino acid of the protein. For

example, the C-terminal domain of FGF21 begins at any amino acid from amino acid
105 to about amino acid 200 of SEQ ID NO:1 and ends at amino acid 209 of SEQ ID
NO:1 .

[000152]

The term "domain" as used herein refers to a structural part of a biomolecule

that contributes to a known or suspected function of the biomolecule. Domains may be
co-extensive with regions or portions thereof and may also incorporate a portion of a
biomolecule that is distinct from a particular region, in addition to all or part of that
region.

[000153] As used herein, the term "signal domain" (also called "signal sequence" or
"signal peptide") refers to a peptide domain that resides in a continuous stretch of amino
acid sequence at the N-terminal region of a precursor protein (often a membrane-bound
or secreted protein) and is involved in post-translational protein transport. In many
cases the signal domain is removed from the full-length protein by specialized signal
peptidases after the sorting process has been completed. Each signal domain specifies
a particular destination in the cell for the precursor protein. The signal domain of FGF21
is amino acids 1-28 of SEQ ID NO:1 .

[000154] As used herein, the term "receptor binding domain" refers to any portion or
region of a protein that contacts a membrane-bound receptor protein, resulting in a
cellular response, such as a signaling event.

[000155] As used herein, the term "ligand binding domain" refers to any portion or
region of a fusion protein of the invention retaining at least one qualitative binding
activity of a corresponding native sequence.

[000156]

The term "region" refers to a physically contiguous portion of the primary

structure of a biomolecule. In the case of proteins, a region is defined by a contiguous
portion of the amino acid sequence of that protein. In some embodiments a "region" is

associated with a function of the biomolecule.

[000157]

The term "fragment" as used herein refers to a physically contiguous portion

of the primary structure of a biomolecule. In the case of proteins, a portion is defined by
a contiguous portion of the amino acid sequence of that protein and refers to at least 3-5
amino acids, at least 8-10 amino acids, at least 1 1-15 amino acids, at least 17-24 amino
acids, at least 25-30 amino acids, and at least 30-45 amino acids. In the case of
oligonucleotides, a portion is defined by a contiguous portion of the nucleic acid
sequence of that oligonucleotide and refers to at least 9-15 nucleotides, at least 18-30
nucleotides, at least 33-45 nucleotides, at least 48-72 nucleotides, at least 75-90
nucleotides, and at least 90-130 nucleotides. In some embodiments, portions of
biomolecules have a biological activity. In the context of the present invention, FGF21
polypeptide fragments do not comprise the entire FGF21 polypeptide sequence set forth
in SEQ ID NO:1 .

[000158] A "native sequence" polypeptide is one that has the same amino acid
sequence as a polypeptide derived from nature. Such native sequence polypeptides can
be isolated from nature or can be produced by recombinant or synthetic means. Thus, a

native sequence polypeptide can have the amino acid sequence of naturally occurring
human polypeptide, murine polypeptide, or polypeptide from any other mammalian
species.

[000159] As used herein, the phrase "homologous nucleotide sequence," or
"homologous amino acid sequence," or variations thereof, refers to sequences
characterized by a homology, at the nucleotide level or amino acid level, of at least a
specified percentage and is used interchangeably with "sequence identity."
Homologous nucleotide sequences include those sequences coding for isoforms of
proteins. Such isoforms can be expressed in different tissues of the same organism as
a result of, for example, alternative splicing of RNA. Alternatively, isoforms can be
encoded by different genes. Homologous nucleotide sequences include nucleotide
sequences encoding for a protein of a species other than humans, including, but not
limited to, mammals. Homologous nucleotide sequences also include, but are not
limited to, naturally occurring allelic variations and mutations of the nucleotide
sequences set forth herein. Homologous amino acid sequences include those amino

acid sequences which contain conservative amino acid substitutions and which

polypeptides have the same binding and/or activity.

In some embodiments, a

nucleotide or amino acid sequence is homologous if it has at least 60% or greater, up to
99%, identity with a comparator sequence. In some embodiments, a nucleotide or

amino acid sequence is homologous if it shares one or more, up to 60, nucleotide/amino
acid substitutions, additions, or deletions with a comparator sequence. In some

embodiments, the homologous amino acid sequences have no more than 5 or no more
than 3 conservative amino acid substitutions.

[000160]

Percent homology or identity can be determined by, for example, the Gap

program (Wisconsin Sequence Analysis Package, Version 8 for UNIX, Genetics
Computer Group, University Research Park, Madison Wl), using default settings, which
uses the algorithm of Smith and Waterman (Adv. Appl. Math., 1981, 2 , 482-489). In

some embodiments, homology between the probe and target is between about 75% to
about 85%. In some embodiments, nucleic acids have nucleotides that are at least
about 95%, about 97%, about 98%, about 99% and about 100% homologous to SEQ ID
NO:2, or a portion thereof.

[000161]

Homology may also be at the polypeptide level. In some embodiments,

constituent polypeptides of the dual function proteins of the invention may be at least
95% homologous to their full-length wild-type counterparts or corresponding native

sequences, or to portions thereof. The degree or percentage identity of dual function
proteins of the invention, or portions thereof, and different amino acid sequences is
calculated as the number of exact matches in an alignment of the two sequences
divided by the length of the "invention sequence" or the "foreign sequence", whichever is
shortest. The result is expressed as percent identity.

[000162] As used herein, the term "mixing" refers to the process of combining one or
more compounds, cells, molecules, and the like together in the same area. This may be
performed, for example, in a test tube, petri dish, or any container that allows the one or
more compounds, cells, or molecules, to be mixed.

[000163] As used herein, the term "substantially purified" refers to a compound (e.g.,
either a polynucleotide or a polypeptide or an antibody) that is removed from its natural
environment and is at least 60% free, at least 75% free, and at least 90% free from
other components with which it is naturally associated.

[000164]

The term "pharmaceutically acceptable carrier" refers to a carrier for

administration of a therapeutic agent, such as antibodies or a polypeptide, genes, and
other therapeutic agents. The term refers to any pharmaceutical carrier that does not
itself induce the production of antibodies harmful to the individual receiving the
composition, and which can be administered without undue toxicity. Suitable carriers

can be large, slowly metabolized macromolecules such as proteins, polysaccharides,

polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, lipid
aggregates and inactive virus particles. Such carriers are well known to those of
ordinary skill in the art. Pharmaceutically acceptable carriers in therapeutic
compositions can include liquids such as water, saline, glycerol and ethanol. Auxiliary
substances, such as wetting or emulsifying agents, pH buffering substances, and the
like, can also be present in such vehicles.

[000165]

Naturally occurring disulfide bonds, as provided by cysteine residues,

generally increase thermodynamic stability of proteins. Successful examples of
increased thermodynamic stability, as measured in increase of the melting temperature,
are multiple disulfide-bonded mutants of the enzymes T4 lysozyme (Matsumuraet al.,
PNAS 86:6562-6566 (1989)) and barnase (Johnson et al., J . Mol. Biol. 268:198-208

(1997)). A n aspect of the present invention is an enhancement of the physical stability of
FGF21 in the presence of a preservative, achieved by the presence of disulfide bonds

within the variants, which constrain the flexibility of wild-type FGF21 and thereby limit
access of the preservative to the hydrophobic core of the protein. Enhancement of the
physical stability of FGF21 within the proteins of the present invention, due to the
presence of disulfide bonds within the variants, can confer additional protection to said
proteins, whether or not in the presence of a preservative, including but not limited to
protection against fluctuations in environmental conditions such as pH and temperature.

Improvements of the Dual Function Proteins of the Invention Over Wild Type
Protein Comparators and Combinations Thereof
[000166]

It is well known in the art that a significant challenge in the development of

protein pharmaceuticals is to deal with the physical and chemical instabilities of proteins.
This is even more apparent when a protein pharmaceutical formulation is intended to be
a multiple use, injectable formulation requiring a stable, concentrated and preserved
solution, while maintaining a favorable bioactivity profile. Biophysical characterization of
wild-type FGF21 in the literature established that a concentrated protein solution (>5
mg/ml), when exposed to stress conditions, such as high temperature or low pH, lead to

accelerated association and aggregation (i.e., poor physical stability and
biopharmaceutical properties). Exposure of a concentrated protein solution of FGF21 to
pharmaceutical preservatives (e.g., m-cresol) also had a negative impact on physical
stability.

[000167]

Therefore, an embodiment of the present invention is to enhance physical

stability of concentrated solutions, while maintaining chemical stability and biological
potency, under both physiological and preserved formulation conditions. It is thought

that association and aggregation may result from hydrophobic interactions, since, at a
given protein concentration, temperature, and ionic strength have considerable impact
on physical stability.

[000168]

For the most part, non-conserved, presumed surface exposed amino acid

residues are targeted. The local environment of these residues is analyzed and, those
not deemed structurally important are selected for mutagenesis. One method to initiate
specific changes is to further decrease the p i of the protein by introducing glutamic acid
residues ("glutamic acid scan"). The introduction of charged substitutes can inhibit
hydrophobic-mediated aggregation via charge-charge repulsion and potentially improve
preservative compatibility. In addition, one skilled in the art would also recognize that
with sufficient mutagenesis, the pi could be shifted into a basic pH range by the
introduction of positive charge, with or without concomitant decrease in negative charge,
thus allowing for charge-charge repulsion.

[000169] A n additional difficulty associated with therapeutic applications of wild-type
FGF21 as a biotherapeutic, for instance, is that its half-life is very short in vivo (on the

order of 0.5 and 2 h , respectively, in mouse and primate). There is hence a need to
develop follow-up compounds that are more efficacious either through higher potency or
longer half-life. Similarly, various mechanisms have been employed to enhance serum
half-life for GLP-1 (1-2 minutes due to rapid cleavage by endogenous proteases,
particularly dipeptidyl peptidase-4 (DPP4)) through use of Exendin-4 or other analogues
that are resistant to cleavage by DPP4 as well as further modifications and formulations
for extended half-life or slow release of compound.

[000170]

The proteins of the invention, e.g., dual FGF21 receptor agonist and GLP-1

receptor agonist proteins of the invention, were developed as a way to achieve the
desirable effects of FGF21 and GLP-1 treatment at a higher potency and in a half-lifeextended formulation. The co-administration of GLP-1 and FGF21 has been described
in the literature, e.g., in patent publications WO201 0/068735 and WO2009/020802, with

data suggesting additive or synergistic effects of co-administration of GLP-1 and FGF21
for treatment of obesity and type 2 diabetes. However, co-localization of the two
receptor agonists in a single molecule, e.g., in the form of the proteins of the invention,
provides better access of both GLP-1 and FGF21 to tissues or cells and provides
increased benefit over simple co-administration as separate entities. This advantage of
combining two agonists into a single molecule compared to simple co-administration of
each is especially advantageous for tissues in which both the GLP-1 and the FGF21

receptors are expressed in the same tissues, such as adipose, pancreatic β-cells,
hepatic and hypothalamic cells. Dual FGF21 receptor agonist and GLP-1 receptor
agonist proteins of the invention and other single dual activity entities have improved

biological properties due to altered receptor trafficking, altered signal transduction
effects and/or entropic (avidity) effects.

[000171]

Because FGF21 and GLP-1 (or Exendin-4) act through different

mechanisms, it is expected that they will have additive or synergistic effects when, for
example, administered at the same time in the form of the dual function proteins of the
invention. GLP-1 and Exendin-4 act primarily to increase insulin secretion in response
to food intake while FGF21 sensitizes the body to respond better to insulin, which may
provide benefit for both type 1 and type 2 diabetes in managing blood glucose levels.
Beta-cell protective effects combined with the improved beta-cell function and insulin
sensitivity has the potential to provide benefit even in type 1 diabetics.

[000172] Another example is weight loss: The satiety signal and slowed gastric
emptying by GLP-1 or Exendin-4 are expected to lower appetite while FGF21 increases
metabolism in adipose and other tissues which could increase loss of fat. These two
effects could result in an additive or even synergistic weight loss with combined dosing.
Expression of receptors for both FGF21 and GLP-1 in metabolically active tissues
suggests that simultaneous delivery of a FGF21 receptor agonist and a GLP-1 receptor
agonist to such tissues may be beneficial for treating metabolic diseases. A
combination of GLP-1 and Exendin-4's cardioprotective effects and improved lipid
profiles seen with FGF21 could also result in an additive benefit for cardiovascular
disease associated with obesity, type 2 and type 1 diabetes.

[000173] Another likely benefit of GLP-1 and FGF21 dual agonism is an improved, i.e.,
reduced, side effect profile. Recent studies (Wei et al. (2012) PNAS 109, 3143-48)
indicate that treatment of diet-induced obese mice with FGF21 induces bone loss, due
to a diminished inactivation of PPARy (via reduced sumoylation); a shift of mesenchymal
stem cell differentiation from osteoblasts to adipocytes is seen in the presence of
increased PPARy activity in the bone following FGF21 treatment. However, it has also
been reported (Sanz et al. (2010) A m J Physiol Endocrinol Metab 298, E634-E643) that
GLP-1 can reduce the differentiation of human mesenchymal stem cells to adipocytes

by reducing the expression of PPARy. Therefore, as GLP-1 has the potential to be bone

protective, GLP-1 -FGF21 fusion proteins are likely to reduce the risk of bone loss
compared to FGF21-only treatments.

[000174] Although the embodiments of the present invention concern the physical and
chemical stability under both physiological and preserved pharmaceutical formulation
conditions, maintaining the biological potency of the proteins of the invention as
compared to, e.g., wild-type FGF21 is an important factor of consideration as well.
Therefore, the biological potency of the proteins of the present invention is defined by

the ability of the proteins to affect glucose uptake and/or the lowering of plasma glucose
levels, as shown herein in the examples.

[000175]

The proteins, polypeptides, and/or peptides of the invention administered

according to this invention may be generated and/or isolated by any means known in
the art. The most preferred method for producing the variant is through recombinant
DNA methodologies and is well known to those skilled in the art. Such methods are
described in Current Protocols in Molecular Biology (John Wiley & Sons, Inc.), which is
incorporated herein by reference.

[000176]

Additionally, the preferred embodiments include a biologically active peptide

derived from the variant described herein. Such a peptide will contain at least one of
the substitutions described and the variant will possess biological activity. The peptide
may be produced by any and all means known to those skilled in the art, examples of
which included but are not limited to enzymatic digestion, chemical synthesis or
recombinant DNA methodologies.

[000177]

It is established in the art that fragments of peptides of certain fibroblast

growth factors are biologically active. See for example, Baird et al., Proc. Natl. Acad.
Sci (USA) 85:2324-2328 (1988), and J . Cell. Phys. Suppl. 5:101-106 (1987). Therefore,

the selection of fragments or peptides of the variant is based on criteria known in the art.
For example, it is known that dipeptidyl peptidase IV (DPP-IV, or DPP-4) is a serine type
protease involved in inactivation of neuropeptides, endocrine peptides, and cytokines
(Damme et al. Chem. Immunol. 72: 42-56, (1999)). The N-terminus of FGF21
(HisProllePro) contains two dipeptides that could potentially be substrates to DPP-IV,
resulting in a fragment of FGF21 truncated at the N-terminus by 4 amino acids.
Unexpectedly, this fragment of wild-type FGF21 has been demonstrated to retain
biological activity, thus, proteins of the present invention truncated at the N-terminus by
up to 4 amino acids, is an embodiment of the present invention.

[000178]

The invention also encompasses polynucleotides encoding the above-

described variants that may be in the form of RNA or in the form of DNA, which DNA
includes cDNA, genomic DNA, and synthetic DNA. The DNA may be double-stranded
or single-stranded. The coding sequences that encode the proteins of the present
invention may vary as a result of the redundancy or degeneracy of the genetic code.

[000179]

The polynucleotides that encode for the proteins of the invention may

include the following: only the coding sequence for the variant, the coding sequence for
the variant and additional coding sequence such as a functional polypeptide, or a leader
or secretory sequence or a pro-protein sequence; the coding sequence for the variant
and non-coding sequence, such as introns or non-coding sequence 5' and/or 3' of the

coding sequence for the variant. Thus the term "polynucleotide encoding a variant"

encompasses a polynucleotide that may include not only coding sequence for the
variant but also a polynucleotide, which includes additional coding and/or non-coding
sequence.

[000180]

The invention further relates to variants of the described polynucleotides that

encode for fragments, analogs and derivatives of the polypeptide that contain the
indicated substitutions. The variant of the polynucleotide may be a naturally occurring
allelic variant of the human FGF21 sequence, a non-naturally occurring variant, or a
truncated variant as described above. Thus, the present invention also includes
polynucleotides encoding the variants described above, as well as variants of such
polynucleotides, which variants encode for a fragment, derivative or analog of the
disclosed variant. Such nucleotide variants include deletion variants, substitution
variants, truncated variants, and addition or insertion variants as long as at least one of
the indicated amino acid substitutions of the first or second embodiments is present.

[000181]

The polynucleotides of the invention will be expressed in hosts after the

sequences have been operably linked to (i.e., positioned to ensure the functioning of) an
expression control sequence. These expression vectors are typically replicable in the
host organisms either as episomes or as an integral part of the host chromosomal DNA.
Commonly, expression vectors will contain selection markers, e.g., tetracycline,
neomycin, and dihydrofolate reductase, to permit detection of those cells transformed
with the desired DNA sequences. The dual function proteins or fragments thereof can
be expressed in mammalian cells, insect, yeast, bacterial or other cells under the control

of appropriate promoters. Cell free translation systems can also be employed to produce
such proteins using RNAs derived from DNA constructs of the present invention.

[000182]

E . coli is a prokaryotic host useful particularly for cloning the polynucleotides

of the present invention. Other microbial hosts suitable for use include Bacillus subtilus,
Salmonella typhimurium, and various species of Serratia, Pseudomonas, Streptococcus,
and Staphylococcus, although others may also be employed as a matter of choice. In

these prokaryotic hosts, one can also make expression vectors, which will typically
contain expression control sequences compatible with the host cell (e.g., an origin of
replication). In addition, any of a number of well-known promoters may be present, such
as the lactose promoter system, a tryptophan (Trp) promoter system, a beta-lactamase

promoter system, or a promoter system from phages lambda or T7. The promoters will
typically control expression, optionally with an operator sequence, and have ribosome
binding site sequences and the like, for initiating and completing transcription and
translation.

[000183]

One skilled in the art of expression of proteins will recognize that methionine

or methionine-arginine sequence can be introduced at the N-terminus of the mature

sequence (SEQ ID NO: 3) for expression in E . coli and are contemplated within the
context of this invention. Thus, unless otherwise noted, proteins of the present invention
expressed in E . coli have a methionine sequence introduced at the N-terminus.

[000184]

Other microbes, such as yeast or fungi, may also be used for expression.

Pichia pastoris, Saccharomyces cerevisiae, Schizosaccharomyces pombe, and Pichia
angusta are examples of preferred yeast hosts, with suitable vectors having expression
control sequences, such as promoters, including 3-phosphoglycerate kinase or other
glycolytic enzymes, and an origin of replication, termination sequences and the like as
desired. Aspergillus niger, Trichoderma reesei; and Schizophyllum commune, are
examples of fungi hosts, although others may also be employed as a matter of choice.

[000185]

Mammalian tissue cell culture may also be used to express and produce the

polypeptides of the present invention. Eukaryotic cells are actually preferred, because a
number of suitable host cell lines capable of secreting intact variants have been
developed in the art, and include the CHO cell lines, various COS cell lines, NSO cells,
Syrian Hamster Ovary cell lines, HeLa cells, or human embryonic kidney cell lines (i.e.
HEK293, HEK293EBNA).

[000186]

Expression vectors for these cells can include expression control

sequences, such as an origin of replication, a promoter, an enhancer, and necessary
processing information sites, such as ribosome binding sites, RNA splice sites,
polyadenylation sites, and transcriptional terminator sequences. Preferred expression
control sequences are promoters derived from SV40, adenovirus, bovine papilloma
virus, cytomegalovirus, Raus sarcoma virus, and the like. Preferred polyadenylation
sites include sequences derived from SV40 and bovine growth hormone.

[000187]

The vectors containing the polynucleotide sequences of interest (e.g., the

Proteins of the invention and expression control sequences) can be transferred into the
host cell by well-known methods, which vary depending on the type of cellular host. For
example, calcium chloride transfection is commonly utilized for prokaryotic cells,
whereas calcium phosphate treatment or electroporation may be used for other cellular
hosts.

[000188]

Various methods of protein purification may be employed and such methods

are known in the art and described, for example, in Deutscher, Methods in Enzymology
182: 83-9 (1990) and Scopes, Protein Purification: Principles and Practice, Springer-

Verlag, NY (1982). The purification step(s) selected will depend, for example, on the
nature of the production process used for the Proteins of the invention.

[000189]

The proteins, polypeptides, and/or peptides of the invention, e.g., the dual

activity fusion proteins of the invention, should be formulated and dosed in a fashion
consistent with good medical practice, taking into account the clinical condition of the

patient, the site of delivery of the protein compositions, the method of administration, the

scheduling of administration, and other factors known to practitioners. The
"therapeutically effective amount" of the proteins of the invention for purposes herein is
thus determined by such considerations.

[000190]

The pharmaceutical compositions of the proteins of the present invention

may be administered by any means that achieve the generally intended purpose: to
treat type 1 and type 2 diabetes mellitus, obesity, metabolic syndrome, or critically ill
patients. Non-limiting permissible means of administration include, for example, by
inhalation or suppository or to mucosal tissue such as by lavage to vaginal, rectal,
urethral, buccal and sublingual tissue, orally, nasally, topically, intranasally,

intraperitoneally, parenterally, intravenously, intramuscularly, intrasternally, by
intraarticular injection, intralymphatically, interstitially, intra-arterially, subcutaneously,
intrasynovial, transepithelial, and transdermally. In some embodiments, the
pharmaceutical compositions are administered by lavage, orally or inter-arterially. Other
suitable methods of introduction can also include rechargeable or biodegradable
devices and slow or sustained release polymeric devices. The pharmaceutical
compositions of this invention can also be administered as part of a combinatorial
therapy with other known metabolic agents.

[000191]

The dosage administered will be dependent upon the age, health, and weight

of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the
nature of the effect desired. Compositions within the scope of the invention include all
compositions wherein an FGF21 variant is present in an amount that is effective to
achieve the desired medical effect for treatment type 1 or type 2 diabetes mellitus,
obesity, or metabolic syndrome. While individual needs may vary from one patient to
another, the determination of the optimal ranges of effective amounts of all of the
components is within the ability of the clinician of ordinary skill.

[000192]

The proteins of the present invention can be formulated according to known

methods to prepare pharmaceutically useful compositions. A desired formulation would
be one that is a stable lyophilized product that is reconstituted with an appropriate

diluent or an aqueous solution of high purity with optional pharmaceutically acceptable
carriers, preservatives, excipients or stabilizers [Remington's Pharmaceutical Sciences
16th edition (1980)]. The proteins of the present invention may be combined with a

pharmaceutically acceptable buffer, and the pH adjusted to provide acceptable stability,
and a pH acceptable for administration.

[000193]

For parenteral administration, in one embodiment, the proteins of the

invention are formulated generally by mixing one or more of them at the desired degree
of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a

pharmaceutically acceptable carrier, i.e., one that is non-toxic to recipients at the
dosages and concentrations employed and is compatible with other ingredients of the
formulation. Preferably, one or more pharmaceutically acceptable anti-microbial agents
may be added. Phenol, m-cresol, and benzyl alcohol are preferred pharmaceutically
acceptable anti-microbial agents.

[000194]

Optionally, one or more pharmaceutically acceptable salts may be added to

adjust the ionic strength or tonicity. One or more excipients may be added to further
adjust the isotonicity of the formulation. Glycerin, sodium chloride, and mannitol are
examples of an isotonicity adjusting excipient.

[000195]

Those skilled in the art can readily optimize pharmaceutically effective

dosages and administration regimens for therapeutic compositions comprising Proteins
of the invention, as determined by good medical practice and the clinical condition of the
individual patient. A typical dose range for the proteins of the present invention will
range from about 0.01 mg per day to about 1000 mg per day (or about 0.05 mg per
week to about 5000 mg per week administered once per week) for an adult. Preferably,
the dosage ranges from about 0.1 mg per day to about 100 mg per day (or about 0.5 mg
per week to about 500 mg per week administered once per week), more preferably from
about 1.0 mg/day to about 10 mg/day (or about 5 mg per week to about 50 mg per week
administered once per week). Most preferably, the dosage is about 1-5 mg/day (or
about 5 mg per week to about 25 mg per week administered once per week). The
appropriate dose of an FGF21 variant administered will result in lowering blood glucose
levels and increasing energy expenditure by faster and more efficient glucose utilization,
and thus is useful for treating type 1 and type 2 diabetes mellitus, obesity and metabolic

syndrome.

[000196]

In addition, because hyperglycemia and insulin resistance are common in

critically ill patients given nutritional support, some intensive care units (ICUs) administer
insulin to treat excessive hyperglycemia in fed critically ill patients. In fact, recent studies
document the use of exogenous insulin to maintain blood glucose at a level no higher
than 110 mg per deciliter reduced morbidity and mortality among critically ill patients in
the surgical intensive care unit, regardless of whether they had a history of diabetes
(Van den Bergheet al. N Engl J Med., 345(19):1359, (2001)). Thus, proteins of the
present invention are uniquely suited to help restore metabolic stability in metabolically
unstable critically ill patients. Proteins of the invention such as those containing variants
of FGF21 are unique in that they stimulate glucose uptake and enhances insulin
sensitivity but do not induce hypoglycemia.

[000197]

In another aspect of the present invention, proteins of the invention for use

as a medicament for the treatment of obesity, type 1 and type 2 diabetes mellitus,

pancreatitis, dyslipidemia, nonalcoholic fatty liver disease (NAFLD), nonalcoholic
steatohepatitis (NASH), insulin resistance, hyperinsulinemia, glucose intolerance,
hyperglycemia, metabolic syndrome, acute myocardial infarction, conditions associated
with severe inactivating mutations in the insulin receptor, lipodystrophies including HIVassociated lipodystrophy, and other metabolic disorders is contemplated.

[000198]

Having now described the present invention in detail, the same will be more

clearly understood by reference to the following examples, which are included herewith
for purposes of illustration only and are not intended to be limiting of the invention.

[000199]

The practice of the present invention will employ, unless otherwise indicated,

conventional methods of chemistry, biochemistry, molecular biology, immunology and
pharmacology, within the skill of the art. Such techniques are explained fully in the
literature. See, e.g., Remington's Pharmaceutical Sciences, 18th Edition (Easton,
Pennsylvania: Mack Publishing Company, 1990); Methods In Enzymology (S. Colowick
and N . Kaplan, eds., Academic Press, Inc.); and Handbook of Experimental

Immunology, Vols. I-IV (D.M. Weir and C.C. Blackwell, eds., 1986, Blackwell Scientific
Publications); and Sambrook et al., Molecular Cloning: A Laboratory Manual (2nd
Edition, 1989).

Site-Specific FGF21 Mutants

[000200]

In some embodiments, the fusion proteins of the invention include additional

mutants of GLP-1 or Exendin-4, GLP-1/Glucagon hybrid peptides, GLP-1 analogues
with unnatural amino acids (to convey DPP-4 resistance, for PEGylation, or for other
purposes).

[000201]

In some embodiments, the proteins of the invention comprise FGF21

agonists with one or more of the following additional modifications of wild-type FGF21 :

[000202]

(i) additional disulfides, unnatural amino acids, or modifications to promote

dimerization such as formation of a disulfide at R154C or introduction of a cysteine at
another site, or dimerization through a fused Fc domain, or dimer formation through a
cross-linker such as a bifunctional PEG;

[000203]

(ii) fragments of FGF21 ;

[000204]

(iii) proteins selected to have FGF21 activity (binding to beta-klotho and

binding and activation of the FGFR's); and

[000205]

(iv) an FGF21 mimetic antibody (of various formats such as Fab, unibody,

svFc etc.).

[000206]

In some embodiments, the dual activity proteins of the invention comprise

one or more of the following linkers: a simple amide bond, short peptides (particularly
Ser/Gly repeats), additional residues from the FGF21 translated sequence, or a larger

linker up to an entire protein (such as an Fc domain, an HSA-binding helix bundle, HSA,
etc.). The two moieties can also be linked by other chemical means, such as through

unnatural amino acids or standard chemical linkers (maleimide-Cys, NHS-Lys, "click
chemistry", etc.) "Linker" for the FGF21 mimetic antibody approach could include those
already listed and also an insertion into a loop with subsequent cleavage to release the
GLP-1 N-terminus.

[000207]

In some embodiments, the fusion protein of the invention comprises

PEGylation occurring at one, two, or more specific sites. In preferred embodiments, the
PEGylation occurs within the FGF21 molecule or the linker. In some embodiments, the
PEGylation is not within -10 amino acids of the N-terminus of the dual function protein,
preferably not within -10 amino acids of the start of FGF21 . PEGylation attachment
chemistries can include NHS-Lys, maleimide-Cys, unnatural amino acids (aldehyde,
"click chemistry", Pel, etc.) and can be combined with suitable protein variants to control
the stoichiometry of the reaction.
[000208]

The PEG group of the fusion proteins of the invention can be of any size

(e.g., 1, 2 , 3.4, 5 , 10, 20, 24, 29, 30, 40 kDa), and can be linear, branched, or comb

structured, with a preference for a total PEGylation of greater than or equal to 40 kDa.
Optimal PEGylation achieves half-life extension sufficient for once weekly dosing.
PEGylation of protein dimers, trimers, tetramers etc. may result in adequate serum halflife extension using shorter PEG polymers. Branched and comb PEG structures may be
beneficial in terms of lower viscosity.
[000209]

Preferred half-life extension methodologies for the fusion proteins of the

invention include integrating an IgG Fc domain or HSA into the linker and may not
require PEGylation. Additionally, using Fc domain fusions will result in dimerization and
may result in enhanced potency in addition to half-life extension.
[00021 0]

Other embodiments of the invention include but are not limited to the

following attachments, for half-life extension: HSA-binding lipid or small molecule or
micelle to either the monomeric or a dimeric version of the fusion.
[00021 1]

In certain embodiments of the invention, other attachments may be made to

proteins, polypeptides, and/or peptides of the invention, to achieve half-life extension
and other improved biological properties. They can include attaching PEG-cholesterol

conjugates (including micelles and liposomes) to the proteins, polypeptides, and/or
peptides of the invention, and/or attaching sugars (glycosylate) to the proteins,
polypeptides, and/or peptides of the invention. In still other embodiments, similar
techniques are employed to add conjugates of , e.g., polysialic acid (PSA), hydroxyethyl
starch (HES), albumin-binding ligands, or carbohydrate shields to proteins,
polypeptides, and/or peptides.

[000212]

The HESylation technique, for example, couples branched

hydroxyethylstarch (HES) chains (60 kDa or 100 kDa, highly branched amylopectin
fragments from corn starch) to a protein, polypeptides, and/or peptides via reductive
alkylation. Polysialation conjugates proteins, polypeptides, and/or peptides of interest
with polysialic acid (PSA) polymers in a manner similar to PEGylation. PSA polymers
are negatively charged, non-immunogenic polymers that occur naturally in the body and
are available in molecular weights of 10-50kD.

[000213]

In still other embodiments of the invention, other attachments or

modifications may be made to proteins, polypeptides, and/or peptides of the invention,
to achieve half-life extension and other improved biological properties. These include
the creation of recombinant PEG (rPEG) groups, and their attachment to the proteins,
polypeptides, and/or peptides of the invention. As developed by the company Amunix,
Inc. The rPEG technology is based on protein sequences with PEG-like properties that

are genetically fused to biopharmaceuticals, avoiding the extra chemical conjugation
step. rPEGs are extended half-life Exenatide constructs that contain a long
unstructured tail of hydrophilic amino acids, and which are capable of both increasing a
protein or peptide's serum half-life and slowing its rate of absorption, thus reducing the
peak-trough ratio significantly. rPEGs have an increased hydrodynamic radius and
show an apparent molecular weight that is about 15-fold their actual molecular weight,
mimicking the way PEGylation achieves a long serum half-life. Similar recombinant
polypeptide sequences are also developed by XL-protein GmbH for the "PASylation" of
proteins.

Chemically-Modified Dual Function Protein Mutants
[000214]

Chemically modified forms of the fusion proteins described herein, including,

e.g., truncated and variant forms of the dual function fusion proteins described herein,
can be prepared by one skilled in the art, given the disclosures described herein. Such

chemically modified dual function proteins are altered such that the chemically modified
mutant is different from the unmodified mutant, either in the type or location of the
molecules naturally attached to the mutant. Chemically modified mutants can include
molecules formed by the deletion of one or more naturally-attached chemical groups.

[000215]

In one embodiment, proteins of the present invention can be modified by the

covalent attachment of one or more polymers. For example, the polymer selected is
typically water-soluble so that the protein to which it is attached does not precipitate in
an aqueous environment, such as a physiological environment. Included within the

scope of suitable polymers is a mixture of polymers. Preferably, for therapeutic use of
the end-product preparation, the polymer will be pharmaceutically acceptable. Non-

water soluble polymers conjugated to proteins of the present invention also form an
aspect of the invention.
[00021 6]

Exemplary polymers each can be of any molecular weight and can be

branched or unbranched. The polymers each typically have an average molecular
weight of between about 2 kDa to about 100 kDa (the term "about" indicating that in
preparations of a water-soluble polymer, some molecules will weigh more and some
less than the stated molecular weight). The average molecular weight of each polymer
is preferably between about 5 kDa and about 50 kDa, more preferably between about
12 kDa and about 40 kDa, and most preferably between about 20 kDa and about 35

kDa.

[000217]

Suitable water-soluble polymers or mixtures thereof include, but are not

limited to, N-linked or O-linked carbohydrates, sugars, phosphates, polyethylene glycol

(PEG) (including the forms of PEG that have been used to derivatize proteins, including
mono-(C1-C10), alkoxy-, or aryloxy-polyethylene glycol), monomethoxy-polyethylene
glycol, dextran (such as low molecular weight dextran of, for example, about 6 kD),

cellulose, or other carbohydrate based polymers, poly-(N-vinyl pyrrolidone) polyethylene
glycol, propylene glycol homopolymers, polypropylene oxide/ethylene oxide c o

polymers, polyoxyethylated polyols (e.g., glycerol), and polyvinyl alcohol. Also
encompassed by the present invention are bifunctional crosslinking molecules that can
be used to prepare covalently attached dual function protein variant multimers. Also

encompassed by the present invention are dual function protein variants covalently
attached to polysialic acid.
[000218]

In some embodiments of the present invention, a dual function protein

variant is covalently, or chemically, modified to include one or more water-soluble
polymers, including, but not limited to, polyethylene glycol (PEG), polyoxyethylene
glycol, or polypropylene glycol. See, e.g., U.S. Pat. Nos. 4,640,835; 4,496,689;
4,301 ,144; 4,670,417; 4,791 ,192; and 4,179,337. In some embodiments of the present

invention, adual function protein comprises one or more polymers, including, but not
limited to, monomethoxy-polyethylene glycol, dextran, cellulose, another carbohydratebased polymer, poly-(N-vinyl pyrrolidone)-polyethylene glycol, propylene glycol

homopolymers, a polypropylene oxide/ethylene oxide co-polymer, polyoxyethylated
polyols (e.g., glycerol), polyvinyl alcohol, or mixtures of such polymers.
[000219]

In some embodiments of the present invention, a dual function protein is

covalently-modified with PEG subunits. In some embodiments, one or more watersoluble polymers are bonded at one or more specific positions (for example, at the Nterminus) of the dual function protein mutant. In some embodiments, one or more watersoluble polymers are randomly attached to one or more side chains of a dual function

protein mutant. In some embodiments, PEG is used to improve the therapeutic capacity
of a dual function protein mutant. Certain such methods are discussed, for example, in
U.S. Pat. No. 6,133,426, which is hereby incorporated by reference for any purpose.

[000220]

In embodiments of the present invention wherein the polymer is PEG, the

PEG group can be of any convenient molecular weight, and can be linear or branched.

The average molecular weight of the PEG group will preferably range from about 2 kD
to about 100 kDa, and more preferably from about 5 kDa to about 50 kDa, e.g., 10, 20,
30, 40, or 50 kDa. The PEG groups will generally be attached to the dual function

protein mutant via acylation or reductive alkylation through a reactive group on the PEG
moiety (e.g., an aldehyde, amino, thiol, or ester group) to a reactive group on the dual
function protein mutant (e.g., an aldehyde, amino, or ester group).

[000221]

Branched PEG derivatives, also known as

-shaped" PEG derivatives,

contain two linear methoxy PEG chain attached to a central core. The sterically bulky
structure of these Ύ -shaped" PEG derivatives will facilitate the single point attachment
of the modified molecules. By way of example, three kinds of Ύ -shaped" PEG
derivatives are Y-NHS-40K (useful for amine PEGylation); Y-MAL-40K (useful for thiol
PEGylation); and Y-ALD-40K (e.g., Y-AALD-40K and Y-PALD-40K)(useful for N-terminal
PEGylation). For amine PEGylation, the Ύ -shape" NHS ester will react with the amino
group of lysine(s) or the N-terminal amine in biological active molecules to produce a
stable amide linkage(s). This NHS ester will couple with the targeted molecules at pH 78.5. For thiol PEGylation, the Ύ -shape" maleimide will react with the thiol groups in

biological active molecules to generate a stable 3-thiosuccinimidyl ether linkage. This
maleimide will couple with the targeted molecules at an approximate pH of 7.4 in the
presence of other functional groups. For N-terminal PEGylation, the

-shape"

aldehyde will preferably react with the N-terminal amine in biological active molecules to
produce a stable amine linkage in the presence of a reducing reagent such as sodium
cyanoborohydride. This aldehyde will couple with the N-terminal amine of the targeted
molecules at pH 5-8. Reagents for performing branched PEGylation are available
through, e.g., JenKem Technology.

[000222]

The PEGylation of a polypeptide, including the proteins of the invention, can

be specifically carried out using any of the PEGylation reactions known in the art. Such

reactions are described, for example, in the following references: Francis et al., 1992,
Focus on Growth Factors 3 : 4-10; European Patent Nos. 0 154 316 and 0 401 384; and
U.S. Pat. No. 4,179,337. For example, PEGylation can be carried out via an acylation

reaction or an alkylation reaction with a reactive polyethylene glycol molecule (or an
analogous reactive water-soluble polymer) as described herein. For the acylation
reactions, a selected polymer should have a single reactive ester group. For reductive

alkylation, a selected polymer should have a single reactive aldehyde group. A reactive
aldehyde is, for example, polyethylene glycol propionaldehyde, which is water stable, or
mono C1-C10 alkoxy or aryloxy derivatives thereof (see, e.g., U.S. Pat. No. 5,252,714).

[000223]

In some embodiments of the present invention, a useful strategy for the

attachment of the PEG group to a polypeptide involves combining, through the
formation of a conjugate linkage in solution, a peptide and a PEG moiety, each bearing
a special functionality that is mutually reactive toward the other. The peptides can be
easily prepared with conventional solid phase synthesis. The peptides are
"preactivated" with an appropriate functional group at a specific site. The precursors are
purified and fully characterized prior to reacting with the PEG moiety. Ligation of the
peptide with PEG usually takes place in aqueous phase and can be easily monitored by
reverse phase analytical HPLC. The PEGylated peptides can be easily purified by
preparative HPLC and characterized by analytical HPLC, amino acid analysis and laser
desorption mass spectrometry.

[000224]

Polysaccharide polymers are another type of water-soluble polymer that can

be used for protein modification. Therefore, the Proteins of the invention fused to a

polysaccharide polymer form embodiments of the present invention. Dextrans are
polysaccharide polymers comprised of individual subunits of glucose predominantly
linked by alpha 1-6 linkages. The dextran itself is available in many molecular weight
ranges, and is readily available in molecular weights from about 1 kD to about 70 kD.
Dextran is a suitable water-soluble polymer for use as a vehicle by itself or in
combination with another vehicle (e.g., Fc). See, e.g., International Publication No. WO
96/1 1953. The use of dextran conjugated to therapeutic or diagnostic immunoglobulins

has been reported. See, e.g., European Patent Publication No. 0 315 456, which is

hereby incorporated by reference. The present invention also encompasses the use of
dextran of about 1 kD to about 20 kD.

[000225]

In general, chemical modification can be performed under any suitable

condition used to react a protein with an activated polymer molecule. Methods for
preparing chemically modified polypeptides will generally comprise the steps of: (a)
reacting the polypeptide with the activated polymer molecule (such as a reactive ester or
aldehyde derivative of the polymer molecule) under conditions whereby a FGF21 protein
variant becomes attached to one or more polymer molecules, and (b) obtaining the
reaction products. The optimal reaction conditions will be determined based on known
parameters and the desired result. For example, the larger the ratio of polymer
molecules to protein, the greater the percentage of attached polymer molecule. In one
embodiment of the present invention, chemically modified FGF21 mutants can have a

single polymer molecule moiety at the amino-terminus (see, e.g., U.S. Pat. No.
5,234,784)

[000226]

In another embodiment of the present invention, proteins of the invention can

be chemically coupled to biotin. The biotinylated proteins of the invention are then

allowed to bind to avidin, resulting in tetravalent avidin/biotin/proteins of the invention.
Proteins of the invention can also be covalently coupled to dinitrophenol (DNP) or
trinitrophenol (TNP) and the resulting conjugates precipitated with anti-DNP or anti-TNPIgM to form decameric conjugates with a valency of 10.

[000227]

Generally, conditions that can be alleviated or modulated by the

administration of the present chemically modified dual function proteins mutants include
those described herein for proteins of the invention. However, the chemically modified
dual function proteins mutants disclosed herein can have additional activities, enhanced

or reduced biological activity, or other characteristics, such as increased or decreased
half-life, as compared to unmodified dual function proteins mutants.

Therapeutic Compositions of Dual Function Proteins and Administration Thereof

[000228]

Therapeutic compositions comprising the dual function proteins of the

invention are within the scope of the present invention, and are specifically
contemplated in light of, e.g., the identification of several mutant dual function proteins
sequences exhibiting enhanced properties. Such dual function proteins mutant
pharmaceutical compositions can comprise a therapeutically effective amount of a dual
function proteins protein variant in admixture with a pharmaceutically or physiologically
acceptable formulation agent selected for suitability with the mode of administration.

[000229] Acceptable formulation materials preferably are nontoxic to recipients at the
dosages and concentrations employed.

[000230]

The pharmaceutical composition can contain formulation materials for

modifying, maintaining, or preserving, for example, the pH, osmolarity, viscosity, clarity,
color, isotonicity, odor, sterility, stability, rate of dissolution or release, adsorption, or

penetration of the composition. Suitable formulation materials include, but are not limited
to, amino acids (such as glycine, glutamine, asparagine, arginine, or lysine),

antimicrobials, antioxidants (such as ascorbic acid, sodium sulfite, or sodium hydrogensulfite), buffers (such as borate, bicarbonate, Tris-HCI, citrates, phosphates, or other

organic acids), bulking agents (such as mannitol or glycine), chelating agents (such as
ethylenediamine tetraacetic acid (EDTA)), complexing agents (such as caffeine,
polyvinylpyrrolidone, beta-cyclodextrin, or hydroxypropyl-beta-cyclodextrin), fillers,
monosaccharides, disaccharides, and other carbohydrates (such as glucose, mannose,
or dextrins), proteins (such as serum albumin, gelatin, or immunoglobulins), coloring,

flavoring and diluting agents, emulsifying agents, hydrophilic polymers (such as
polyvinylpyrrolidone), low molecular weight polypeptides, salt-forming counterions (such
as sodium), preservatives (such as benzalkonium chloride, benzoic acid, salicylic acid,

thimerosal, phenethyl alcohol, methylparaben, propylparaben, chlorhexidine, sorbic
acid, or hydrogen peroxide), solvents (such as glycerin, propylene glycol, or

polyethylene glycol), sugar alcohols (such as mannitol or sorbitol), suspending agents,
surfactants or wetting agents (such as pluronics; PEG; sorbitan esters; polysorbates
such as polysorbate 20 or polysorbate 80; triton; tromethamine; lecithin; cholesterol or

tyloxapal), stability enhancing agents (such as sucrose or sorbitol), tonicity enhancing
agents (such as alkali metal halides; preferably sodium or potassium chloride; or
mannitol sorbitol), delivery vehicles, diluents, excipients and/or pharmaceutical
adjuvants (see, e.g., Remington's Pharmaceutical Sciences (18th Ed., A . R . Gennaro,
ed., Mack Publishing Company 1990), and subsequent editions of the same,

incorporated herein by reference for any purpose).

[000231]

The optimal pharmaceutical composition will be determined by a skilled

artisan depending upon, for example, the intended route of administration, delivery
format, and desired dosage (see, e.g., Remington's Pharmaceutical Sciences, supra).
Such compositions can influence the physical state, stability, rate of in vivo release, and
rate of in vivo clearance of the fusion protein of the invention.

[000232]

The primary vehicle or carrier in a pharmaceutical composition can be either

aqueous or non-aqueous in nature. For example, a suitable vehicle or carrier for
injection can be water, physiological saline solution, or artificial cerebrospinal fluid,
possibly supplemented with other materials common in compositions for parenteral
administration. Neutral buffered saline or saline mixed with serum albumin are further
exemplary vehicles. Other exemplary pharmaceutical compositions comprise Tris buffer
of about pH 7.0-8.5, or acetate buffer of about pH 4.0-5.5, which can further include
sorbitol or a suitable substitute. In one embodiment of the present invention, dual
function pharmaceutical compositions can be prepared for storage by mixing the
selected composition having the desired degree of purity with optional formulation
agents (Remington's Pharmaceutical Sciences, supra) in the form of a lyophilized cake
or an aqueous solution. Further, the dual function protein product can be formulated as
a lyophilizate using appropriate excipients such as sucrose.

[000233]

The pharmaceutical compositions containing the fusion proteins of the

invention can be selected for parenteral delivery. Alternatively, the compositions can be
selected for inhalation or for delivery through the digestive tract, such as orally. The
preparation of such pharmaceutically acceptable compositions is within the skill of the
art.

[000234]

The formulation components are present in concentrations that are

acceptable to the site of administration. For example, buffers are used to maintain the
composition at physiological pH or at a slightly lower pH, typically within a pH range of
from about 5 to about 8 .

[000235]

When parenteral administration is contemplated, the therapeutic

compositions for use in this invention can be in the form of a pyrogen-free, parenterally
acceptable, aqueous solution comprising the desired dual function protein in a
pharmaceutically acceptable vehicle. A particularly suitable vehicle for parenteral
injection is sterile distilled water in which a dual function protein is formulated as a
sterile, isotonic solution, properly preserved. Yet another preparation can involve the

formulation of the desired molecule with an agent, such as injectable microspheres, bioerodible particles, polymeric compounds (such as polylactic acid or polyglycolic acid),
beads, or liposomes, that provides for the controlled or sustained release of the product

which can then be delivered via a depot injection. Hyaluronic acid can also be used,
and this can have the effect of promoting sustained duration in the circulation. Other

suitable means for the introduction of the desired molecule include implantable drug
delivery devices.

[000236]

In one embodiment, a pharmaceutical composition can be formulated for

inhalation. For example, a dual function protein of the invention can be formulated as a
dry powder for inhalation. Dual function protein inhalation solutions can also be

formulated with a propellant for aerosol delivery. In yet another embodiment, solutions
can be nebulized. Pulmonary administration is further described in International

Publication No. WO 94/20069, which describes the pulmonary delivery of chemically
modified proteins.

[000237]

It is also contemplated that certain formulations can be administered orally.

In one embodiment of the present invention, dual function proteins of the invention that

are administered in this fashion can be formulated with or without those carriers

customarily used in the compounding of solid dosage forms such as tablets and
capsules. For example, a capsule can be designed to release the active portion of the
formulation at the point in the gastrointestinal tract when bioavailability is maximized and
pre-systemic degradation is minimized. Additional agents can be included to facilitate
absorption of the dual function proteins of the invention. Diluents, flavorings, low
melting point waxes, vegetable oils, lubricants, suspending agents, tablet disintegrating

agents, and binders can also be employed.

[000238] Another pharmaceutical composition can involve an effective quantity of the
proteins of the invention in a mixture with non-toxic excipients that are suitable for the
manufacture of tablets. By dissolving the tablets in sterile water, or another appropriate

vehicle, solutions can be prepared in unit-dose form. Suitable excipients include, but are
not limited to, inert diluents, such as calcium carbonate, sodium carbonate or
bicarbonate, lactose, or calcium phosphate; or binding agents, such as starch, gelatin,
or acacia; or lubricating agents such as magnesium stearate, stearic acid, or talc.

[000239] Additional pharmaceutical compositions comprising dual function proteins of
the invention will be evident to those skilled in the art, including formulations involving
dual function proteins of the invention in sustained- or controlled-delivery formulations.
Techniques for formulating a variety of other sustained- or controlled-delivery means,
such as liposome carriers, bio-erodible microparticles or porous beads and depot
injections, are also known to those skilled in the art (see, e.g., International Publication
No. WO 93/15722, which describes the controlled release of porous polymeric

microparticles for the delivery of pharmaceutical compositions, and Wischke &
Schwendeman, 2008, Int. J Pharm. 364: 298-327, and Freiberg & Zhu, 2004, Int. J
Pharm. 282: 1-18, which discuss microsphere/microparticle

preparation and use).

[000240] Additional examples of sustained-release preparations include
semipermeable polymer matrices in the form of shaped articles, e.g. films, or
microcapsules. Sustained release matrices can include polyesters, hydrogels,
polylactides (U.S. Pat. No. 3,773,919 and European Patent No. 0 058 481 ) , copolymers
of L-glutamic acid and gamma ethyl-L-glutamate (Sidman et al., 1983, Biopolymers 22:
547-56), poly(2-hydroxyethyl-methacrylate)

(Langer et al., 1981 , J . Biomed. Mater. Res.

15: 167-277 and Langer, 1982, Chem. Tech. 12: 98-105), ethylene vinyl acetate (Langer

et al., supra) or poly-D-3-hydroxybutyric acid (European Patent No. 0 133 988).
Sustained-release compositions can also include liposomes, which can be prepared by
any of several methods known in the art. See, e.g., Epstein et al., 1985, Proc. Natl.
Acad. Sci. U.S.A. 82: 3688-92; and European Patent Nos. 0 036 676, 0 088 046, and 0
143 949.

[000241]

The pharmaceutical compositions of the invention to be used for in vivo

administration typically must be sterile. This can be accomplished by filtration through
sterile filtration membranes. Where the composition is lyophilized, sterilization using this
method can be conducted either prior to, or following, lyophilization and reconstitution.
The composition for parenteral administration can be stored in lyophilized form or in a
solution. In addition, parenteral compositions generally are placed into a container
having a sterile access port, for example, an intravenous solution bag or vial having a
stopper pierceable by a hypodermic injection needle.

[000242]

Once the pharmaceutical composition has been formulated, it can be stored

in sterile vials as a solution, suspension, gel, emulsion, solid, or as a dehydrated or

lyophilized powder. Such formulations can be stored either in a ready-to-use form or in a
form (e.g., lyophilized) requiring reconstitution prior to administration.

[000243]

In a specific embodiment, the present invention is directed to kits for

producing a single-dose administration unit. The kits can each contain both a first
container having a dried protein and a second container having an aqueous formulation.
Also included within the scope of this invention are kits containing single and multichambered pre-filled syringes (e.g., liquid syringes and lyosyringes).

Dosages of Dual Function Proteins and Administration Thereof

[000244]

The effective amount of a pharmaceutical composition of the invention to be

employed therapeutically will depend, for example, upon the therapeutic context and
objectives. One skilled in the art will appreciate that the appropriate dosage levels for
treatment will thus vary depending, in part, upon the molecule delivered, the indication
for which the fusion protein variant is being used, the route of administration, and the
size (body weight, body surface, or organ size) and condition (the age and general
health) of the patient. Accordingly, the clinician can titer the dosage and modify the
route of administration to obtain the optimal therapeutic effect. A typical dosage can
range from about 0.1 µg kg to up to about 100 mg/kg or more, depending on the factors
mentioned above. In other embodiments, the dosage can range from 0.1 µg/kg up to
about 100 mg/kg; or 1 g/ kg up to about 100 mg/kg.

[000245]

The frequency of dosing will depend upon the pharmacokinetic parameters

of the dual function protein in the formulation being used. Typically, a clinician will
administer the composition until a dosage is reached that achieves the desired effect.
The composition can therefore be administered as a single dose, as two or more doses
(which may or may not contain the same amount of the desired molecule) over time, or
as a continuous infusion via an implantation device or catheter. Further refinement of

the appropriate dosage is routinely made by those of ordinary skill in the art and is within
the ambit of tasks routinely performed by them. Appropriate dosages can be
ascertained through use of appropriate dose-response data.

[000246]

The route of administration of the pharmaceutical composition is in accord

with known methods, e.g., orally; through injection by intravenous, intraperitoneal,
intracerebral (intraparenchymal), intracerebroventricular, intramuscular, intraarterial,
intraportal, or intralesional routes; by sustained release systems (which may also be
injected); or by implantation devices. Where desired, the compositions can be
administered by bolus injection or continuously by infusion, or by implantation device.

[000247] Alternatively or additionally, the composition can be administered locally via
implantation of a membrane, sponge, or other appropriate material onto which the

desired molecule has been absorbed or encapsulated. Where an implantation device is
used, the device can be implanted into any suitable tissue or organ, and delivery of the

desired molecule can be via diffusion, timed-release bolus, or continuous administration

Therapeutic Uses of Dual Function Proteins

[000248]

Proteins of the invention can be used to treat, diagnose, ameliorate, or

prevent a number of diseases, disorders, or conditions, including, but not limited to
metabolic disorders. In one embodiment, the metabolic disorder to be treated is
diabetes, e.g., type 2 diabetes mellitus. In another embodiment, the metabolic disorder
is obesity. Other embodiments include metabolic conditions or disorders such as type 1

diabetes mellitus, pancreatitis, dyslipidemia, nonalcoholic fatty liver disease (NAFLD),
nonalcoholic steatohepatitis (NASH), insulin resistance, hyperinsulinemia, glucose
intolerance, hyperglycemia, metabolic syndrome, hypertension, cardiovascular disease,
acute myocardial infarction, atherosclerosis, peripheral arterial disease, stroke, heart
failure, coronary heart disease, kidney disease, diabetic complications, neuropathy,
disorders associated with severe inactivating mutations in the insulin receptor,
lipodystrophies including HIV-associated lipodystrophy, gastroparesis and other
metabolic disorders.

[000249]

In application, a disorder or condition such as type 1 or type 2 diabetes

mellitus or obesity can be treated by administering a dual function protein variant as
described herein to a patient in need thereof in the amount of a therapeutically effective
dose. The administration can be performed as described herein, such as by IV

injection, intraperitoneal injection, intramuscular injection, or orally in the form of a tablet

or liquid formation. In most situations, a desired dosage can be determined by a
clinician, as described herein, and can represent a therapeutically effective dose of the
dual function protein polypeptide. It will be apparent to those of skill in the art that a

therapeutically effective dose of dual function protein polypeptide will depend, inter alia,
upon the administration schedule, the unit dose of antigen administered, whether the

nucleic acid molecule or polypeptide is administered in combination with other
therapeutic agents, the immune status and the health of the recipient. The term
"therapeutically effective dose," as used herein, means that amount of dual function
protein polypeptide that elicits the biological or medicinal response in a tissue system,
animal, or human being sought by a researcher, medical doctor, or other clinician, which

includes alleviation of the symptoms of the disease or disorder being treated.

Pharmaceutical Compositions

[000250]

The present invention also provides pharmaceutical compositions comprising

one or more of the dual function proteins of the invention or mutants described herein
and a pharmaceutically acceptable carrier. In some embodiments the pharmaceutical

compositions are prepared as injectables, either as liquid solutions or suspensions; solid
forms suitable for solution in, or suspension in, liquid vehicles prior to injection can also
be prepared. Liposomes are included within the definition of a pharmaceutically

acceptable carrier. Pharmaceutically acceptable salts can also be present in the
pharmaceutical composition, e.g., mineral acid salts such as hydrochlorides,
hydrobromides, phosphates, sulfates, and the like; and the salts of organic acids such
as acetates, propionates, malonates, benzoates, and the like. A thorough discussion of

pharmaceutically acceptable excipients is available in Remington: The Science and
Practice of Pharmacy (1995) Alfonso Gennaro, Lippincott, Williams, & Wilkins.

Fusion Proteins and Peptidic Compounds

[000251]

In another embodiment, the proteins of the present invention can be made

into a fusion protein or peptidic compound derived from the dual function proteins of the

invention amino acid sequences. Such fusion proteins and peptidic compounds can be
made using standard techniques known in the art. For example, peptidic compounds
can be made by chemical synthesis using standard peptide synthesis techniques and

then introduced into cells by a variety of means known in the art for introducing peptides
into cells (e.g., liposome and the like).

[000252]

The in vivo half-life of the fusion protein or peptidic compounds of the

invention can be improved by making peptide modifications, such as the addition of
linked glycosylation sites into the dual function proteins of the invention, or conjugating
dual function proteins of the invention to poly(ethylene glycol)(PEG; pegylation), e.g., via

lysine-monopegylation or cysteine-monopegylation.

Such techniques have proven to be

beneficial in prolonging the half-life of therapeutic protein drugs. It is expected that
pegylation of the proteins of the invention of the invention may result in similar
pharmaceutical advantages.

[000253]

In addition, PEGylation can be achieved in any part of a polypeptide of the

invention by the introduction of a non-natural amino acid. Certain non-natural amino
acids can be introduced by the technology described in Deiters et al., J Am Chem Soc
125:1 1782-1 1783, 2003; Wang and Schultz, Science 301 :964-967, 2003; Wang et al.,

Science 292:498-500, 2001; Zhang et al., Science 303:371-373, 2004 or in US Patent
No. 7,083,970. Briefly, some of these expression systems involve site-directed

mutagenesis to introduce a nonsense codon, such as an amber TAG, into the open
reading frame encoding a polypeptide of the invention. Such expression vectors are

then introduced into a host that can utilize a tRNA specific for the introduced nonsense
codon and charged with the non-natural amino acid of choice. Particular non-natural
amino acids that are beneficial for purpose of conjugating moieties to the polypeptides
of the invention include those with acetylene and azido side chains. The proteins of the
invention containing these novel amino acids can then be PEGylated at these chosen
sites in the protein.

[000254]

Similarly PEGylation can be achieved in any part of a protein of the invention

by the introduction of pyrrolysine or pyrroline-carboxy-lysine as described by Ou et al.
(Proc Natl Acad Sci U S A . 201 1 Jun 28; 108(26): 10437-42. Epub 201 1 Jun 13).

EXAMPLES
Example 1: Design of GLP-1/Proteins of the invention.
[000255]

In order to test the efficacy of GLP-1 and FGF21 together, a fusion molecule

was designed. Because GLP-1 requires a free N-terminus and FGF21 requires a free
C-terminus for receptor binding and activation, the two were cloned in the order of NGLP-1-linker-FGF21-C.

Initial constructs were made with GLP-1 residues 7-35 and with

or without several modifications to the N-terminus for DPP-4 protection (discussed
below). Further modifications of GLP-1 (point mutants or deletions) were tested and
scored by in vitro potency.

[000256]

Linkers of 3 , 8 , 10 , or 20 amino acids were cloned. For FGF21 , residues 33-

209 of the wild-type human protein were used. Constructs with and without PEGylation
sites were produced. PEGylation was accomplished using maleimide-PEG reagents (40
kDa linear and branched PEGs) reactive toward an introduced Cys. The Cys was

placed at position R154 of FGF21 and at several sites in the GLP-1 or Exendin-4 and
linker. Constructs have also been designed for modification through incorporation of a
Pel, Pyl, Pyl analog or a reactive non-naturally occurring amino acid by introducing a

TAG (amber) codon at position R154 of FGF21 or K34 of GLP-1 . Additional constructs
were designed for two different modifications by inclusion of the Cys at R154 or K34 and
a TAG codon for incorporation of a Pel, Pyl, Pyl analog or a reactive non-naturally
occurring amino acid at the other site. Constructs were made fusing GLP-1 and FGF21
to an Fc domain of a human antibody. Variant 76 (V76) sequence of FGF21 was
introduced into the fusion format.

[000257]

Expression and purification of the fusions: Fusion proteins were typically

expressed in E . coli by cloning the DNA sequence encoding the particular dual function
variant into a vector containing coding sequences for one of several removable domains
(for example, NPro or NPro variants with or without His6 tag, or His6 tag with a TEV-

protease recognition peptide, or His6-Ubiquitin, or His6-Smt3) The vectors further
included an inducible promoter to initiate mRNA transcription for protein expression
such as the lac, T7 or arabinose promoters). Briefly, the vectors were transformed to
DH1 Ob-derived E . coli cells or BL21(DE3)-derived cells, grown under standard

conditions, and induced to express protein with 0.2% arabinose or IPTG added to the
culture media. Cells were harvested 3-4 hours post-induction, spun, and frozen. Pellets
were thawed and resuspended for lysis by sonication and insoluble protein was isolated
by centrifugation. The pellet was then solubilized in 6M guanidine, and the dissolved,
clarified proteins were loaded to Ni-NTA columns. The columns were washed with
denaturing and then non-denaturing buffers and eluted in a non-denaturing buffer
according to standard practice. The eluates were buffer exchanged to remove
imidazole, digested with specific proteases for removal of tags, (for example TEV
protease, ubquitinase Usp2, or Ulp1 for specific removal of smt3), and purified by NiNTA. The fusion protein-containing fractions were further purified by size exclusion
chromatography before PEGylation (typically with NOF Sunbright GL2-400MA 40kDa
branched PEG maleimide). PEGylated proteins were isolated by anion exchange
chromatography, placed in PBS, and concentrated or stored for various assays.

[000258]

Protection of GLP-1 by mutation of the N-terminus: Because processing of

the N-terminus of GLP-1 by DPP-4 is known to inactivate the peptide toward its primary
receptor, several mutations reported in the literature were explored to slow this process.
Constructs with the addition of an extra glycine to the N-terminus, mutation of Glu9 to
Pro, or mutation of Ala8 to Gly or Ser, were all tested in a cell-based assay of GLP-1

activity. In the context of the fusion to FGF21 with a 40 kDa PEG attached to FGF21 ,
the mutations at Ala8 retained superior activity to the other N-terminal modifications
(Figure 1a), and the A8S mutation was used in subsequent designs. In addition, the
DPP-4-resistant analogue, Exendin-4 was also tested in the fusions as an alternative
moiety with extended half-life in vivo (Figure 1b). [See, e.g., J . Y . Ohet al. (2009)
Bulletin of the Korean Chemical Society 30, 2471-2474; K . Adelhorst, (1994) JBC 269,
6275; B . D. Green et al. (2003) Biological Chemistry 384, 1543; J . C . Parkeret al. (1998)
Journal of Peptide Research 52, 398; C . F. Deaconet al. (1998) Diabetologia 4 1 , 271; R .
Burcelinet al. (1999) Metabolism-Clinical and Experimental 48, 252; U. Ritzelet al.
(1998) Journal of Endocrinology 159, 93.]

[000259]

The A8S mutation was also compared to wild-type GLP-1 for

pharmacokinetic properties in vivo. A fusion protein with wild-type GLP-1 (V329) and
one with the GLP-1 (A8S) mutation (V232) were injected intravenously into rats at 1
mg/kg, and the serum levels were measured against standard curves produced with the
dosing solutions. When measured with a human FGF21 -reactive ELISA kit, the

molecules appeared to behave similarly to each other and to FGF21 alone with the
same size (40 kDa) PEG attached (Figure 2). To measure the half-life extension of
GLP-1 activity, C57BL/6J mice were injected with the same two dual function protein

variants with either wild-type GLP-1 or GLP-1 (A8S). While both acutely lowered the fed
glucose level after dosing, the GLP-1 (A8S) variant retained greater activity in an oral
glucose tolerance test (OGTT) measurement 3 days after dosing (Figure 3). These data
demonstrate that the A8S mutation increases the effective half-life of the GLP-1 moiety
of the fusion while the PK of the FGF21 moiety is not much affected by the addition of
GLP-1 .

[000260]

Design of the peptide linker between GLP-1 and FGF21 : Linkers of 3 , 8 , 10,

or 20 amino acids were tested. No significant difference in activity was observed for the
variants with different linkers, although there were differences in expression yields in
some fusion contexts. Additionally, constructs were tested with various lengths of GLP1 (8 to 3 1 residues) or Exendin-4 (30 or more residues) and tested for in vitro activity in
the GLP-1 R cell-based assay.

Example 2 : Test of fusions in the ob/ob and db/db diabetic mouse models.
[000261]

FGF21 has been shown to improve blood glucose levels, liver lipid levels,

and body weight in the ob/ob mouse model of type-2 diabetes (T2D; see, e.g., A .

Kharitonenkovet al. (2005) Journal of Clinical Investigation 115, 1627; T. Coskun et al.
(2008) Endocrinology 149, 6018; and E . D. Berglund et al. (2009) Endocrinology 150,
4084). Likewise, GLP-1 analogues have been shown to improve glucose control, beta
cell function and liver health in this genetic mouse diabetes model (Gallwitz B.,

Glucagon-like peptide-1 as a treatment option for type 2 diabetes and its role in
restoring beta-cell mass. Diabetes Techno! Ther. 2005, 7:651-7).

[000262]

To determine if the fusion of GLP-1 to FGF21 would lead to additional

efficacy, the WT GLP-1 and GLP-1 (A8S) versions were tested against an equivalent
FGF21 molecule each with the same 40 kDa branched PEG attached. In a two week

study with twice weekly dosing, the FGF21(R154C)-PEG (V238) and GLP-1 FGF21 (R1 54C)-PEG (V239) showed similar effects on blood glucose, body weight, and

liver health (assessed by alanine aminotransferase (ALT) serum levels, weight, and
appearance) (Figure 4). Glucose measurements showed a faster improvement for the
fusion than for FGF21 alone after the first dose. The two converged at time points more
than a day after dosing, suggesting that the additional benefit due to GLP-1 was shorter
lived than the FGF21 efficacy.

[000263]

The GLP-1 (A8S)-FGF21(R154C)-PEG (V235) fusion also showed similar

effects at 0.2 mg/kg, rather than the 1 mg/kg used for the other compounds. This

compound also generally gave more consistent results between dosing, suggesting that
the DPP-4-resistance was critical to the overall improvement in efficacy as compared to
the up-and-down behavior of GLP-1-FGF21(R154C)-PEG (V239). It was also observed
that the GLP-1(A8S)-FGF21(R154C)-PEG (V235) at 1 mg/kg showed additional
lowering of glucose, body weight, ALT/AST, and liver weight.

[000264] Additional studies were conducted to see if the improved efficacy could be
replicated with co-administration of separate FGF21 and GLP-1 compounds. To make
dosing of proteins similar between groups, a tool compound was made in which 14
amino acids were removed from the FGF21 C-terminus. This molecule (V253) was at
least 1000x less potent in the FGF21 receptor assay but retained equal potency in the
GLP-1 R assay as compared to the other fusions and was unable to inhibit wild-type
FGF21 activity. This compound had pharmacokinetics in rat similar to the other fusions

when assessed by FGF21 levels (Figure 2).

[000265]

Results of a four week study in which ob/ob mice were treated with

FGF21 (V76)-PEG, GLP-1 (A8S)-PEG (V253), both together, or GLP-1 ( A8S)FGF21 (V76)-PEG fusion (V272) are shown in Figure 5 . The fusion was significantly

more efficacious than co-treatment of the individual FGF21(V76)-PEG and GLP-1 (A8S)PEG molecules on fed glucose AUC, OGTT glucose AUC, body weight at the end of the

study, hepatic lipid content, and ALT measurement (p-values < 0.05 for all) .

[000266]

Serum exposure of human FGF21 and GLP-1 were checked in the terminal

serum samples to confirm exposure in the various groups.

Human FGF21 was

detected in all treated groups, and a significant increase in active GLP-1 was measured
in all groups treated with GLP-1 (A8S)-PEG (V253) or GLP-1 (A8S)-FGF21(V76)-PEG

(V272) . The GLP-1 (A8S)-FGF21 (V76)-PEG (V272) group showed similar levels of
human FGF21 to the 0.2 mg/kg FGF21(V76)-PEG group, suggesting that the improved
efficacy is not due to a higher systemic accumulation of the fusion in the animals. The
GLP-1 (A8S)-PEG (V253) molecule was fully active in vitro (Table 8). These data

demonstrate that the efficacy of the fusion was dependent on both moieties being in a
single molecule, and, e.g., benefitted from a synergy at the cellular level.

[000267]

To further test GLP-1 (A8S)-FGF21 (V76)-PEG (V272) vs. co-administration,

three studies were conducted in db/db mice. In each study, male db/db mice (8-1 1
weeks old were dosed i.p. twice weekly. In an initial three week study, the dual function
fusion protein, GLP-1 (A8S)-FGF21(V76)-PEG (V272), matched the glucose lowering of
the co-administration at equal doses and surpassed the efficacy of single entity dosing.
The dual function fusion protein also showed superior body weight loss.

[000268]

In a second two week study, GLP-1 (A8S)-FGF21 (V76)-PEG (V272) showed

similar glucose lowering compared to FGF21 (V76)-PEG at a 25-fold lower dose and

GLP-1(A8S)-PEG (V253) at a 5-fold lower dosing. In addition, GLP-1 (A8S)FGF21 (V76)-PEG (V272) lowered HbA1c significantly more and lowered body weight

significantly more than the mono-therapies or the maximally efficacious dose of the c o
administration groups (Figure 8 , Table 2). Unexpectedly, altering the dosing ratio of the
co-treatments higher than 1: 1 did not improve the observed efficacy (Table 2). This
suggests that dual function proteins including equal numbers of GLP-1 moieties and
FGF21 moieties can achieve optimal efficacy during in vivo treatments.

Table 2 . Therapeutic Dosages

[000269]

[000270]

p-value vs. vehicle < 0.05.

2

p-value vs. co-treatment groups < 0.05

Table 2 shows efficacy of mono-therapies and co-treatments at different

doses compared to dual function proteins in a db/db mouse study with 2 weeks of
dosing. The reported values are averages of measurements made in eight animals with
standard deviation. In a four week study, male db/db mice (n=8) were dosed twice
weekly for four weeks with mono-therapies, co-treatments, or dual function fusion
proteins. On day 27, the mice were fasted and the blood insulin levels were measured
for all animals. At the end of the study, pancreatic insulin contents were extracted and
measured (n=3). GLP-1 (A8S)-FGF21 (V76)-PEG (V272) showed a robust dose
response from 0.1-1 mg/kg with efficacy equal to or better than FGF21(V76)-PEG or
GLP-1 (A8S)-PEG (V253) alone on glucose levels, HbA1c, and body weight at more

than 10-fold lower dose, and improved efficacy over the maximally efficacious dosing of
the co-administration. GLP-1 (A8S)-FGF21 (V76)-PEG (V272) also lowered fasting

insulin levels in the serum while increasing insulin content of the pancreas to a greater

extent than the single or combination treatments of GLP-1(A8S)-PEG (V253) and
FGF21 (V76)-PEG (Figure 7). GLP-1 (A8S)-FGF21(V76)-PEG (V272) -treated animals

were close to lean control mice in fed glucose, HbAlc, and body weight numbers.

[000271]

To estimate metabolic rate and substrate utilization, we measured

oxygen consumption and carbon dioxide production using an Oxymax indirect
calorimetry system (Columbus Instruments, Columbus, OH). Mice were housed in the
chamber with a 12-h light/1 2-h dark cycle in an ambient temperature of 22-24°C. V

2

and VC0 2 rates were determined under Oxymax system settings and protocol. The

system was calibrated against a standard gas mixture to measure 0 2 consumed {V
ml/kg/h) and C0 2 generated (VC0 2, ml/kg/h). Metabolic rate { V
exchange ratio (RER) (ratio of VC

2/V0 2)

2)

2,

and respiratory

were evaluated over a 72-h period.

Calculated RER values indicated that animals treated with fusion protein relied more on
lipid substrates (RER values close to 0.75-0.85) particularly during the 24-72 hours after

the second dose when compared to vehicle or combination treated groups. During this
period, vehicle and combination treated groups showed RER values were close to 0.9

suggesting more of carbohydrate substrate utilization for energy and to a lesser extent
lipid substrate utilization for energy expenditure. The data suggest that fusion protein

treatment caused an increase in fatty acid oxidation that may be contributing to its body
weight reduction effect in db/db mice

[000272] A dual function fusion protein, when compared to combination, showed
improved beta-cell function in vivo. After four doses of either dual function protein GLP1(A8S)-FGF21(V76)-PEG (V272) or GLP-1( A8S)-PEG (V253) plus FGF21 (V76)-PEG,
db/db mice were dosed orally with glucose and arginine. The glucose excursion of the
dual function protein-treated group (72% lower than vehicle) was significantly lower than

the combination-treated group (56% lower than vehicle). During the experiment, the
amount of insulin secreted was also higher for the dual function protein-treated group
(279% higher than vehicle) than for the combination-treated group (122% higher than
vehicle).

[000273]

Overall, the figures and tables, as well as data not shown herein,

demonstrate the ability of the dual function fusion proteins of the invention, e.g., GLP1(A8S)-FGF21 (V76)-PEG (V272), to improve metabolic parameters for in vitro and in

vivo rodent models of diabetes, when compared to a combination of individual GLP-1
and FGF21 (e.g.,FGF21(V76)-PEG and GLP-1 (A8S)-PEG (V253)). Said improved

parameters (as used herein, "metabolic parameters") include but are not limited to fed
glucose (AUC), body weight, liver triglycerides, plasma HbAlc, serum triglyceride levels

total cholesterol levels, oral glucose tolerance test serum glucose measurement (AUC),
fasting serum insulin, pancreatic insulin content, and body fat percentage.

Example 3 : Design of GLP-1 /Proteins of the invention from FGF21 Variants.

[000274] A fusion was made with the following FGF21 variant sequence, which we
refer to herein as "Variant 76" or "V76":

1

DSSPLLQFGG

QVRQRYLYTD

DAQETEAHLE

IREDGTVGGA AHQSPESLLE

LKALKPGVIQ

61

ILGVKTSRFL

CQKPDGALYG

SLHFDPEACS

FRELLLEDGY

NVYQSEAHGL

PLHLPGNRSP

121

HCDPAPQGPA

RFLPLPGLPP

ALPEPPGILA

PQPPDVGSSD

PLAMVGPSQG

RSPSYAS

(SEQ ID NO: 130)

[000275]

FGF21 (V76)-PEG features a 40 kDa branched PEG linked through Cys1 54,

and eight point mutations relative to the 177 amino acid wild-type protein (Q56E, D74H,

Q82E, R105K, K150R, R154C, R159Q, S195A, all made relative to full-length FGF21
protein sequence (NCBI reference sequence number NP_061 986.1 )). The risk of
clinical immunogenicity toward this molecule is considered low based on an EpiScreen
time course assay of human T-cell responses. The molecule has a serum half-life time
of more than 30 h in mouse and rat and significantly lowers glucose AUC in ob/ob mice
with twice-weekly injections of 1 mg/kg.

[000276]

The GLP-1 (A8S)-FGF21 (V76)-PEG (V272) molecule was tested against the

GLP-1 (A8S)-FGF21(R154C)-PEG (V235) fusion at three doses (0.05, 0.1 and 0.2

mg/kg). Both fusions showed a dose response in lowering glucose AUC, body weight,
food intake, and ALT(Figure 6). GLP-1 (A8S)-FGF21(V76)-PEG (V272) was generally
equal or better and showed higher efficacy for all parameters at the 0.2 mg/kg dose.
GLP-1 (A8S)-FGF21(V76)-PEG (V272) also showed lowering of serum triglycerides and

cholesterol at both 0.1 and 0.2 mg/kg. Based on these data, the GLP-1 (A8S)FGF21 (V76)-PEG (V272) molecule shows similar or improved properties to the initial

fusions and is suitable for further study and development.

[000277]

Ex4(1 -30)-L20-FGF21 (V76)-PEG (V277) also showed similar efficacy to

GLP-1 (A8S)-FGF21(V76)-PEG (V272) in an ob/ob 2 week study for glucose control,

body weight and lipid levels.

[000278]

Choice of PEGylation site for half-life extension. As seen for example in

Figure 2 , PEGylation was used to extend the half-life of the molecule from a few minutes
for GLP-1 or less than an hour for FGF21 to longer than 30 hours as measured in rats.
To see if the two moieties of the fusion could be modulated by placement of the PEG, a
series of constructs was made with the extra cysteine not in the FGF21 sequence but in

that of GLP-1 or the linker. These constructs were tested for both GLP-1 and FGF21
activity in cell-based assays. Experiments reveal a stretch of positions within the fusion
protein sequences at which PEGylation does not greatly impact either activity. Careful
placement of the PEG at the N-terminal end of this stretch could be used to make a
molecule with knocked-down GLP-1 activity while placement in the linker could be used
to knock-down FGF21 activity. Such a molecule may be useful in tuning the potency of
the fusion (for example, if the high potency of GLP-1 or Exendin-4 resulted in a poor
therapeutic window when dosed at the efficacious level of a lower potency FGF21).

[000279]

Based on these data, fusions with PEGylation at K34C of GLP-1 (V273) or

K27C of Exendin-4 (V274) were prepared with FGF21 (V76-C154R) whose sequence is
as follows:

DSSPLLQFGG

QVRQRYLYTD

DAQETEAHLE

IREDGTVGGA

AHQSPESLLE

LKALKPGVIQ

ILGVKTSRFL

CQKPDGALYG

SLHFDPEACS

FRELLLEEGY

NVYQSEAHGL

PLHLPGNRSP

HRDPAPQGPA

RFLPLPGLPP

ALPEPPGILA

PQPPDVGSSD

PLAMVGPSQG

RSPSYAS

(SEQ ID NO 131)

[000280] A two week study in ob/ob mice demonstrates that, although the new fusions
(V273 and V274) exhibited potency in vitro similar to the previous fusions and similar
pharmacokinetics in rat, they were not as efficacious in vivo. At 0.2 mg/kg, the GLP-1
fusion variant showed no significant efficacy for glucose or body weight. The Exendin-4
fusion variant showed significant lowering of ALT and body weight and a trend toward
lower AST compared to vehicle but no significant effect on blood glucose. Although
these fusions may show efficacy at higher doses, the original format with PEGylation at
R 1 54C in FGF21 was chosen for further study. It is unclear if this unexpected difference

indicates a special property of the GLP-1 (A8S)-FGF21 (V76-1 54R)-PEG version of the
fusion that is blocked by PEGylation at the alternate site or if there is another
explanation such as the PEG blocking the GLP-1 R interaction more on the native cells
with native receptor levels than on the transfected cells used for the in vitro assay.

Example 4 : Further Characterization of GLP-1/FGF21 Proteins of the invention.

[000281]

In order to further optimize and rank the GLP-1 -FGF21 -PEG dual activity

proteins of the invention, and to gain a fuller appreciation of their improved efficacy over
co-administration models, the fusions are tested in the ob/ob model of efficacy. These
include but are not limited to molecules with longer or shorter linkers, additional proteins
of the invention (which may include but are not limited to mutants based on Variant 76

or additional variants in development such as additional or different point mutations,
insertions or deletions, dimerized molecules, alternative PEGylation strategies,
molecules with additional disulfide bridges, molecules produced in different expression
systems), and variants of Exendin-4 or GLP-1 to improve serum stability or activity.
Candidates are also filtered by in silico immunogenicity prediction, expression levels,
and quality of final products (related to solubility, aggregation and stability).

[000282]

In order to further characterize the synergy of FGF21 and GLP-1 for

treatment of diabetes and obesity, interaction dynamics of the two molecules are
mapped, and the fusion proteins are compared to the maximally efficacious coadministration of the individual parent molecules. These experiments are conducted in
models that focus on obesity and weight loss (Diet Induced Obesity in rat or mouse) and
those that better model aspects of diabetes such as hyperglycemia, dislipidemia, and
impaired beta cell function (ob/ob or db/db mice). The extent of synergy achieved by
the dual activity proteins of the invention can be further determined by mapping the
efficacy of each individual molecule, the combination of the two at different ratios, and
the fusion.

[000283]

Testing in cell-based assays with primary or immortalized rat islets and

primary human islets is conducted to assess the efficacy of the fusion for cell
proliferation, protection from apoptosis, and function, e.g., to validate the dual activity
proteins of the invention in accepted models of Type 1 Diabetes (see further Van Belle,
T.L. et al. Drug Discovery today: disease models. 209 pp. 41-45). Preferred in vivo
models are those featuring pancreatic ablation by streptozotocin (STZ); targeted betacell ablation in a genetically modified and inducible mouse strain (RIP-DTA) in which the

beta-cells are destroyed by supplementing the diet with doxycycline to induce targeted
expression of diphtheria toxin; or the non-obese diabetic (NOD) mouse model of Type-1
diabetes with an autoimmunity mechanism. In these models, testing is possible in both
prophylactic dosing to assess beta-cell protection (particularly in NOD) as well as postchallenge dosing to assess beta-cell stimulation and proliferation (particularly in STZ
and RIP-DTA).

[000284]

The following experiments are conducted to more fully realize the

mechanism of efficacy synergy achieved by the dual activity proteins of the invention
over the co-administration regimens: Cells co-transfected with both receptors (GLP-1 R ;
FGFRI(lllc), 2(lllc),

3(1 lie),

or 4 ; and beta-klotho) can be used to determine if the

receptors are able to potentiate the opposing signal at the cell surface. Crosstalk
between downstream signals can be detected in cells naturally expressing both
receptors (e.g., beta cells). In animals, the contribution of food intake (investigated with
pair-fed cohorts), increased metabolic rate (investigated in clamp and metabolic

chamber experiments), and other mechanisms could be more thoroughly investigated to
elucidate a mode of action for the synergistic effects of the two signals. Gene
expression profiling of key tissues (liver, pancreas, adipose, intestine, heart, aorta,
brain, etc.) may also be conducted in order to elucidate the unique signaling of the

fusion proteins, potentially accounting for their improved efficacy.

[000285]

The following experiments are conducted to understand the activity of dual

function proteins of the invention to control or modify differentiation of mesenchymal
stem cells (MSC): MSC can be treated with proteins of the invention alone or with
compounds or mixtures of compounds known to induce osteogenesis or with
compounds or mixtures of compounds known to induce adipogenesis and the resulting
rates of differentiation to osteoblast-like cells or adipocyte-like cells can be measured.

Example 5 : Design of GLP-1 and Exendin-4-containing proteins of the invention
from Fc-fusion FGF21 variants.
[000286]

Constructs were made with alternative linkers (for example,

SGGGGSGGGGSGGGGSA (SEQ ID NO:138), GGGGS (SEQ ID NO:173), GG, and
GGGGSGGGGSGGGGS (SEQ ID NO:174)), FGF21 variants, and GLP-1-related
peptides. Typically the dual function proteins containing an Fc domain were expressed
in HEK293 cells. The DNA coding sequences of these fusions were cloned into vectors

containg sequence encoding a leader peptide to direct the proteins for secretion and
further containing sequences necessary to promote mRNA syntehsis and protein
expression of the desired products. HEK293 cells were transiently transfected with the
vectors. The media from these cell cultures were collected, filtered, and purified by
protein A affinity chromatography. The eluates were brought to netural pH and further
purified by size exclusion chromatography. The products were then concentrated and
stored for various assays. Variants were tested for activity in vitro in four assays: CREluciferase expression induction in HEK293 transfected with GLP-1 R (Table 3) and
glucose stimulated insulin secretion in INS1 E cells (Table 6) to measure activity through
GLP-1 R ; ERK phosphorylation induction in HEK293 transfected with beta-klotho (Table

4) and 2-deoxyglucose uptake by 3T3L1 cells (Table 5) to measure FGF21 activity.
Variants with GLP-1 (A8S) and a 15 amino acid linker were more active than variants
with GLP-1 and shorter linkers. Exendin-4 (1-39) variants with all linkers tested were
active. Exendin-4 (1-30)-containing variants had similar in vitro potency to Exendin-4 (139)-containing constructs. A variant with a tandem repeat of Exendin-4(1-39) was not
as potent as variants with a single copy of a GLP-1 -related peptide.

Table 3 . GLP-1 R activation in HEK293-GLP-1 R-CRE-Luciferase Reporter Cells.

Variant#

GLP-1R EC

V193

0.024

V194

0.042

V195

0.041

V196

0.027

V197

0.085

V198

0.024

V199

0.046

V202

0.025

V203

0.252

V206

0.047

V207

0.088

V208

0.044

V209

0.033

V210

0.038

V211

0.032

V212

5.90

V213

18.4

V214

0.023

V215

8.99

V216

0.025

V217

4.53

(nM)

Table 4 . Activity measured in an ERK phosphorylation assay of FGF21 activity in
HEK293-KLB cells.
Pklotho pERK
Variant#

EC

(nM)

% y-max vs.

Potency

W T FGF21

(Fold over W T FGF21)

V193

2.1

101

1.2

V194

9.8

97

5.8

V195

13

76

7.6

V196

0.87

58

0.18

V197

0.92

63

0.19

V198

0.94

67

0.24

V199

1.04

58

0.27

V202

1.78

67

0.37

V203

1.01

70

0.21

V206

0.51

83

0.15

V207

1.10

83

0.34

V208

0.53

54

0.20

V209

0.70

83

0.21

V210

0.84

88

0.24

V211

0.58

73

0.17

V212

1.24

89

0.37

V213

1.00

61

0.37

V214

0.55

50

0.21

V215

0.92

51

0.34

V216

0.85

56

0.32

V217

2.23

46

0.83

Table 5 . Activity measured in a 2-deoxyglucose uptake in 3T3L1 mouse adipocytes.

Table 6 . Activity measured by glucose-stimulated insulin secretion (GSIS) in INS1 E rat
insulinoma cells.

[000287]

Eight ob/ob mice were dosed with variants twice per week at 0.5 mg/kg for

two weeks. Blood glucose and body weight were measured during the studies, and
hepatic lipids were measured at the end of the study. As seen in the following table
(Table 7), treated animals had reduced blood glucose, lower body weight, and lower

hepatic lipids throughout the study, when compared to vehicle-treated age-matched
animals.

Table 7 . Summary of results of treating ob/ob mice twice per week at 0.5 mg/kg for two
weeks.

p-value vs. vehicle < 0.05

Example 6 : Further characterization of proteins of the invention in receptor
pharmacology assays.
[000288]

As seen, for example, in Figure 9 , dual agonist proteins of the invention were

compared to various forms of FGF21 and Exenatide for their ability to induce ERK
phosphorylation in HEK293 transfected with beta-klotho. At 10 minutes, cells treated
with GLP-1 (A8S)-FGF21 (V76)-PEG (V272) showed a higher potency and higher
maximal proportion of phospho-ERK to total ERK when compared to cells treated with
FGF21 (V76)-PEG plus Exenatide. The higher maximal phospho-ERK signal shows that

the dual function protein V272 is a superior agonist for signaling through FGFR1 c/betaklotho when compared to the FGF21(V76)-PEG molecule, possibly due to better

interaction with the receptor (for example, the N-terminal extension causing the dual
function protein to attain a more favorable structure for receptor binding or activation).

[000289]

Select dual function proteins were tested for their ability to induce phospho-

ERK signaling in human adipocytes. When compared to a single function FGF21
molecule (V101), the dual function proteins V208, V209, V21 1, V14, and V272 were
more potent for stimulating phosphorylation of ERK. Because these are human cells, it
may also suggest that the dual function proteins of the invention will be highly active in
treatment of human disease when compared to treatments including other FGF21
mimetics, similar to what has been demonstrated for activity in rodents to date.

[000290] As seen, for example, in Table 8 and Figure 10, dual agonist proteins of the
invention were compared to Exenatide, GLP-1 peptide, Exendin-4(1-39)-L5-Fc (V201 ) ,
and GLP-1 (A8S)-PEG (V253) for their ability to signal through GLP-1 R in HEK293 cells

transfected with GLP-1 R or cells co-transfected with GLP-1 R , beta-klotho and FGFRIc.
Cells were treated with compound for 30 minutes, and cAMP levels were measured.
Table 8 shows that in cells with both the GLP-1 R and the FGF21 receptor complex, the
dual agonist proteins (V272 and V21 1) showed higher potency than the single agonists

(V253 and V101) alone or in combination with Exendin-4. In cells with only GLP-1 R , the
potency of the single agonists alone or in combination with Exendin-4 was equal to that
of the dual agonist proteins. FGF21 variants alone were inactive in the assay.

[000291]

Table 8 . Assay of cAMP induction in cells treated with dual function proteins

of the invention.

[000292]

Two additional HEK293 cell lines were generated in Discoverx's PathHunder

assay format which utilizes complementation of beta-galactosidase fragments on betaarrestin and the C-terminus of GLP-1 R to measure recruitment of arrestin upon receptor
activation. Figures 10a-10d show that with a 1 hour incubation of cells with protein or
peptide, GLP-1 (A8S)-FGF21(V76)-PEG (V272), Exendin-4(1-39)-L15-Fc-L15-

FGF21 (V103) (V21 1), GLP-1(A8S)-PEG (V253), and Exendin-4(1-39)-L5-Fc (V201),

were less potent than Exenatide for recruitment of beta-arrestin and that no difference in
behavior was noted whether cells contained GLP-1 R/FGFR1 c/beta-klotho or GLP-1 R
alone.

[000293]

The receptor pharmacology studies presented here suggest that the dual

function proteins of the invention will be superior in activity and efficacy when compared
to combinations or co-treatments of conventional FGF21 and GLP-1/Exenatide
molecules. The PEGylated dual function protein GLP-1 (A8S)-FGF21 (V76)-PEG (V272)
unexpectedly showed higher potency and maximal signal for phospho-ERK induction
when compared to the FGF21 (V76)-PEG molecule. These data show that the dual
function proteins are equivalent or superior for FGF21 signaling when compared to other
FGF21 variants. Likewise, the dual function proteins exhibit higher potency for cAMP

signaling downstream of GLP-1 R when cells express both the GLP-1 and FGF21
receptors. These properties may reflect a direct interaction between the receptors or an
indirect effect such as a boost in local concentration through avidity toward the two
receptors. These observations suggest a mechanism for improved activity of the dual
function proteins that may explain why co-treatments of individual GLP-1 and FGF21
variants have not been sufficient to match the in vivo efficacy of the dual function
proteins, as presented in other examples of this invention.

Example 7 : Characterization of proteins of the invention in models of Type-1
Diabetes (T1D)
[000294]

RIP-DTA transgenic mice (9-10 weeks old) were treated with doxycycline for

3 days to induce controlled beta-cell ablation (similar to Thorel et al., Nature
2010(464)1 149-1 154). The mice were then treated for three weeks, twice per week with
FGF21 (V76)-PEG, FGF21 (V76)-PEG + GLP-1 (A8S)-PEG (V253), or GLP-1 (A8S)FGF21 (V76)-PEG (V272). Treated animals in all three groups showed lower basal fed

glucose levels during the study. The dual function protein treatment resulted in
significantly lower glucose AUC (64% reduced from vehicle) compared to combination
treatment (55% reduced from vehicle). After fasting, the mice were given a glucose
bolus, and glucose excursion was measured. All three treatments lowered blood
glucose levels compared to vehicle-treated animals, with the dual function protein
treatment resulting in a 76% reduction compared to 66% for the combination treatment.
All treated groups had increased pancreatic insulin content compared to vehicle, with
the dual function protein treatment resulting in a 76% greater insulin content than
combination treatment.

[000295]

NOD mice were treated twice per week for three weeks with GLP-1 (A8S)-

FGF21 ( 1 54C)-PEG (V235) or GLP-1 (A8S)-PEG (V253) + FGF21 ( 1 54C)-PEG (V238).

After two weeks, the mice were fasted and given a glucose bolus for an OGTT. The
dual function protein-treated mice showed significantly lower fasted glucose (-60% of

vehicle) and glucose excursion during challenge (-45%) compared to vehicle while
combination-treated animals had fasted glucose levels that were not significantly
different from vehicle (-70%) and similar glucose excursion during challenge compared
to vehicle-treated animals. At the end of the study, the dual function protein-treated
animals had significantly lower basal glucagon levels (-50%) than vehicle, while
combination-treated animals had levels similar to vehicle.

Example 8 . Predictive immunogenicity results - MHC-associated Peptide
Proteomics (MAPPs) and T-cell assay results.
[000296]

The formation of anti-drug antibodies (ADA) to mAbs and other

therapeutic proteins could potentially lead to severe immunotoxicological reactions, such
as IgE-mediated anaphylactic reactions (Chung et al. (2008) N Eng J Med, 358, 1 10917) or immune complex disease, e.g., vasculitis, glomerulonephritis (Descotes and

Gouraud (2008) Expert Opin Drug Metab Toxicol 4 , 1537-49) as well as to a loss of
clinical exposure and efficacy. Some patients treated with the therapeutic proteins
PEGylated megakaryocyte growth and development factor (PEG-MGDF) and
erythropoietin (EPO; Eprex) developed neutralizing ADA that were cross-reactive to
their respective endogenous counterparts, leading to severe thrombocytopenia with
PEG-MGDF and pure red-cell aplasia with Eprex (Li et al. (2007) Blood 98, 3241-8;
Casadevall et al. (2002) N Engl J Med 346, 469-75). Hence, it is important to assess the
immunogenicity risk prior to human testing. Evaluating the immunogenicity risk and
putting in place a solid immunogenicity risk mitigation plan for the clinical development
phase will be especially important for therapeutic proteins containing modified, nonhuman sequences such as the FGF21 variants that are the subject of this invention.

[000297]

Formation of ADA can be induced in at least two different ways. T cell-

dependent and -independent pathways have been described for B cell activation. A
strong, high affinity IgG response is T cell-dependent and requires involvement of CD4+

T helper cells (TH cells). The immune response is analogous to a response against
foreign antigens: naive T H cells are specifically activated by professional antigen
presenting cells (APCs), such as dendritic cells (DCs), and in turn induce activation of
drug-specific B cells.

[000298]

The MHC-associated Peptide Proteomics (MAPPs) assay involves in

vitro identification of HLA class

II

associated peptides, which are processed by

professional antigen presenting cells (APCs) such as dendritic cells. Antigen uptake,
processing and presentation processes are taken into account. In this approach,
immature human monocyte-derived DCs of different healthy blood donors, are
incubated with different biotherapeutic drug candidates in the presence of an activation
stimulus. The naturally processed HLA class ll-associated peptides, which are derived
from the biotherapeutic protein, are identified by liquid chromatography-mass
spectrometry (Kropshofer and Spindeldreher (2005) in Antigen Presenting Cells: From
Mechanisms to Drug Development, eds. Kropshofer and Vogt, Wiley-VCH, Weinheim,
159-98).

[000299]

T cell assays provide a format in which the potential risk for

immunogenicity of whole protein therapeutics can be assessed. T cell assays evaluate
the capacity of a therapeutic protein to induce a CD4 + T cell response. Using a cohort of
healthy blood donors covering a broad panel of HLA class

II

haplotypes, purified

therapeutic proteins are tested for T cell proliferation and / or cytokine secretion in vitro.
This technology been used successfully to compare protein variants for the potential to
induce an immune response in vivo (Jones et al. (2004) J Interferon Cytokine Res. 24,
560-72.; Jones et al. (2005) J Thromb Haemost. 3 , 991-1000) and this assessment of
currently approved monoclonal antibodies does show some degree of correlation
between the activation of T cells observed in vitro and immunogenicity in the clinic
(Perry et al. (2008) Drugs R D 9 , 385-96). In the context of this invention, peripheral
blood mononuclear cells (PBMCs) from a cohort of 50 healthy donors representing the
world population (based on HLA allotypes) are incubated with the FGF21 variants and T
cell responses are measured using proliferation assays ([ H]-Thymidine uptake) and IL-

2 cytokine secretion (ELISpot). Subsequently, analysis of the frequency and magnitude
of the CD4 + T cell responses are carried out to assess the risk of clinical
immunogenicity.

[000300]

The combined use of the T cell and MAPPs assays provides an effective

process for evaluation of immunogenicity risk in the clinic using human cells.
Modifications to a therapeutic protein candidate that results in a reduced number of
peptides presented by dendritic cells and a reduced number of responding donors in the
T-cell assay will be advantageous as these proteins bear a lower risk to develop
immunogenicity in the clinic. A n example of a protein modification that has been
described to reduce immunogenicity is PEGylation. However, reduced immunogenicity
does not always occur with PEGylation (Li et al. (2007) Blood 98, 3241-8).

[000301]

In the MAPPs assay, all tested PEGylated GLP-1(A8S) and Exendin-4

FGF21 -fusion molecules, including V272 (PEGylated) and V277 (PEGylated) and the

non-PEGylated Fc-FGF21 variants containing the Q55C, G148C mutations (V101 , V103

and V188), show a low number of clusters, and peptide length variants that are

comparable to V76 (PEGylated) and lower than wild-type FGF21 or V76 (nonPEGylated). In the T cell assay, the frequency of T-cell responses was <10% of the
study cohort and the magnitude of the responses were low for V272 (PEGylated) and
V277 (PEGylated) and the non-PEGylated Fc-FGF21 variants containing the Q55C,
G148C mutations (V101, V103 and V188) (Table 10). The absence of a PEG moiety or
the absence of the additional disulfide bond at Q55C, G148C may contribute to the
increased MAPPs and T-cell assay responses seen with wild-type FGF21 and V76
(non-PEGylated) (Tables 9 and 10). Based on the results from the MAPPs and T cell
assays, the risk to develop immunogenicity in the clinic can be considered to be low for
V76 (PEGylated), V272 (PEGylated), V277 (PEGylated) and the non-PEGylated FcFGF21 variants containing the Q55C, G148C mutations (V101, V103, V188). It is known

that the addition of disulfide bonds to proteins can enhance their proteolytic stability and
this feature of the Fc-FGF21 variants containing the Q55C, G148C mutations may
contribute to the reduced number of peptides displayed by antigen-loaded mature
dendritic cells in the MAPPs assay.

[000302]

In addition, the increased MAPPs response in the assays to non-

PEGylated V76 may be explained by the free cysteine leading to dimerization of the
molecule and thereby impacting antigen processing and presentation. This is in line with
the observation that wild type FGF21 with the introduced free cysteine showed the same
tendency to dimerize and resulted in increased presentation of peptides. It is likely that
additional PEGylated dual function proteins, and the GLP-1(A8S)-Fc-FGF21 variants
(V202, V203, V212, V213, V214, V215, V216, V218 etc.) and the Exendin-4-Fc-FGF21

variants (V196, V197, V198, V199, V206, V207, V208, V209, V210, V21 1 etc.)
containing the Q55C, G148C mutations, will also exhibit MAPPs and T cell assay
responses that would be consistent with a low risk of developing immunogenicity in the
clinic.

[000303]
Table 9 . T-cell assay summary with wild-type FGF21 , V76 (non-PEGylated) and V76
(PEGylated) Experiment
Outcome T cell
assay

KLH
(positive
control)

FGF21 -WT
(nonPEGylated)

FGF21 -WT(PEGylated)

V76 (nonPEGylated)

V76
(PEGylated)

Proliferation %

90

6

4

16

4

ELISpot %

82

10

8

10

4

Proliferation
and ELISpot %

78

6

4

10

2

Table 10. T-cell assay summary with V76 (PEGylated), V272 (PEGylated), V277
(PEGylated), V101 , V103 and V188 Experiment

Outcome T cell
assay

KLH
(positive
control)

V76
(PEGylated)

V272
(PEGylated)

V277
(PEGylated)

V101

V103

V188

Proliferation %

92

4

6

4

4

6

4

ELISpot %

91

6

6

4

4

6

9

Proliferation
and ELISpot %

85

4

6

4

4

6

4

CLAIMS
What is claimed is:

1.

A dual function fusion protein comprising a GLP-1 receptor agonist region

and an FGF21 receptor agonist region.

2.

The dual function fusion protein of claim 1 comprising a GLP-1 receptor

agonist peptide fused to a FGF21 variant, a linker, and a PEG group attached in such a
way so as enhance the biological function of said GLP-1 receptor agonist or FGF21
variant.

3.

The dual function fusion protein of claim 2 , wherein the FGF21 variant is

variant 76.

4.

The dual function fusion protein of claim 3 , wherein the linker is an Fc.

5.

The dual function fusion protein of claim 3 , wherein the linker is an Fc

6.

The dual function fusion protein of claim

variant.

1,

wherein said dual function

fusion protein of further comprises variant 208, variant 209, variant 2 1 1, variant 214,
variant 272, variant 277, or variant 3 1 1.

7.

A method of treating a metabolic disorder by administering to a subject in

need a dual function fusion protein comprising a GLP-1 receptor agonist and an FGF21

receptor agonist.

8.

The method of claim 7 , wherein said dual function fusion protein

improves metabolic parameters in subjects over the administration of individual GLP-1
receptor agonists and FGF21 receptor agonists in combination.

9.

The method of claim 7 , wherein said dual function fusion protein further

comprises variant 208, variant 209, variant 2 1 1, variant 214, variant 272, variant 277, or
variant 3 1 1.

